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General introduction and 









According to a report of the American Heart Association, cardiac arrest is defined as “the 
cessation of cardiac mechanical activity, confirmed by the absence of signs of circulation”.1 If 
this occurs to someone not admitted to a hospital, thus in a community setting, this is called 
out-of-hospital cardiac arrest (OHCA). In the Western World, the estimated annual incidence 
of treated OHCA-cases is about 50 per 100.000 person years.2 Outcomes are rather poor, 
with survival to discharge percentages ranging between 5% and 25%.2, 3 In The Netherlands, 
±150 patients are treated for OHCA on a weekly basis, with relatively high probabilities of 
survival of 23%.4
SHOCKABLE OR NON-SHOCKABLE?
The underlying cardiac rhythm during cardiac arrest can be divided in two categories: either 
non-shockable or shockable. Non-shockable rhythms include asystole and pulseless electrical 
activity (PEA), while shockable rhythms include ventricular fibrillation (VF) and pulseless 
ventricular tachycardia. The presenting heart rhythm is the strongest predictor of survival 
and is also an important determinant of the underlying cause of the arrest.5 In case of a 
non-shockable rhythm, chances of survival are very poor (1-5%).2, 5 OHCAs with a shockable 
rhythm have markedly higher survival percentages (10-50%, varying according to geographic 
location), are treatable by means of defibrillation and typically have a cardiac cause, in about 
half of the cases an acute myocardial infarction (MI).3, 5-7
THE CHAIN OF SURVIVAL
Besides the presenting heart rhythm, survival from OHCA is importantly determined by 
circumstantial factors, such as recognition of the cardiac arrest by a witness, activation of 
the emergency medical services (EMS) and performance of bystander cardiopulmonary 
resuscitation (CPR).5 Moreover, early availability and use of an automated external defibrillator 
(AED) is essential and played a key role in the improved survival of shockable OHCA over the 
last years.8 The most important links that contribute to favorable outcome after OHCA have 
been summed up in the so-called “Chain of Survival” (Figure 1). Overall, the critical and time-
dependent nature makes OHCA a unique medical situation, of which the outcome strongly 
relies on community factors in the first, and adequate care by emergency medical services 












FIGURE 1. THE SIX LINKS OF THE “CHAIN OF SURVIVAL” FOR OUT-OF-HOSPITAL CARDIAC ARREST.10
CARDIOPULMONARY RESUSCITATION
To bridge the period from the start of the arrest to specialized treatment and restoration 
of the patient’s own circulation, it is crucial to perform CPR by external chest compressions 
and ventilations. Performance of bystander CPR by a layperson is associated with a 1.5-2 
fold increase in the chances of survival.5 The development of the “modern” CPR has been 
achieved by a combination of contributions by investigators William Kouwenhoven, Guy 
Knickerbocker and James Jude, whose re-introduction of closed-chest cardiac massage 
changed the outcome of patients with cardiac arrest markedly.9 
Following the current guidelines, CPR consists of chest compressions and ventilations in 
a 30:2 ratio, performed in cycles of 2 minutes, with the intention to minimize the “hands 
off” time (Figure 2).10 At the end of every cycle, the underlying cardiac rhythm is assessed. 
If a non-shockable rhythm is present during this rhythm check, CPR has to be continued 
immediately for 2 minutes. In case of a shockable rhythm a defibrillation attempt has to be 
applied, after which chest compressions should be continued for the next cycle. Resuscitative 
treatment ends when return of spontaneous circulation (ROSC) is achieved, or when the 
patient is declared dead.
If ROSC is not being achieved after the initial phase of the resuscitation, the underlying 
(reversible) cause of the arrest comes into play. In case of prolonged arrest, which is associated 
with lower survival11, 12, mechanical CPR devices (e.g. Autopulse, LUCAS) can be used to 
take over chest compressions for transportation of the patient to a hospital.13-15 Moreover, 
extracorporeal support (“invasive CPR”) has emerged over the years.16, 17 Such innovative 
new techniques, in particular extracorporeal membrane oxygenation (ECMO) devices, have 
caused a paradigm shift in advanced resuscitation care, as health care providers now have the 
opportunity to transport OHCA-patients with artificial circulation, with the goal to increase 
the chances of survival. The ongoing question, however, is who benefits most of these new 
techniques. Although not routinely used, observational studies showed associations of ECMO 
with favorable survival in patients with initial shockable rhythms, who had periods of ROSC 
during resuscitation.16 To ensure that we use these costly but potentially lifesaving techniques 
adequately in the future, prospective, randomized studies are mandatory to investigate if – 
and in particular for which patients – routine ECMO use can improve OHCA-outcomes. As 
such, we can move towards a more individualized treatment approach for cardiac arrest, 
based on the patient’s individual needs.




















- CPR for 2 min
- Minimise interruptions
FIGURE 2. FLOWCHART FOR CARDIOPULMONARY RESUSCITATION.
Asys = Asystole; CPR = cardiopulmonary resuscitati on; PEA = pulseless electrical acti vity; VF = ventricular fi brillati on; 
VT = ventricular tachycardia. The lightning icon represents a defi brillati on att empt.
VENTRICULAR FIBRILLATION
The most frequently presenti ng shockable rhythm in case of OHCA, is VF. Key features of 
VF were likely recognized as early as 3500 BC, and were described as follows in the Ebers 
Papyrus: “If the heart trembles, has litt le power and sinks, the disease is advancing and death 
is near”.18 The fi rst scienti fi c eff orts to understand fi brillati on stem from 1643, when Vesalius 
described “worm-like” movements in animal hearts during dissecti on just before they died. 
The fi rst actual recordings of VF were made by Hoff a and Ludwig, in 1850, with use of a 
kymograph (Figure 3), while it was Hoff man in 1912 who recorded the fi rst electrocardiogram 
(ECG) of VF in a human being.19
Although the electrophysiological mechanisms of VF remain largely unknown, it is commonly 
assumed that reentrant circuits and focal acti vators are the main initi ators and maintainers 
of fi brillati on within the myocardium.19, 20 On the ECG, VF is diagnosed as a rapid and irregular 
ventricular rhythm with a dominant frequency of 150-500 min-1 and an amplitude of >0.1 mV, 




The key treatment action to terminate VF is defibrillation; the administration of an electrical 
current through the myocardium, to cause synchronous depolarization of the cardiac muscle 
cells and restore the patient’s own organized rhythm. It was William Kouwenhoven in 1933 
who discovered that VF could be electrically induced in a dog, and terminated by a second 
electrical current, the so-called “countershock”.21 The first successful defibrillation in a human 
being was performed by Claude Beck in 1947, on a 14-year old boy experiencing VF during 
cardiac surgery, while the first closed chest defibrillation was successfully performed by Paul 
Maurice Zoll in 1956.21
FIGURE 3: HOFFA AND LUDWIG’S FIRST RECORDINGS OF VF. 
The first visual recordings of ventricular fibrillation (VF) as obtained by Hoffa and Ludwig using a kymograph (left 
figure).19 C.J. Wiggers performed the first imaging studies of VF, using fast cinematography (right figure). Figure 
reprinted from Wiggers, Am Heart J, 1940 with permission.46
PHASES OF VF
In cardiac arrest, the time from the collapse to the first defibrillation attempt is one of the key 
determinants of successfully achieving return of spontaneous circulation (ROSC) and survival.22 
As a rule of thumb, it has been assumed that every minute of delay decreases the chances of 
a successful shock with about 7-10%. In 2002, Weisfeldt and Becker introduced a “three phase 
model” of VF in which they stated that VF consists of three phases: the electrical phase (0-4 min 
after onset) in which VF is a purely electrical problem that benefits from immediate defibrillation, 
the circulatory phase (4-10 minutes) in which VF has become a more severe problem which 
may benefit from chest compressions and tissue oxygen delivery prior to defibrillation, and the 
metabolic phase (>10 minutes) in which chances of survival have become very low.23
Based on this model, it has been hypothesized that some patients – with prolonged 
untreated VF – do not benefit from the standard “shock first” protocol, but may need a 
“chest compression first” strategy with an extra period of CPR prior to the first defibrillation 
attempt. Two randomized trials investigated a CPR-first strategy.24, 25 Both studies found no 
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direct benefits (nor harm) of such a new strategy, however, subgroup analyses indicated 
that patients with prolonged response times had a slightly better outcome when chest 
compressions were performed prior to the first shock. 
THE VF-WAVEFORM
Prolonged VF will result in a decreased VF-waveform amplitude on the ECG, ultimately 
degenerating into asystole if being untreated. In the mid-1980s, Douglas Weaver and 
colleagues were the first to demonstrate that VF-amplitude was associated with the time from 
collapse until the start of basic life support and the delay until assessment by paramedics, in 
a cohort of 394 cardiac arrest patients.26 Moreover, they showed that from all patients with 
“fine” VF (i.e. VF with a peak-to-peak amplitude ≤0.2 mV) only 6% survived the arrest, while 
this was 36% in patients with “coarse” VF (>0.2 mV).26
Over the last decades, analysis of the VF-waveform has increasingly been studied in animal 
and human studies. The amplitude spectrum are (AMSA), a measure combining amplitude 
and frequency information of the VF-signal, became the key characteristic. It was shown in 
animal studies that a lower AMSA is associated with depleted ATP concentrations, suggesting 
an association with the VF-waveform and the myocardial metabolic state.27 Animal studies 
on untreated VF demonstrated a progressively declining AMSA over time, while return of 
coronary blood flow by extracorporeal circulation led to an increase of AMSA.28
The observations that quantitative measures of the VF-waveform are related with the 
time-in-VF and the metabolic state of the myocardium, led to investigations in real-world 
VF-patients. Numerous clinical studies, mainly retrospective in design, demonstrated 
associations between morphologic VF-characteristics and clinical outcome measures, such 
as defibrillation success and sustained ROSC.29-35 Moreover, it was shown that AMSA could 
even predict neurologically intact survival.36
Another important finding came from the group of Eftestol in 2004. In a study on 105 VF-
patients, they showed that an interval of high-quality chest compressions caused an increase 
in VF amplitude and frequency (Figure 4).37 
All collective findings led to the hypothesis that VF-waveform analysis could be used during 
a resuscitation as an indicator of shock success and, more importantly, to guide resuscitative 
strategies based on the patient’s individual needs. In case of a low AMSA, a patient is likely 
to be in the “circulatory phase” of VF and may therefore benefit from a CPR-first approach, 
while in case of a high AMSA an immediate shock is recommended.
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FIGURE 4: VF AMPLITUDE AND FREQUENCY INCREASE BY A PERIOD OF CPR. 
Figure reprinted from Eftestol, Circulation 2004, with permission.37 CPR = cardiopulmonary resuscitation; 
VF = ventricular fibrillation.
AMSA-TRIAL
The first randomized controlled trial on VF-waveform-guided treatment was published by 
Freese and colleagues in 2013.38 In this study, the VF-waveform of the defibrillator ECG was 
analyzed upon arrival of the EMS. VF-patients were randomized to either standard “shock 
first” therapy or a VF-waveform based approach. In the intervention arm, chest compressions 
were continued for two minutes in case of fine VF (i.e. under a specific threshold), while a 
shock was immediately applied in case of coarse VF (above the threshold). In this trial, no 
differences in survival were observed between the study groups, questioning the potential 
of VF-waveform analysis as a tool to guide treatment strategies. However, there were some 
important remarks with regard to the methodology of this study. The VF-algorithm used in 
the study was rather unconventional and known to yield a sensitivity of 80% and a specificity 
of 60% in predicting defibrillation success, thereby mainly focusing on predicting defibrillation 
failure. In response, the group of Ristagno searched for a more robust algorithm for actual 
prediction of ROSC.35 In the largest VF-waveform cohort to date, they demonstrated that a 
threshold value of AMSA of above 15.5 mVHz has a positive predictive value of 78% and a 
specificity of 98% for prediction of defibrillation success, defined as restored organized rhythm 
> 40/min. Data from simulations suggested that defibrillation success may increase to 67% 
when using AMSA to guide shock delivery, compared with 26% with the standard approach.35 
Moreover, they introduced a threshold for a low AMSA, for which a successful shock is very 
unlikely (negative predictive value >97%). These findings have led to the currently ongoing 
AMSA-trial, the second and more promising randomized clinical trial on VF-waveform guided 
resuscitative approaches, testing the hypothesis that real-time AMSA analysis may optimize 
the timing of defibrillation during CPR and may increase ROSC.39 
IDENTIFICATION OF MYOCARDIAL INFARCTION
A potential novel application of VF-waveform analysis may be identification of the underlying 
cause of the arrest. In several studies, the relation between VF-morphology and underlying 
heart disease has been investigated. Especially the impact of a myocardial infarction (MI) 
on the VF-waveform has been studied, since this is the most frequent and potentially 
reversible cause of VF. It has been demonstrated in animal and human studies that in case 
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of an MI, amplitude, frequency and organization characteristics of VF differ when compared 
to structurally normal hearts.40-44 As such, the VF-waveform might be a new instrument to 
identify an MI during cardiac arrest. This is of particular interest, since early identification 
of an MI as a reversible cause of VF, may pave the way for new patient-tailored treatment 
strategies, such as early transportation and intervention in this patient subset.45
Outline of the thesis
Over the past decades, assessment of quantitative measures of the VF-waveform has emerged 
as a potential new tool to guide resuscitative strategies and facilitate a more patient-tailored 
approach to treat cardiac arrest patients in a near future. Improved knowledge of the next 
steps to take towards the use of so-called ‘smart defibrillators’ are highly needed in the 
process of making this technique clinically and technically applicable.
In this thesis, we investigate the VF-waveform and provide insights into technical and clinical 
issues before VF-characteristics can be used for innovative smart defibrillator applications. 
In Part I, we introduce out-of-hospital cardiac arrest and focus on its unique, time-critical 
nature, plus the fact that OHCA-outcome strongly relies on community factors as well as on 
the available technology. In Chapter 2, we give an update on current and future innovations 
in the crucial initial phase of prehospital treatment and highlight the most important steps 
for maintaining the positive trend of OHCA survival. Given that early cardiopulmonary 
resuscitation by (trained) bystanders is a key determinant of OHCA-survival, new methods of 
CPR-training are under current investigation. In Chapter 3 we study whether CPR-training by 
a novel virtual reality application leads to similar CPR-quality when compared to conventional 
face-to-face training.
In Part II, we study clinical and technical aspects with regard to the assessment and use of 
morphologic characteristics of the VF-waveform, in particular the amplitude spectrum area 
(AMSA). As a means to improve our understanding of the VF-waveform, we describe AMSA 
in a real-world cohort of VF-patients in Chapter 4. We assessed the association of AMSA with 
shock success over the entire course of a cardiac arrest, and investigated potential differences 
between the early and late phase of the resuscitation. In Chapter 5 we report on a study 
in which we used induced VF of patients receiving an implantable cardioverter defibrillator 
(ICD). This setting provides a unique opportunity to study VF-waveform characteristics under 
controlled circumstances. As such, we investigated the impact of ECG-recording direction on 
the resulting value of the AMSA. In Chapter 6 we performed a systematic review on AMSA-
methodology, and highlighted the importance of a uniform methodologic approach for this 
promising marker in future studies.
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In Part III, we study the VF-waveform in relation to etiology. For this purpose, we firstly 
used data of induced VF in ICD-patients and investigated whether amplitude and frequency 
dependent VF-characteristics differ in patients who had a prior myocardial infarction 
(Chapter 7) and patients with increased left ventricular mass or diameter (Chapter 8), when 
compared to patients without such a medical history. Chapter 9 builds upon the results of 
these studies, as we investigated the feasibility of machine learning models to detect patients 
with a prior MI. This proof-of-concept study can be regarded the first in-human investigation 
on the ability of VF-waveform based discriminative algorithms to diagnose underlying heart 
disease. In Chapter 10, we study a real-world VF-cohort and describe coronary angiography 
findings in two patient categories: patients who received three or less defibrillation attempts, 
and patients with so-called ‘shock-resistant VF’, meaning that they needed more than three 
shocks. We hypothesized that patients with shock-resistant VF more often had an acute 
coronary occlusion (ACO) as the underlying cause of VF. In Chapter 11, we study VF OHCA 
patients and focus on detection of this specific patient subset with an ACO related myocardial 
infarction, using VF-waveform based discriminative models.
Chapter 12 contains the general discussion, in which we highlight the most important clinical 
and technical implications, as well as recommendations for future research on this topic. In 
Chapter 13, we summarize the main findings and conclusions of the studies presented in this 
thesis. Moreover, a Dutch translation of the summary is provided.
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Out-of-hospital cardiac arrest (OHCA) is a major healthcare problem, with approximately 
200 weekly cases in the Netherlands. Its critical, time-dependent nature makes it a unique 
medical situation, of which outcomes strongly rely on infrastructural factors and on-
scene care by emergency medical services (EMS). Survival to hospital discharge is poor, 
although it has substantially improved, to roughly 25% over the last years. Recognized key 
factors, such as bystander resuscitation and automated external defibrillator use at the 
scene, have been markedly optimized with the introduction of technological innovations. 
In an era with ubiquitous smartphone use, the Dutch nationwide text message alert 
platform HartslagNu (www.hartslagnu.nl) increasingly contributes to timely care for 
OHCA victims. Guidelines emphasize the role of cardiac arrest recognition and early 
high-quality bystander resuscitation, which calls for education and improved registration 
at HartslagNu. As for EMS care, new technological developments with future potential 
are the selective use of mechanical chest compression devices and extracorporeal life 
support. As a future innovation, ‘smart’ defibrillators are under investigation, guiding 
resuscitative interventions based on ventricular fibrillation waveform characteristics. 
Taken together, optimization of available prehospital technologies is crucial to further 
improve OHCA outcomes, with particular focus on more available trained volunteers in 
the first phase and additional research on advanced EMS care in the second phase.




Out-of-hospital cardiac arrest (OHCA) is a major healthcare issue, with 100–200 treated cases 
each week in the Netherlands.1, 2 Survival to hospital discharge has increased to about 25%, 
which is relatively favorable when compared with the reported 10% worldwide.3 Technical 
innovations in the prehospital infrastructure have played a key role in this process. 
The so-called ‘Chain of Survival’ defines the critical series of actions in the treatment of OHCA 
(Figure 1). Crucial prehospital factors include cardiac arrest recognition by a witness, initiation of 
basic life support (BLS), activation of the emergency response system, access to an automated 
external defibrillator (AED), and advanced life support by emergency medical services (EMS).
In this article, we provide an update on technical innovations that have contributed to the 
optimization of recognized prognostic factors. In addition, we highlight the most promising 
future techniques to further improve prehospital OHCA management.
Bystander care
CARDIAC ARREST RECOGNITION
Over the years, the impact of civilians in terms of cardiac arrest recognition and adequate 
initiation of BLS has been increasingly recognized. Early recognition of typical and atypical 
signs of cardiac arrest (e.g., gasping, uncontrolled movements) is key, in combination with 
early EMS activation and bystander cardiopulmonary resuscitation (CPR) until ambulance 
arrival.4, 5 Educational programs have been set up worldwide because of their potential to 
increase survival by higher rates of timely bystander CPR.6 Innovative technologies such 
as virtual reality (VR) applications have evolved, which can present OHCA victims more 
realistically than standard manikins, thereby potentially improving cardiac arrest recognition. 
Moreover, VR training has the potential to reach a much larger target population at home and 
schools. Such low-cost and incomprehensible modalities have the advantage that they can be 
(repeatedly) used where and whenever it is convenient.7 
BASIC LIFE SUPPORT
Besides facilitation of CPR training, technical innovations also have an important role in the 
optimization of some of the key factors of survival: the rate of bystander CPR and the time 
to first defibrillation.8 In an era where smartphones are ubiquitous, mobile applications have 
arisen to alert trained individuals to a nearby OHCA victim.8, 9 To follow up on promising data 
on postal code–based applications, GPS-based systems have been developed to direct some 
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FIGURE 1. SCHEMATIC ILLUSTRATION OF THE CHAIN OF SURVIVAL. 
Figure is based on the fi gure presented in the 2020 American Heart Associati on (AHA) guidelines for cardiopulmonary 
resuscitati on.34 Important links in the prehospital phase include acti vati on of emergency medical services (EMS) 
by (lay) responders, high-quality basic life support including cardiopulmonary resuscitati on (CPR), availability 
and att achment of automated external defi brillators to provide quick defi brillati on, and advanced life support by 
healthcare professionals.
To further improve the potenti al of this system, the Dutch Heart Foundati on sti mulates 
civilians to att end BLS training and acti vely register as a volunteer (HartslagNu, www.
hartslagnu.nl), to achieve its goal that every future OHCA victi m is reached within 6 minutes. 
The introducti on of this digital platf orm has markedly facilitated CPR initi ati on by volunteers 
(Figure 2).
To improve bystander CPR quality, guidelines now recommend witnesses to use their mobile 
device’s speaker functi on when calling the emergency telephone number.11 This provides a 
unique opportunity of direct contact with dispatchers, to get real-ti me instructi ons to check 
for breathing, perform CPR and provide them with the precise arrest locati on. A fu ture 
challenge appears to be developing innovati ve soluti ons to recognize unwitnessed cardiac 
arrest, a topic for which the Dutch Heart Foundati on recently launched a project call. 
DEFIBRILLATION
Appreciati ng the importance of ti me to fi rst defi brillati on in pati ents with a shockable 
rhythm, the introducti on of AEDs has signifi cantly contributed to reduced treatment delays 
and improved survival.12, 13 Over  the past years, studies have been undertaken to develop 
and opti mize shock advisory algorithms to ensure accurate, fast detecti on of ventricular 
arrhythmias.14 Noti fi cati on of the police was one of the fi rst initi ati ves, which resulted in 
faster response ti mes than alerti ng the EMS15, but civilians may arrive even earlier with an 
AED.10
Although AED availability in public buildings and areas has increased, accessibility during out-
of-offi  ce hours can be improved and registrati on at HartslagNu is sti ll subopti mal. Recently, 
the Dutch Heart Foundati on has started a program for AED placement in ‘opti mal’ locati ons, 
with  the intenti on of building a nati onal AED network (www.hartsti chti ng.nl/aed). In the city 
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of Nijmegen, the Netherlands, an initi ati ve of Ra dboudumc, the municipality and volunteers 
has resulted in the placement of AEDs outside buildings. A novel initi ati ve, especially in rural 
or remote areas, is AED delivery through drone networks.16
EMS care and advanced life support
MEDI CATION
To facilitate administrati on of medicati on and/or fl uids, devices have been developed for 
intraosseous infusion, but their eff ecti vity is currently questi oned.17 Despite its use since 
the 1960s, it was not unti l the PARAMEDIC-2 trial that a randomized trial demonstrated a 
survival benefi t of epinephrine in cardiac arrest; yet, its use should be restricted to guideline-
endorsed protocols.18 Notably, ancillary analyses in this trial suggested worse neurological 
outcome among survivors. With available databases worldwide, big-data analyses on this 
topic seem warranted.
AIRWAY MANAGEMENT
Over the years, a variety of innovati ve venti lati on techniques have been developed, but 
their exact role needs to be further established. Inserti on of supraglotti  c airway devices is 
associated with shorter chest compression interrupti ons than conventi onal endotracheal 
intubati on, although a randomized trial did not demonstrate favorable outcomes.19 As for 
laryngeal tube devices, improved 72-hour survival was reported compared with endotracheal 
intubati on.20
SEE-THROUGH DEFIBRILLATION
The EMS defi brillator has developed from a plain shock device to a ‘smart’ defi brillator. 
Altho ugh evidence on survival benefi t is lacking, real-ti me feedback on CPR quality has 
shown to opti mize chest compression rate and depth and to minimize hands-off  ti mes. A 
development with future potenti al may be ‘see-through’ defi brillati on.21 With the use of 
innovati ve fi lter techniques, rescuers are able to see and analyze rhythm registrati ons during 
chest compressions, aiming to further reduce hands-off  ti mes related to pauses needed for 
rhythm analysis.
VENTRICULAR FIBRILLATION WAVEFORM ANALYSIS
The introducti on of automated analysis of the defi brillator/ECG has made it possible to 
quanti tati vely characterize ventricular fi brillati on (VF). While short-durati on VF is known for its 
high frequency and high amplitude, VF of longer durati on typically has low-amplitude, low-
frequency characteristi cs. Imp ortantly, delivery of CPR can improve VF waveform characteristi cs. 
The key VF characteristi c in this context is the amplitude spectrum area (AMSA), which has 
been associated with myocardial energy levels and chances of successful defi brillati on.22, 23
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In an ongoing randomized trial, defibrillation success is currently being compared between 
the prevailing resuscitation protocol and a VF-waveform-guided protocol (ClinicalTrials.gov: 
NCT03237910). This new protocol directs prompt defibrillation in case of a high AMSA, while 
continued chest compressions are indicated in case of low AMSA values. In contrast to the 
first study on VF-waveform guided defibrillation, which showed a negative outcome24, this 
study uses a derived and validated, publicly available algorithm based on 1617 patients.23 
Notably, AMSA has also been proven to be associated with favorable neurological survival.25 
As such, it is a very early marker that may contribute to timely triage and treatment.
MECHANICAL CHEST COMPRESSIONS
With the availability of mechanical chest compression devices, it has become possible 
to deliver long-term, sustained high-quality CPR as a safe alternative to manual chest 
compressions.26, 27 Mechanical delivery of chest compressions results in higher-quality CPR in 
a driving vehicle, as compared with manual CPR.28 However, its routine use does not result in 
superior outcomes, and mechanical chest compression delivery should therefore be tailored 
to specific cases and situations.27 In particular, mechanical chest compressions may pave 
the way to hospital transportation for treatment of the underlying cause, for example by 
percutaneous intervention.
EXTRACORPOREAL LIFE SUPPORT
Although the first small randomized trial with extracorporeal membrane oxygenation (ECMO) 
showed promising results in patients with refractory VF29, randomized trials such as the Dutch 
INCEPTION study (NCT03101787) are eagerly awaited. Infrastructure and experience are key 
elements, and time to initiation is crucial.30 With ongoing technical developments, some research 
groups are now able to provide prehospital treatment with portable extracorporeal CPR devices. 
Further identification of groups that may derive particular benefit is warranted.30, 31
Future directions: Optimize what we have, develop what we need
The development of new resuscitative options raises the question whether OHCA treatment 
should become more patient-tailored. In general, all OHCA patients are treated the same, 
regardless of the clinical scenario or underlying cause.
The conventional ‘stay and play’ strategy — on-scene CPR until return of spontaneous 
circulation is achieved — may need refinement, with conversion to a ‘scoop and run’ strategy 
in well-defined situations. Especially in case of VF refractory to standard in-field treatment, 
early transportation with mechanical chest compressions and timely ECMO may be of value. 
The first initiatives of routine early transport to the catheterization lab in case of refractory 
VF reported high rates of underlying coronary substrate and promising clinical outcomes.29 
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The recent COACT trial showed that routine coronary angiography does not improve survival 
in VF patients with return of spontaneous circulation and no signs of ST-elevation myocardial 
infarction (STEMI).32 Hence, the actual challenge seems to be identifying patients with an 
acute coronary occlusion in the prehospital setting. 
At present, detection of STEMI is restricted to those who regain organized rhythm, which is 
a subgroup of patients who are often in a later phase of the arrest. One of the potential new 
technologies that may result in early identification of patients with a myocardial infarction 
is VF waveform analysis. In experimental work, the first in-human study has suggested that 
this technique may not only predict defibrillation success and survival but also underlying 
myocardial infarction.33 Future clinical studies on this topic are warranted. 
Conclusion
Technical innovations have played a role in the positive survival trend for OHCA in the 
Netherlands, with current survival rates of roughly 25%. With the growing accessibility of 
smartphones, performance of bystander CPR and availability of AEDs at the scene have 
substantially improved. Registration of AEDs and trained volunteers on national text message 
alert platforms are crucial to reach the full potential of this life-saving, mobile network. For 
EMS care, developments such as mechanical chest compression devices and ECMO and 
the future potential of ‘smart’ defibrillators may pave the way towards more individualized 
treatment approaches for cardiac arrest.
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FIGURE 2. OHCA CASES WITH CPR BY A TRAINED VOLUNTEER. 
Percentage of out-of-hospital cardiac arrest (OHCA) cases in which initi al cardiopulmonary resuscitati on (CPR) was 
delivered by a trained volunteer, who arrived at the scene aft er receiving a message from the Dutch nati onwide text 
message alert platf orm (HartslagNu). Data from all 25 Safety Regions in the Netherlands, [1] in 2018 and [2] in 2020. 
Source: HartslagNu. Graphic design: Contented (Apeldoorn, the Netherlands).
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CHAP T ER  3
Effect of face-to-face vs virtual reality 
training on cardiopulmonary resuscitation 
quality: A randomized clinical trial




IMPORTANCE Bystander cardiopulmonary resuscitation (CPR) is crucial for survival after 
cardiac arrest but not performed in most cases. New, low-cost, and easily accessible 
training methods, such as virtual reality (VR), may reach broader target populations, but 
data on achieved CPR skills are lacking. In this study, we compared CPR quality between 
VR and face-to-face CPR training. 
METHODS Design: Randomized noninferiority trial with a prospective randomized open blinded 
end point design. Participants were adult attendees from the science section of the Lowlands 
Music Festival (August 16 to 18, 2019) in the Netherlands.  Interventions: Two standardized 
20-minute protocols on CPR and automated external defibrillator use: instructor-led face-to-
face training or VR training using a smartphone app endorsed by the Resuscitation Council 
(United Kingdom). Outcomes and measures: During a standardized CPR scenario following the 
training, we assessed the primary outcome CPR quality, measured as chest compression depth 
and rate using CPR manikins. Overall CPR performance was assessed by examiners, blinded 
for study groups, using a European Resuscitation Council–endorsed checklist (maximum 
score 13). Additional secondary outcomes were chest compression fraction, proportions of 
participants with mean depth (50-60 mm) or rate (100-120 min−1) within guideline ranges, and 
proportions compressions with full release. 
RESULTS A total of 381 participants were randomized: 216 women (57%); median 
(interquartile range [IQR]) age, 26 (22-31) years. The VR app (n = 190 [49.9%]) was 
inferior to face-to-face training (n = 191 [50.1%]) for chest compression depth (mean 
[SD], VR: 49 [10] mm vs face to face: 57 [5] mm; mean [95% CI] difference, −8 [−9 to −6] 
mm), and noninferior for chest compression rate (mean [SD]: VR: 114 [12] min−1 vs face 
to face: 109 [12] min−1; mean [95% CI] difference, 6 [3 to 8] min−1). The VR group had 
lower overall CPR performance scores (median [IQR], 10 [8-12] vs 12 [12-13]; p < 0.001). 
Chest compression fraction (median [IQR], 61% [52%-66%] vs 67% [62%-71%]; p < 0.001) 
and proportions of participants fulfilling depth (51% [n = 89] vs 75% [n = 133], p < 0.001) 
and rate (50% [n = 87] vs 63% [n = 111], p = 0.01) requirements were also lower in the 
VR group. The proportion of compressions with full release was higher in the VR group 
(median [IQR], 98% [59%-100%] vs 88% [55%-99%]; p = 0.002). 
CONCLUSIONS AND RELEVANCE In this randomized noninferiority trial, VR training resulted in 
comparable chest compression rate but inferior compression depth compared with face-
to-face training. Given the potential of VR training to reach a larger target population, 
further development is needed to achieve the compression depth and overall CPR skills 
acquired by face-to-face training. 




Cardiac arrest constitutes a major health care problem, with more than 300,000 deaths 
annually in the United States alone.1 Early automated external defibrillator (AED) use and 
high-quality cardiopulmonary resuscitation (CPR) are important determinants of survival.2-6 
However, most individuals with cardiac arrest do not receive any form of bystander CPR, 
which may be because most civilians are not currently trained in CPR.2,3,7-10 Therefore, 
increasing awareness, willingness, and capability to perform CPR is promoted as a key issue 
in international practice guidelines and by leading health care authorities.11-17 
Face-to-face training has long been the standard, but new, low-cost, and fast training methods 
have recently emerged that may hold the potential to reach a much larger target population. 
Lifesaver VR (http://lifesavervr.org.uk/) is an innovative, immersive, and interactive 
educational smartphone app that virtually teaches CPR to app users; the app was developed 
and endorsed by the Resuscitation Council (United Kingdom) and is specifically mentioned in 
current CPR guidelines.14,18 It has recently been updated to incorporate a virtual reality (VR) 
enhancement, allowing users to learn CPR in a realistic, interactive VR setting. Experts in the 
field consider VR as one of the most promising tools in medical training in general and CPR 
training in particular.19,20 Virtual reality training through the app can be performed at home 
at a low cost at any moment and takes approximately 20 minutes to complete. Virtual reality 
training may therefore overcome important barriers for layperson CPR training.14,21 However, 
data on the achieved CPR quality are lacking. 
To address this gap in knowledge, we performed the Lowlands Saves Lives trial, a randomized 
clinical trial comparing CPR quality between face-to-face and VR training using the smartphone 
app. This study was conducted during Lowlands Science, a section of the 3-day Lowlands 
Music Festival that is specifically dedicated to conducting scientific research.
Methods
AIM AND HYPOTHESIS
The methodology of the present study was previously published.22 The primary aim of this 
study was to compare CPR quality between face-to-face CPR training and training using the 
VR app. Our hypothesis was that training with the VR app would result in CPR quality that is 
noninferior to CPR quality achieved by face-to-face training. 
OVERVIEW OF THE STUDY DESIGN AND OVERSIGHT
The Lowlands Saves Lives trial was a parallel, 1:1 randomized clinical trial with a prospective 
randomized open blinded end point (PROBE) design.23,24 The Consolidated Standards of 
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Reporting Trials (CONSORT) reporting guideline was also followed.
The study complied with the principles of the Declaration of Helsinki.25 The protocol, available 
in Supplement 1, was approved by the research ethics committee of the Radboud University 
Medical Center (Radboudumc, Nijmegen, the Netherlands). An independent clinical research 
organization (Diagram BV) was responsible for monitoring participant data. 
Participants were randomized to either face-to-face CPR training or CPR training using the VR 
app (eFigure 1 in Supplement 2). All participants provided written informed consent. 
SETTING 
This study was conducted from August 16 to 18, 2019, at Lowlands Science, a section of the 
3-day Lowlands Music Festival (Biddinghuizen, The Netherlands; 55,000 attendees) dedicated 
exclusively to scientific research.26 Lowlands Science was located at an area separated from 
the rest of the festival, providing a closed section with an optimal infrastructure for conducting 
scientific research (eFigure 2 in Supplement 2). 
POPULATION 
Eligible for inclusion were adult (≥18 years) attendees of Lowlands Science. Participants 
who were deemed not capable of performing either the training or the posttraining CPR 
test (e.g., physical or cognitive impairment) were excluded by the physicians dedicated to 
this task. Second, participants with elevated alcohol levels (≥0.5‰, the Dutch legal driving 
limit)who failed a tandem gait test were also excluded. For this purpose, we performed a 
law enforcement–grade alcohol breathalyzer test in all participants (AlcoTrue P; Bluepoint 
Medical). As such, participants with an alcohol level of 0.5‰ or higher who passed a tandem 
gait test were included. 
RANDOMIZATION AND BLINDING 
Randomization was performed online using Castor Electronic Data Capture. We used a 
random block randomization algorithm and stratified randomization according to alcohol 
level, using a binary cutoff value of less than 0.5‰ vs 0.5‰ or higher. The rationale was that 
in music festivals, alcohol consumption is allowed and common, and alcohol intake may affect 
CPR skills. Randomization was performed on site in real time. Owing to the nature of the 
intervention, participants were not blinded, but the outcome assessors were. 
INTERVENTIONS
A standardized 20-minute CPR training was provided by an independent, experienced 
instructor certified by the Dutch Resuscitation Council, who was not part of the study 
team and not an employee of the Radboudumc. The training protocol was designed under 
supervision of our national Basic Life Support course director and based on CPR guidelines 
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and previous brief training protocols.14,27 The ratio of instructors to participants was 1:5. 
Chest compressions and ventilations were taught using certified CPR manikins (Little Anne; 
Laerdal Medical). Automated external defibrillator use was practiced using training AEDs (Zoll 
AED Trainer 3; Zoll Medical). 
During VR training, individuals participated in a filmed CPR scenario while wearing VR 
goggles and headphones, which took approximately 20 minutes. Users became actively 
involved with the resuscitation of an individual experiencing cardiac arrest and simulated 
chest compressions by performing compressions on a pillow. The app provided feedback on 
compression speed and instructions on compression depth. It also taught skills needed for 
adequate AED use. As equipment, we used smartphones (Samsung S7), headphones and 
VR goggles (Zeiss VR One Plus; Carl Zeiss). Both training protocols, a graphical impression 
of the training areas and in-game footage from the VR app, can be found in eAppendix 1 in 
Supplement 2. 
OUTCOMES
After the training, CPR quality and overall CPR performance were assessed during a 
standardized CPR scenario.28 Cardiopulmonary resuscitation tests were performed in closed 
examination rooms by assessors blinded for study group. The protocol can be found in 
eAppendix 2 in Supplement 2. Outcome measures were based on current CPR guidelines 
and on a consensus document describing the preferred outcomes for reporting on CPR 
quality.16,17,29 
The primary outcome measure was CPR quality, expressed as depth (millimeters) and 
rate (minute−1) of chest compressions. A 2019 review on CPR education confirmed that 
compression rate and depth are the most widely studied CPR-quality parameters, with 
strong associations with patient outcome.30 These were measured objectively using certified 
CPR manikins (Resusci Anne QCPR ; Laerdal Medical). The manikins recorded CPR quality 
parameters, which were stored on an operating device (SimPad; Laerdal Medical) and 
downloaded for offline analysis. 
The key secondary outcome measure was the overall CPR performance expressed as a real-
time appointed score by assessors blinded for study group, using the European Resuscitation 
Council endorsed CPR checklist (eAppendix 2 in Supplement 2). Video recordings of CPR skill 
tests were made of a subset of participants who provided consent for this additional study 
feature. A random sample of 20% of all video recordings was reviewed by an external event 
committee, blinded for study group.
In addition, we gathered data on a series of additional secondary outcome measures. For 
the present analysis, we report on flow fraction (percentage of time where compressions are 
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given, i.e., chest compression fraction) and proportion of compressions with full release (as 
a measure for leaning). Finally, we calculated proportions of participants meeting guideline 
CPR quality criteria (i.e., the proportion of participants with an average chest compression 
rate of 100 min−1 to 120 min−1 and the proportion with a mean chest compression depth of 
50 mm to 60 mm).16,17 
STATISTICAL ANALYSIS
In this noninferiority trial, the null hypothesis was that the VR training app is inferior to face-
to-face training. To ensure adequate sample size for both quality parameters, we defined 
our noninferiority margins based on previouswork.27,28,31,32 Appreciating that the increase in 
compression depth for instructor-led training is 5mm when compared with pre training, and 
that a decrease of 5mm has been associated with lower survival changes after cardiac arrest, 
the noninferiority margin was 5mm.31,32 With an expected standard deviation of 10mm27,28,31, 
an α of 5%, and a power of 90%, we calculated 69 participants per group. 
A priori, we determined that our study should be adequately powered in the sample of 
participants without recent CPR training (within 2 years)31,33 and that we also wanted to 
explore results in those with training. We anticipated a maximum of 20% of participants with 
previous training.33 Thus, 80% or more was anticipated not to have had previous training. To 
achieve adequate power in the sample without training, required groups size was increased 
with 25%. 
Finally, sample size was further increased to account for a 10% dropout rate. Hence, the 
desired sample size was 1.25 × 1.10 × 69 = 95 participants per group. This also provides 
adequate power to test noninferiority for chest compression rate, with a noninferiority 
margin of 17 min−1 and standard deviation of 20 min−1, based on the same studies as for 
depth.27,28,31 
Study parameters were assessed for normal distribution and accordingly reported as means 
(SDs) or medians (interquartile ranges [IQR]). Primary outcomes were tested for noninferiority 
using 1-sided 2-sample t tests. Continuous data were compared using t tests or Mann-
Whitney U tests and categorical variables reported as numbers (%) and compared using χ2 or 
Fisher exact tests, whichever appropriate. Prespecified subgroup analyses were performed. 
A p-value of less than 0.05 was considered statistically significant. Analyses were performed 
using Stata version 15.1 (StataCorp). Analysis began in September 2019.
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FIGURE 1. CONSORT FLOW DIAGRAM.
CPR indicates cardiopulmonary resuscitation; VR, virtual reality. a All included participants were able to pass the 
tandem gait test, if applicable.
Results
PARTICIPANT FLOW AND RECRUITMENT 
Overall, 396 participants provided informed consent (Figure 1). Of these, 15 (4%) were 
excluded before randomization; participant withdrawal was mainly related to long waiting 
lines. As such, 381 participants were randomized: 190 (49.9%) to the VR training app group 
and 191 (50.1%) to the face-to-face training group. Of all randomized participants, 29 (8%) 
(15 in the VR and 14 in the face-to-face group, p = 0.84) decided not to participate in the 
post training CPR test, mainly owing to long waiting lines. Thus, outcome assessment was 




Of 381 individuals, 216 (57%) were women. The median (IQR) age was 26 (22-31) years, 
and the median (IQR) weight was 70 (63-79) kg (Table 1). The predominant education level 
was university education (171 of 381 [45%]). Of all participants, 62 of 381 (16%) had an 
alcohol level of 0.5% or higher. A total of 58 of 358 participants (16%) had recent CPR training. 
Baseline characteristics did not differ between both study groups, with the exception of the 
proportion of health care professionals, which was 16% (n = 31) in the VR training group and 
25% (n = 48) in the face-to-face training group (p = 0.03).
PRIMARY OUTCOMES 
The mean (SD) chest compression depth was 49.1 (10.0) mm in the VR group compared with 
56.8 (5.4) mm in the face-to face group. The mean difference between VR and face-to-face 
training was −7.7 (95% CI, −9.4 to −6.0) mm. Given the predefined noninferiority margin of 
−5 mm, VR training was inferior to face-to-face training for chest compression depth, with a 
p-value for inferiority of 0.99. The mean (SD) chest compression rate was 114.3 (11.8) min−1 
in the VR group, compared with 108.6 (11.6) min−1 in the face-to-face group. The mean (95% 
CI) difference between VR and face-to-face was 5.7 (3.3-8.2) min−1. Given the predefined 
noninferiority margin of −17 min−1, VR training was noninferior to face-to-face training for 
chest compression rate, with a p-value for noninferiority of <0.001 (Figure 2). 
SECONDARY OUTCOMES 
Median (IQR) CPR performance score (maximum score, 13) was 10 (8-12) in the VR group 
compared with 12 (12-13) in the face-to-face training group (p < 0.001). Individual items of 
the checklist are reported in the Table in Supplement 2. The intraclass correlation coefficient 
for assessment by the on-site examiners and the event committee was 0.81. Given this high 
level of agreement, the reported CPR scores are those of the on-site assessors. 
Average chest compression depth within the guideline endorsed range of 50mm to 60mm 
was seen in 51% (n = 89) of the VR group, compared with 75% (n = 133) in the face-to-face 
training group (χ2 = 22.28; p<0.001). For the guideline-endorsed chest compression rate of 
100 min−1 to 120 min−1, these proportions were 50% (n = 87) in the VR group and 63% (n = 
111) in the face-to-face training group (χ2 = 6.04; p = 0.01). Compression depth and rate in 
relation to guideline ranges can be found in Figure 3.
Median flow fraction (i.e., chest compression fraction) was 61% (IQR, 52%-66%) in the VR 
group compared with 67% (IQR, 62%-71%) in the face-to-face training group (p < 0.001). The 
proportion of compressions with full release was higher in the former than in the latter (98% 
[IQR, 59%-100%] vs 88% [IQR, 55%- 99%]; p = 0.002).
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TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION. 
No. (%)
Characteristic Total No. Overall (n=381) VR (n=190) Face to Face (n=191) p-value
Women 379 216 (57) 109 (57) 107 (57) 0.88
Age, median (IQR), y 381 26 (22-31) 26 (23-31) 26 (22-31) 0.69
Weight, median (IQR), kg 378 70 (63-79) 70 (64-78) 71 (62-80) 0.86
University education 381 171 (45) 86 (45) 85 (45) 0.88
Health care professional 380 79 (21) 31 (16) 48 (25) 0.03
Alcohol level, median (IQR), ‰ 381 0 (0-0.34) 0 (0-0.36) 0 (0-0.31) 0.64
Alcohol level ≥ 0.5, ‰ 381 62 (16) 35 (18) 27 (14) 0.26
Drugs or narcotics ≤ 24 h 369 93 (25) 42 (23) 51 (28) 0.27
Previous CPR course ≤ 2y 358 58 (16) 28 (16) 30 (17) 0.77
 BLS course NA 49 (84) 24 (86) 25 (83)
>0.99
 ALS course NA 9 (16) 4 (14) 5 (17)
Witnessed a cardiac arrest 381 57 (15) 30 (16) 27 (14) 0.65
ALS = advanced life support; BLS = basic life support; CPR = cardiopulmonary resuscitation; IQR = interquartile range; 
NA = not applicable; VR = virtual reality. Missing data can be either missing or reported as “Do not wish to disclose” 
by the participants.
FIGURE 2. FOREST PLOTS OF THE MEAN DIFFERENCE IN CHEST COMPRESSION DEPTH AND RATE: VR VS. FACE-TO-FACE TRAINING. 
Forest plots for the mean difference (95% CI) in chest compression depth and rate between virtual reality (VR) and 
face-to-face training. The prespecified noninferiority margins were −5 mm for depth and −17 min−1 for rate. For 




FIGURE 3. BOXPLOTS OF CHEST COMPRESSION DEPTH AND RATE IN RELATION TO GUIDELINE RECOMMENDATIONS.
Boxplots of chest compression rate and depth. Whiskers are 10th and 90th percentiles. Percentages at the side of 
each graph indicate the proportion of participants with compression depth or rate that is below, within, or above 
guideline-endorsed ranges respectively. VR indicates virtual reality.
ANCILLARY ANALYSES 
Prespecified subgroup analyses are shown in Figure 4. Heterogeneity of the effect of VR 
training on chest compression depth was suggested in subgroup analyses according to being 
a health care professional (p = 0.007 for interaction) and previous CPR training (p = 0.003 
for interaction). Differences between VR and face-to-face training were significantly smaller 
in the subgroups with previous training and the subgroup of health care professionals. No 
other intervention-by-subgroup interactions were identified, neither for compression depth 
nor for rate.




In this randomized trial including 381 participants recruited on the science section of 
a music festival, VR compared with face-to-face CPR-training resulted in noninferior 
chest compression rate but inferior chest compression depth. Overall CPR performance, 
proportions of participants with average compression depth or rate within guideline ranges, 
and chest compression fraction were lower in the VR group. Contrastingly, the proportion 
of compressions with full release was higher. This study confirms the potential of brief face-
to-face training to achieve adequate CPR skills27 and provides valuable input for further 
development of VR training. Although VR may lead to more widely disseminated CPR training, 
this study suggests that it should be developed further to achieve CPR skills comparable with 
those acquired by face-to-face training, particularly in terms of compression depth. 
PREVIOUS STUDIES AND CURRENT METHODOLOGY 
In follow-up of previous studies on professional pre- and in-hospital treatment strategies, we 
now performed this study on layperson cardiac arrest care.34,35 Given the prognostic effect 
of bystander CPR, several health care authorities call for studies on innovative CPR training 
methods to further disseminate CPR skills among civilians.11,14,15,36,37 Of these innovations, 
VR is considered one of the most promising, as demonstrated by feasibility studies and 
reports on questionnaires conducted among CPR professionals.19,20,38-41 To our knowledge, 
this is the first study to evaluate the effect of Lifesaver VR training on CPR quality. Whereas 
previous studies compared VR with other (mobile) apps or compared face-to-face training 
with apps or games without VR, we now compared VR training directly with face-to-face CPR 
training.18,33,42
Notably, evaluation of lay education in resuscitation strategies is still a relatively new field of 
research, with limited high quality data, and studies are heterogenous in design and prone 
to bias.14,43 We aimed to address these issues by using a PROBE design and standardized CPR 
skill assessment, with independent data monitoring. 
CPR QUALITY AND PERFORMANCE METRICS
Our results show that VR training results in noninferior chest compression rate but inferior 
compression depth. This indicates that VR seems less suitable than face-to-face training 
to provide adequate bystander CPR. However, even in the VR group, at least half of the 
participants met the guideline-endorsed depth or rate requirements. Moreover, previous 
studies showed decreased survival in case of compression depth less than 38 mm, which we 
found in only 14% of participants in the VR group and 2% in the face-to-face group.32,44 This 
confirms the potential to acquire lifesaving CPR skills in brief CPR training sessions.27 Notably, 
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In a previous study evaluating brief VR CPR training in which compressions were not practiced 
on a pillow but by pressing a button, average compression depth was 38mm, compared 
with 49 mm in the present VR and 57mm in our face-to-face group.33 In a 2019 large study 
on multihour training28, the proportion of participants with an average compression rate 
between 100 min−1 to 120min−1 in their instructor-led group was 41%, compared with 50% in 
the present VR and 63% in the face-to-face groups. For the required average depth of 50mm 
to 60mm, this proportion was 57% in the previous study, compared with 51% in the present 
VR and 75% in the face-to-face groups.28 Notably, the results from our face-to-face group 
are in line with a previous study on brief instructor-led training, in which the brief training 
resulted in similar CPR quality as multihour training.27 To further improve comparisons 
between education strategies, a 2019 review31 underscored the need for uniform reporting 
of outcome measures.
The CPR performance score was lower in the VR group, indicating that VR might be less 
suitable than face-to-face training for acquiring knowledge on the entire CPR algorithm. As 
can be seen in the eTable in Supplement 2, the difference in CPR performance score between 
both groups was mainly driven by lower proportions in the subcategory CPR, whereas the 
AED items were more evenly distributed. With regard to this score, it should be noted that 
although it is the official CPR performance checklist of the European Resuscitation Council, 
we are unaware of studies that evaluated its external validity. 
We found a median chest compression fraction of more than 60% in both groups, which 
is in line with guideline recommendations.16,17 Data on the relationship between leaning 
and survival are scarce, but guidelines recommend minimization of leaning based on 
pathophysiological insights from mechanistic studies.16,17 Proportions of compressions with 
full release were high in both groups and highest in the VR group, indicating that this skill can 
be taught during brief CPR training. 
PRESPECIFIED SUBGROUP ANALYSES 
A prespecified subgroup analysis revealed a significant interaction between previous CPR 
training and compression depth and between being a health care professional and depth: 
the difference between study groups was smaller in participants with previous CPR training 
or participants who were health care professionals. It could be interesting to study VR for 
retraining of individuals who were initially trained using the standard approach. Retraining is 
a major topic in current CPR guidelines, and the optimal training method for such trainings is 
under active investigation.11,14,15,36,37 
Owing to our study setting, we studied a sample of young festival attendees. Inherent to this 
setting, there had been alcohol and drug use among participants. Although the subgroup 
analyses on these factors should be considered merely hypothesis generating, our findings 
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indicate no significant effect of alcohol or drug use on differences in depth or rate between 
VR and face-to-face training. 
DIRECTIONS FOR FURTHER VR APP DEVELOPMENT 
The lower compression depth in the VR group could relate to compressions being practiced 
on a pillow instead of a manikin, to mimic the situation where the app is used at home. 
Therefore, no feedback is given on depth, but only on rate. A previous study reported on a 
VR system with real-time feedback on depth, which may also be beneficial for the present 
VR app.45 We also found lower scores on the CPR checklist possibly because the steps of the 
CPR algorithm only appear once in the VR scenario, whereas in face-to-face training these are 
repeated multiple times. Teaching a complex procedure in small portions prevents cognitive 
fatigue, therefore providing the CPR algorithm in small steps with repetition in between may 
be beneficial as well.15,46
LIMITATIONS
Although our 20-minute face-to-face training protocol resulted in similar outcomes as 
a previous brief training protocol in which outcomes and retention were comparable 
with multihour training, it differs from the standard of current CPR courses.14,47 However, 
our protocol complies with all guideline requirements on CPR training.14 The study setting 
resulted in a young, highly educated group of participants. Although this is an important 
target group for CPR education, it may limit generalizability of our findings to, for example, 
elderly civilians. Owing to logistical reasons, CPR skills prior to the test were not assessed 
and no data on retention of CPR skills will be collected. In total, 8% did not perform the 
examinations because of the sometimes long waiting lines for the 2 examination rooms, 
which was related to the appointed restriction in square footage for each research group. 
Furthermore, we unexpectedly found a baseline difference between both groups in the 
proportion of healthcare professionals. This was addressed in stratified analyses, which did 
not alter our conclusions. Lastly, although we found overall acceptable CPR quality in both 
groups, the actual CPR performance in real life and the corresponding effect on patient 
outcome are unknown. 




In this randomized trial, we found that VR training was noninferior compared with face-
to-face training with respect to chest compression rate but inferior with respect to chest 
compression depth. Although VR training may hold the potential to reach a larger target 
population, further development is needed to achieve the chest compression depth and 
overall CPR skills acquired by face-to-face training.
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CHAP T ER  4
The ventricular fibrillation waveform in 
relation to shock success in early vs. late 





BACKGROUND The amplitude spectrum area (AMSA) of the ventricular fibrillation (VF) 
waveform predicts shock success and clinical outcome after out-of-hospital cardiac arrest 
(OHCA). Recently, also AMSA-changes demonstrated prognostic value. Until now, most 
studies focus on early shocks, while many patients require prolonged resuscitations. We 
studied AMSA and its changes in relation to shock success, for both the early and later 
phase of resuscitation.
METHODS Per-shock VF-waveform analysis in a prospective OHCA-cohort (Nijmegen, The 
Netherlands). The absolute AMSA and relative AMSA-changes (ΔAMSA) were calculated 
from three-second VF-segments prior to defibrillation. Shocks were categorized as early 
(#1-3) or late (#4-8). Shock success was defined as return of organized rhythm.
RESULTS Shock success was 46% for early (131/286) and 52% for late shocks (85/162), 
p=0.18. Early shock success varied from 23% to 70% with increasing quartiles of AMSA 
(p-trend<0.001). For late shocks, there also was an association with AMSA, with a 
narrower range in shock success from 43% to 68% (p-trend=0.04). Higher values of 
ΔAMSA were associated with shock success in the early, but not in the later phase.
CONCLUSION AMSA relates to shock success during the entire resuscitation, but associations 
were most apparent for early shocks. AMSA-changes were also associated with shock 
success, but only in the early phase of resuscitation. In an era of smart defibrillators, 
absolute AMSA and relative changes hold promise for studies on early guidance of 
resuscitation, whereas additional studies are warranted to further characterize shock 
prediction in the later phase.




Ventricular fibrillation (VF) is the first observed rhythm in ±30% of all out-of-hospital cardiac 
arrests (OHCAs)1, with dismal survival despite achieved improvements in the chain of care.2-4 
Appreciating that defibrillation of so-called “coarse” VF is more likely to be successful than of 
“fine” VF, the VF-waveform has become a topic of increasing interest to predict and improve 
outcomes.5-7 In this context, the amplitude spectrum area (AMSA) has been introduced as a 
quantitative measure, based on a combination of frequency and amplitude characteristics.8
Several OHCA-studies demonstrated the potential of AMSA, in that it predicts both shock 
success and survival with good neurological outcome.9, 10 Currently, a randomized trial is 
running, investigating shock timing with an AMSA-guided ‘smart defibrillator’, with prolonged 
chest compressions and delayed defibrillation if AMSA is considered too low.11
More recently, changes in AMSA have been studied as well. Given the correlation of AMSA 
with coronary perfusion and myocardial energy levels, an increasing AMSA might reflect 
an improvement of the myocardial metabolic state.12-14 Recent analyses on human data 
confirmed that increases of AMSA are associated with favorable outcome.9, 15
In follow up on data for first defibrillation attempts, recent studies suggested that AMSA 
also predicts favorable outcome when obtained beyond the first shock delivery.6, 16 This is 
of specific interest, given that 40-50% of all VF-patients need more than three defibrillation 
attempts.17-19 However, most information on AMSA, and particularly its changes, has been 
derived from studies restricted to the early phase of resuscitation, predominantly in cohorts 
with on average two shocks per patient.6, 9, 15, 16 At present, little information is available on 
how AMSA evolves over a longer period of resuscitation, and how these changes relate to 
shock success. 
In view of the above, we aimed to improve our understanding of the VF-waveform and its 
association with shock success over a long period of resuscitation. In a cohort of prolonged 
resuscitations, we therefore assessed AMSA and AMSA-changes in relation to shock success 





From our prospective OHCA-registry (Nijmegen, The Netherlands) we studied all adult (>18 
years), non-traumatic arrests with VF as first observed rhythm, with at least one defibrillation 
attempt.18 To ensure comparability of the included shocks, we excluded patients who 
received AED-shocks prior to arrival of the emergency medical services (EMS). Hence, we 
solely included patients who received their first shock by EMS-personnel. Further exclusion 
criteria were the absence of either paddle ECG-recordings or shock outcome data. Given the 
observational design, written informed consent was not necessary to obtain according to the 
Dutch Act on Medical Research involving Human Subjects.
EMERGENCY MEDICAL SERVICES
The Nijmegen area (Gelderland-Zuid) has a population of about 530,000 residents and 
covers 1,040 square kilometers, including urban, suburban and rural areas. The EMS-system 
is activated by calling 112. Paramedics give instructions to the caller to initiate basic life 
support, and at least one ambulance is dispatched to the scene. CPR-delivery was performed 
by EMS-personnel according to the prevailing guidelines at the time of arrest. At the time of 
our registry, our hospital participated in a randomized trial, in which the protocol dictated 
3-minute CPR-intervals.20 Although data on CPR-quality was not systematically scored, EMS-
personnel were trained intensively, and there was strict feedback on CPR-quality. A mechanical 
chest compression device (Autopulse®) was part of the standard EMS-equipment, but not 
routinely used.
DATA ACQUIISTION
Demographic and arrest characteristics were collected using EMS and hospital records, 
according to the Utstein style definitions, except for sustained return of spontaneous circulation 
(ROSC), which was defined as ROSC followed by hospital transport.21 Electrocardiogram 
(ECG, sample frequency 125 Hz) and transthoracic impedance (TTI) data were recorded 
with defibrillator paddles. All patients were treated with the same defibrillator (Lifepak12, 
PhysioControl, Redmond, USA), with identical signal processing characteristics (e.g. built-in 
filters). Biphasic shocks were manually delivered in a standard sequence of 200-360-360 
Joule. ECG and TTI-data were visualized with Codestat (V7.0, PhysioControl, Redmond, USA) 
and exported to Matlab compatible files for signal analysis.
VF-WAVEFORM ANALYSIS
VF-waveform analysis was performed with Matlab (R2014b, Mathworks, Natick, USA). We 
performed a per-shock analysis, i.e. an investigation in which we focused on individual shock 
outcomes. In this analysis, we studied the VF-waveform at subsequent measurement points 
(analyses of all first shocks, second shocks, third shocks, etc.). We prospectively specified a 
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minimum number of 10 analyzable shocks per measurement point during the resuscitation. 
VF-waveform segments were selected, visually free of (chest compression) artefacts and as 
close as possible, but with a maximum of 30 seconds, prior to the shock. Signals were pre-
processed with a fourth-order Butterworth bandpass filter with cutoff frequencies of 2-48 Hz. 
A three-second interval of VF was used for calculation of the AMSA.
CALCULATION OF AMSA
A discrete fast Fourier transform was performed on all 376 data points for conversion to 
the frequency domain. In analogy to previous reports, AMSA was calculated from the 
obtained frequency spectrum, as the summed product of individual frequencies and their 
corresponding amplitudes over an interval from 4-48 Hz.7, 10 A more detailed description of 
the AMSA can be found in Supplement 1. Furthermore, we calculated the relative difference 
of AMSA compared to the previous shock delivery (e.g. the relative change of AMSA between 




Shocks were categorized as either shocks in the early phase, or the late phase of resuscitation. 
Dichotomization was performed as follows:
• Early shocks: Shocks earlier than the median number of shocks in our population.
• Late shocks: Shocks later than, or equal to, the median number of shocks in our 
population.
END POINT AND AIM OF THE STUDY
The primary end point was shock success, defined as return of organized rhythm (ROOR), 
i.e. at least 2 QRS-complexes within 5 seconds, within 60 seconds after shock delivery.22 
We analyzed AMSA and ∆AMSA in relation to shock success, for the early and late phase of 
resuscitation respectively.
STATISTICS
Categorical data were reported as numbers (percentages). Continuous variables were 
analyzed for Gaussian distribution and reported as means ± standard deviations or medians 
(interquartile ranges, IQR), whichever appropriate. Continuous values of AMSA and ΔAMSA 
were reported as medians (IQR) and compared between successful and unsuccessful shocks 
using the Mann Whitney U test. VF-characteristics were subsequently divided into quartiles 
and compared in relation to shock success using Chi-square tests for trend. A p-value <0.05 
was considered statistically significant. All statistical analyses were performed using IBM SPSS 





In total, we performed VF-waveform analysis on 448 shocks, in a group of 139 OHCA-patients 
with VF as first observed rhythm. Baseline characteristics of the study population are reported 
in Table 1; Supplement 2 depicts in- and exclusion criteria. Mean age was 63 ± 14 years and 
71% was male. Of all patients, 39% had a public arrest, 60% received bystander-CPR and in 
76% the arrest was witnessed. 
SHOCK CHARACTERISTICS
The median number of shocks per patient was 4 [2-7]. Consequently, shocks 1-3 were 
regarded as the “early phase”, whereas fourth and later shocks were regarded as the “late 
phase” of resuscitation. Of the 448 shocks, 48% was successful (216/448). A total of 286 
analyzed shocks was delivered in the early phase of resuscitation, of which 46% was successful 
(131/286), compared to 162 shocks in the late phase, of which 52% (85/162) was successful, 
p=0.18.
AMPLITUDE SPECTRUM AREA: EARLY VS. LATE PHASE OF RESUSCITATION
Median AMSA of all shocks in the early phase was 9.2 mVHz [6.2-13.3], and higher prior to 
successful vs. unsuccessful shocks (11.3 mVHz [7.8-15.9] vs. 8.1 mVHz [5.1-11.1], p<0.001, 
Table 2). The proportion of shock success was 23% in shocks of the lowest AMSA-quartile and 
increased across quartiles to 70% in the highest AMSA-quartile (p-trend<0.001, Figure 1).
The median AMSA of all shocks in the late phase was 7.6 mVHz [5.8-12.0]. There was a trend 
towards a higher AMSA prior to successful vs. unsuccessful shocks (8.6 mVHz [6.0-12.3] vs. 
6.8 mVHz [5.5-11.0], p=0.07, Table 2). The proportion of shock success ranged between 43% 
and 68% among AMSA-quartiles (p-trend=0.04, Figure 2). AMSA-values in relation to shock 
success over the course of resuscitation can be found in Figure 3 and Supplement 3.
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TABLE 1: BASELINE CHARACTERISTICS OF THE STUDY POPULATION
VF-waveform cohort
Patient characteristics
Age (years) 63 ± 14
Male gender 98 (71)
Arrest characteristics
Public location arrest 53 (39)
Witnessed arrest 97 (76)
   Bystander 93 (73)
   EMS 4 (3)
Bystander CPR 79 (60)
Response time (minutes) 8 (5-10)




Any ROSC during resuscitation 81 (60)
Sustained ROSC 61 (45)
Survival to discharge 32 (24)
Values are reported as means ± standard deviations, medians (interquartile ranges), or n (%). In some cases, 
baseline characteristics were missing and reported for less than 139 patients: public location (n=136), witnessed 
arrest (n=128), bystander CPR (n=131) response time (n=111), number of EMS-shocks (n=138), amiodarone (n=115), 
adrenaline (n=116), any ROSC (n=136), sustained ROSC (n=137) and survival to discharge (n=132). EMS = emergency 




AMSA-CHANGES: EARLY VS. LATE PHASE OF RESUSCITATION
The median ΔAMSA of all shocks in the early phase was 1.06 [0.90-1.35], and higher for 
successful vs. unsuccessful shocks (1.16 [0.94-1.42] vs. 1.02 [0.84-1.25], p=0.03, Table 2). 
The proportion of shock success ranged between 40% and 65% among ΔAMSA-quartiles 
(p-trend=0.03, Figure 1). The median ΔAMSA in the late phase was 0.93 [0.77-1.11], without 
significant differences between successful and unsuccessful shocks (p=0.48, Table 2). The 
proportion of shock success did not differ significantly among ΔAMSA-quartiles (p-trend=0.48, 
Figure 2).
TABLE 2: The amplitude spectrum area (AMSA) in relation to shock success (return of organized rhythm) in early vs. late phases of 
resuscitation.
Shock success No shock success p-value
All shocks
AMSA 9.7 (7.0-14.0) 7.5 (5.3-11.1) <0.001
Δ AMSA 0.98 (0.86-1.23) 1.00 (0.79-1.17) 0.25
Shocks 1-3 
AMSA 11.3 (7.8-15.9) 8.1 (5.1-11.1) <0.001
Δ AMSA 1.16 (0.94-1.42) 1.02 (0.84-1.25) 0.03
Shocks 4-8
AMSA 8.6 (6.0-12.3) 6.8 (5.5-11.0) 0.07
Δ AMSA 0.92 (0.78-1.07) 0.95 (0.76-1.13) 0.48
Shocks were divided in early shocks (shocks 1-3, N=286) and late shocks (shocks 4-8, N=162). Both pre-shock AMSA 
and the ΔAMSA (relative change of AMSA compared to previous shock) were reported. Values were reported as 
medians (interquartile ranges).
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FIGURE 1: AMSA – EARLY PHASE OF RESUSCITATION. 
Quartiles of the amplitude spectrum area (AMSA, left) and the relative change in AMSA (ΔAMSA, right) in relation to 
shock success (return of organized rhythm), for the first three shock deliveries.
FIGURE 2: AMSA – LATE PHASE OF RESUSCITATION. 
Quartiles of the amplitude spectrum area (AMSA, left) and the relative change in AMSA (ΔAMSA, right) in relation to 




In this cohort of prolonged resuscitations, we demonstrated that the association between 
AMSA and ΔAMSA with shock success differs between the early and late phase of resuscitation. 
In concordance with previous reports, restricted to the first few shocks, we found significant 
associations between AMSA, ΔAMSA and shock success. Contrastingly, in the later phase of 
resuscitation, AMSA-changes showed no association. The observed association between 
absolute AMSA-values and shock success in this later phase were less consistent and require 
further study, also with regard to the predictive value. In an era of smart defibrillators, our data 
support future studies on AMSA-guided resuscitative efforts during the first few shocks. For 
later shocks, additional initiatives are eagerly awaited to further characterize determinants 
of shock success.
PREVIOUS STUDIES
Animal studies: Animal studies have provided a unique study design to address the prognostic 
value of the VF-waveform, and it has repeatedly been shown that a higher AMSA is related 
to favorable defibrillation outcome.23, 24 Studies on the course of AMSA report decreasing 
AMSA-values with increasing time delay, and a positive effect of CPR on the VF-waveform.25 
Interestingly, in a porcine study comparing a CPR-first resuscitation strategy with a conventional 
shock-first strategy, subsets with CPR showed improved VF-characteristics and higher shock 
success rates.26 It should be noted that experimental studies focused on VF in the early phase 
of cardiac arrest, hampering comparisons with our analyses in the late phase.23-26
Human studies: A previous study investigated the VF-waveform in relation to individual patient 
outcomes, using the averaged AMSA over the entire resuscitation. In this OHCA-cohort, with 
a median of 2 shocks, the averaged AMSA was a strong predictor of survival.16 In addition, 
several studies reported per-shock analyses with specific focus on the impact of the AMSA 
beyond the first shock.5, 6, 27 In a relatively small study on these so-called “subsequent shocks”, 
the AMSA demonstrated good discriminative abilities for shock success, in that study defined 
as ROOR or asystole.27 The two largest studies to date pertain to resuscitations with an average 
of two shocks, and distinguished between first and later shocks. It was demonstrated that 
AMSA is predictive for shock success in both the first as well as in later shocks.5, 6 However, 
the abovementioned studies did not address the possibility that the observed associations 
between AMSA and shock success may have been primarily driven by the first few shocks.
In our cohort of prolonged CPR-attempts, we observed that AMSA-values became lower 
over time. From a physiological point of view, this is plausible, as the AMSA is as a proxy 
for myocardial metabolic state which deteriorates in the later phase.13, 28 Another potential 
factor that may cause lower AMSA-values compared to the first two shocks, may be the 
administration of amiodarone (55%), which has previously shown to decrease frequency 
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characteristics of VF.29 Our observation that AMSA-values of successful shocks in the late 
phase were lower than in the early phase of resuscitation, may relate to these factors. 
Interestingly, previous literature also describes lower cut-off values for AMSA to predict 
outcome of subsequent shocks (9.2 mVHz), as compared to first defibrillation attempts 
(10.2 mVHz).5 Although the exact mechanisms of decreasing AMSA values over the course of 
resuscitation require further investigation, the observed differences between early and late 
phases may have pragmatic implications for the use of AMSA-guided shock delivery.
 
FIGURE 3: PER-SHOCK ANALYSIS OF THE AMPLITUDE SPECTRUM AREA (AMSA). 
Values presented in relation to shock success (return of organized rhythm); * p<0.05.
WAVEFORM CHANGES
Despite a growing interest on absolute AMSA-values and outcome, evidence on the impact 
of ΔAMSA is limited and restricted to the early phase. A study on OHCA-patients (1993) was 
the first to describe the association of increasing VF-amplitude with survival after VF cardiac 
arrest.30 
A more recent study on the course of AMSA showed that increases between the first three 
shock attempts are independently associated with defibrillation success.9 Although the latter 
study was restricted to the first three shocks in a population with very high survival rates, the 
results are in line with our observations.
Other recent studies on the course of AMSA suggested that predictive models for 
defibrillation success improve when ΔAMSA-measures are accounted for.15, 31 Notably, these 
studies incorporated resuscitations with a median of 1 to 2 shocks per patient, and the 
described AMSA-changes therefore mainly involved early shocks. Our findings on AMSA-
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changes during the first shocks corroborate with these studies, supporting the hypothesis 
that increasing VF-coarseness is a sign of improving myocardial metabolic state in the early 
phase of resuscitation.
To our knowledge, data on waveform changes after the third shock are scarce, and reports 
on how AMSA evolves over time are also limited. Our results indicate that VF-waveform 
characteristics develop from “coarse” to “fine” VF during the course of a resuscitation, and 
that ΔAMSA is not associated with shock success in the later phase of cardiac arrest. As 
opposed to the early phase – in which an increase in AMSA seems to reflect an improving 
metabolic state and thus better chances of shock success – the VF-waveform in later 
phases of resuscitation is typically characterized by a more varying course. Factors such as 
re-fibrillation, periods of ROSC and the total arrest time vary greatly among patients with 
prolonged resuscitations. This may affect the VF-waveform and undermine the use of AMSA 
and its changes as a determinant of shock success. Moreover, there remains uncertainty 
about the impact of underlying heart disease on the VF-waveform and its implications with 
regard to shock outcome.29, 32-35 Underlying etiology might impact a priori chances of shock 
success, thereby potentially influencing the relation between AMSA-measures and shock 
success, especially in later phases of resuscitation.
IMPLICATIONS
For the early phase of the resuscitation, our findings corroborate with previous work and 
support the rationale for further study on AMSA-guided resuscitation efforts, now that smart 
defibrillators are available.11
Our observations with regard to the impact of AMSA and its changes over time, imply that 
it seems worth investigating whether other factors may be of importance for shock success 
in the later phase. Importantly, the observed AMSA for successful shocks in the later phase 
was lower than in the early phase. Operative protocols may therefore require altered cut-
off values of AMSA during prolonged resuscitations. Pragmatically, further study in a larger 
cohort is warranted to confirm our findings and to assess the predictive value of AMSA for 
shock success in the late phase of resuscitation.
Future studies should also further investigate until what time point the association between 
AMSA and shock success is still present. We now used an arbitrary threshold of four shocks, 
based on the median, to define the early and late phase. However, our data suggest that the 
association is no longer present after shock 5/6. Rather than an early and a late phase, future 
studies may define a phase where shock success depends on AMSA, and a phase where 
the impact of AMSA is less apparent. In this “later phase”, other factors may contribute to 
improve current shock success prediction models. One potential factor may be incorporation 
of information of the success of the previous shock.31, 36 With increasing shock attempts, 
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the discriminative value of AMSA seems to become lower, while combining the AMSA with 
success of the previous shock results in higher diagnostic accuracy.36 Appreciating that the 
majority of VF-patients requires prolonged resuscitations, additional efforts are warranted to 
better elucidate potential key factors for shock success of later defibrillation attempts. 
A last point of specific interest is the technical derivation of AMSA. Several factors complicate 
interstudy interpretation of AMSA-values. First, different defibrillators have different built-in 
filter settings. Second, signal processing protocols vary among studies. Third, methodologies 
to derive and calculate the AMSA are not uniform in different studies. In an era of increasing 
interest in AMSA-guided resuscitation, a uniform approach is to be preferred, as it would 
facilitate interstudy comparisons and implementation in ‘smart defibrillators’.
LIMITATIONS
This prospective registry is of modest sample size and analyses were restricted to patients 
with analyzable VF data and known shock outcome. Of note, no baseline differences between 
in- and excluded patients were observed. In the context of our modest sample size, it should 
be noted that this study on prolonged resuscitations reports on associations between AMSA-
measures and shock success. For further optimization of operative protocols, larger data 
sets are warranted to define AMSA cut-offs that predict shock success in later phases of 
resuscitation. 
In addition, we prospectively defined shock success as ROOR, in line with previous work at 
the time of our study design.22, 37, 38 Notably, ROOR does not always imply restored circulation, 
and might in some cases represent pulseless electrical activity. Although the ROOR-definition 
potentially affects AMSA-values, a stricter definition of shock success (>40/min) yielded 
similar results (Supplement 4,5).39 
Finally, we did not systematically score CPR-quality, and although there was strict feedback 





In the early phase of VF OHCA, both a high AMSA and an increase in AMSA indicated a high 
likelihood of a successful defibrillation, supporting future studies on AMSA-guided shock 
delivery. Although less pronounced, associations between AMSA and shock success persisted 
in the late phase of resuscitation. Contrastingly, no associations between AMSA-changes and 
shock success were found in this later phase. While it should be further elucidated whether 
the described associations between AMSA and shock success enable shock outcome 
prediction in the late phase, the use of AMSA-changes seems restricted to the early phase of 
resuscitation.
SUPPLEMENTARY MATERIAL
Supplementary material related to this article can be found in the online version (https://
www.resuscitationjournal.com/article/S0300-9572(19)30124-8/fulltext). 
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CHAP T ER  5
Electrocardiographic recording 
direction impacts ventricular 
fibrillation waveform measurements: 





AIM In cardiac arrest, ventricular fibrillation (VF) waveform analysis has identified the 
amplitude spectrum area (AMSA) as a key predictor of defibrillation success and favorable 
neurologic survival. New resuscitation protocols are under investigation, where prompt 
defibrillation is restricted to cases with a high AMSA. Appreciating the variability of in-
field pad placement, we aimed to assess the impact of recording direction on AMSA-
values, and the inherent defibrillation advice.
METHODS Prospective VF-waveform study on 12-lead surface electrocardiograms (ECGs) 
obtained during defibrillation testing in ICD-recipients (2010-2017). AMSA-values (mVHz) 
of simultaneous VF-recordings were calculated and compared between all limb leads, 
with lead II as reference (proxy for in-field pad position). AMSA-differences between 
leads I and II were quantified using Bland-Altman analysis. Moreover, we investigated 
differences between these adjacent leads regarding classification into high (≥15.5), 
intermediate (6.5-15.5) or low (≤6.5) AMSA-values.
RESULTS In this cohort (n=243) , AMSA-values in lead II (10.2±4.8) differed significantly 
from the other limb leads (I: 8.0±3.4; III: 12.9±5.6, both p<0.001). The AMSA-value in 
lead I was, on average, 2.24±4.3 lower than in lead II. Of the subjects with high AMSA-
values in lead II, only 15% were classified as high if based on assessments of lead I. For 
intermediate and low AMSA-values, concordances were 66% and 72% respectively . 
CONCLUSIONS ECG-recording direction markedly affects the result of VF-waveform analysis, 
with 20-30% lower AMSA-values in lead I than in lead II. Our data suggest that electrode 
positioning may significantly impact shock guidance by ‘smart defibrillators’, especially 
affecting the advice for prompt defibrillation.




Ventricular fibrillation (VF) is the first observed cardiac rhythm in about 20-30% of all out-of-
hospital cardiac arrests (OHCAs).1, 2 In an attempt to improve outcomes, the potential value 
of VF-waveform analysis is under active investigation.3-5 
At present, the key VF-waveform characteristic is the amplitude spectrum area (AMSA), 
a combined measure of VF amplitude and frequency, containing predictive value for 
defibrillation success and survival with favorable neurological outcome.4, 6-8 AMSA correlates 
with arrest duration and myocardial metabolic state and has been shown to increase during 
high-quality cardiopulmonary resuscitation (CPR).9-11 In that context, a current randomized 
trial compares defibrillation success between the conventional resuscitation protocol and 
a strategy of defibrillation timing guided by real-time AMSA assessment.5 In case of a high 
AMSA-value (≥15.5 mVHz) the protocol directs immediate delivery of the first shock, while 
continuation of chest compressions is indicated when AMSA is below 15.5 mVHz.
So-called “smart defibrillators” can automatically perform this real-time analysis of the 
defibrillator electrocardiogram (ECG). Importantly, previous studies demonstrated that 
positioning of the defibrillator electrodes may vary greatly in clinical practice.12, 13 Such 
variations in bipolar lead recordings could impact AMSA-measurements, which has been 
suggested in a small surface ECG study.14 Depending on the magnitude of this effect, this may 
impact the abovementioned defibrillation guidance.
In this context, we performed an electrophysiologic study and sought to quantify the impact 
of recording direction on VF-waveform assessments, in a large series of patients with 12-lead 
surface ECGs. First, we assessed whether and to what extent AMSA-values vary between 
different ECG-leads, covering the total spectrum of AMSA values, from low to high. Second, 
we assessed the impact of ECG recording direction on classification into the currently defined 
categories of AMSA-values for defibrillation guidance.4
Methods
PATIENT POPULATION
From our prospective registry of first implantable cardioverter defibrillator (ICD) implantations 
at the Radboud University Medical Center, we identified all patients with defibrillation testing 
between 2010-2017. From 2010-2013, defibrillation testing was routinely performed in all 
patients, while in 2014-2017 this was only done for specific indications. For the present 
analysis, we included all patients with a standard 12-lead surface ECG of induced VF. 
Exclusion criteria were: age <18 years, congenital heart disease and right-sided ICD implants. 
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Data on demographics, medical history and left ventricular geometry were collected from 
patient records, as described previously.15 Given the observational design of the study, 
written informed consent was not necessary to obtain according to the Dutch Act on Medical 
Research involving Human Subjects.
ICD IMPLANTATION AND TESTING
The devices implanted were Medtronic (Minneapolis, Minn, USA), St Jude Medical (St. Paul, 
Minn, USA) or Biotronik (Berlin, Germany) ICD, cardiac resynchronization therapy-defibrillator 
systems with transvenous single coil leads, or subcutaneous ICD-systems (s-ICDs, Boston 
Scientific, Marlborough, MA, USA). An example of VF induction and termination by an ICD 
shock is shown in Figure 1. Defibrillation testing was performed after ICD implantation to test 
the ability of the implanted device to sense, detect and terminate VF appropriately, according 
to our local hospital protocol. After sedation with propofol, VF was induced using T-wave 
shock, direct current pulses or 50 Hz burst pacing (in case of s-ICDs). The presence of VF was 
confirmed on surface ECG recordings. Transvenous ICDs were programmed to deliver three 
sequential shocks (15-25-35 Joule) until VF was terminated, while s-ICDs were programmed 
to deliver two sequential shocks (50-65 Joule, according to the prevailing protocol at the 
time of study). In case of persisting VF after the third (transvenous devices) or second shock 
(s-ICDs), external defibrillation was performed. 
VF WAVEFORM CHARACTERISTICS
Prior to defibrillation testing, a standard 12-lead surface ECG was attached following 
standardized protocols, recorded with BARD LabSystem (Lowell, Massachusetts, USA; sampling 
frequency 1000Hz; 16-bit A/D converter). For each patient, we studied a single VF-waveform 
segment prior to the first ICD shock given on VF.  All VF-waveform analyses were performed 
using Matlab (version 2018a, Mathworks, Natick, MA, USA). VF-signals were pre-processed 
with a 1-48Hz bandpass filter. In concordance with the key paper that studied threshold 
values of AMSA, we analyzed VF-segments of 2.05 seconds (2048 samples)4 Subsequently, 
the signal was converted to the frequency domain using a fast Fourier transform. From the 
amplitude frequency spectrum, AMSA was calculated as the summed product of individual 
frequencies and their corresponding amplitudes over an interval of 2-48 Hz, as described 
previously.15, 16
AIMS
The primary aim was to quantify the impact of ECG recording directions on the value of 
AMSA, with particular interest for differences between lead I and II. Analogous to previous 
studies, lead II was considered as a proxy for the defibrillator ECG recording direction.16-19 
Secondly, we aimed to investigate whether and to what extent ECG recording direction 
affected classification into the currently prevailing AMSA-categories.4 
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QUANTIFICATION OF IMPACT OF RECORDING DIRECTION
First, we assessed AMSA-values for the bipolar limb leads, augmented leads and precordial 
leads. Subsequently, we focused on differences observed between lead I and lead II, 
representing a 60˚ difference in recording direction. Per subject, AMSA-differences (AMSAdiff 
= AMSAlead I – AMSAlead II) and AMSA-means (AMSAmean = (AMSAlead I + AMSAlead II)/2) were 
obtained from corresponding, simultaneously recorded VF-segments of leads I and II, and 
Bland-Altman analysis was performed.20 In the resulting scatter plots, AMSAdiff is plotted 
against AMSAmean, providing an overview of the magnitude of the observed differences over 
the total range of AMSA-values. 
IMPACT ON CLASSIFICATION INTO AMSA-CATEGORIES
All AMSA-values obtained from VF-waveform calculations in lead I and lead II were categorized, 
based on the three currently prevailing AMSA-categories for defibrillation guidance: high 
(≥15.5 mVHz), intermediate (6.5-15.5 mVHz) or low (≤6.5 mVHz).4, 5 We assessed whether 
classification differed with AMSA-values based on lead I versus lead II.
STATISTICS
All statistical analyses were performed with IBM SPSS statistics software (version 25, IBM 
Corp., Armonk, NY, USA). Categorical variables were presented as numbers (percentages), 
continuous variables were presented as means ± standard deviations (SD). Comparisons 
between AMSA-values in different leads were performed using a one way repeated measures 
analysis of variance (ANOVA). In case of significant differences, post-hoc pairwise comparisons 
were performed using a paired t-test with Bonferroni correction. To assess the level of 
agreement with regard to classification into AMSA-categories, we used Cohen’s kappa. For all 
analyses, a p-value of <0.05 was considered statistically significant.
Results
PATIENT CHARACTERISTICS
In total, we studied 243 patients with available ECG-recordings of induced VF, of whom 
baseline characteristics are reported in Table 1. The mean age was 63 ± 13 years and 77% 
(186/243) was male. ICDs were implanted for secondary prevention in 38% (92/243), 28% 
(68/243) were CRT-D devices and 4% (9/243) were subcutaneous ICD-systems. Forty-three 
percent (105/243) of all patients had a previous myocardial infarction. Twelve percent 
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TABLE 1: BASELINE CHARACTERISTICS. 
Study population (n = 243)
Age (yrs) 63 ± 13
Male gender 186 (77)
Hypertension § 98 (41)
Diabetes § 54 (22)
Atrial fibrillation § 70 (29)
History of myocardial infarction § 105 (43)
Secondary prevention 92 (38)
CRT-D 68 (28)
Subcutaneous ICD 9 (4)
BSA (m2) §§ 2.0 ± 0.2
LV ejection fraction (%) † 37 ± 14
LV internal diastolic diameter index (cm/m2) †† 3.0 ± 0.5
Beta blocker § 215 (89)
Amiodarone § 30 (12)
Values are reported as means ± standard deviation or number (percentage). CRT-D = cardiac synchronization therapy 
defibrillator; ICD = implantable cardioverter defibrillator; BSA = body surface area, LV = left ventricular; ECG = electro-
cardiogram; VF = ventricular fibrillation. § Derived from N=242 patients; §§ Derived from N=195 patients; † Derived 
from N=164 patients; †† Derived from N=189 patients.
VF-WAVEFORM CHARACTERISTICS
AMSA-values, limb leads: Mean AMSA-values obtained from the limb leads of the surface 
ECG are shown in Figure 2a. The highest AMSA-values were found in lead III, while the 
lowest AMSA-values were observed in lead I (12.9 ± 5.5 mVHz vs 8.0 ± 3.4 mVHz, paired 
t-test p<0.001). The mean AMSA-value in lead II was 10.2 ± 4.8 mVHz, which was significantly 
different from lead I and lead III (both pairwise tests p<0.001). 
AMSA-values, augmented limb leads: Mean AMSA-values obtained from the augmented 
leads of the surface ECG are shown in Figure 2b. The highest AMSA-values were found in lead 
aVF, while the lowest AMSA-values were observed in lead aVR (11.0 ± 4.9 mVHz vs 6.6 ± 2.9 
mVHz, paired t-test p<0.001).The mean AMSA-value in lead aVL was 9.5 ± 3.9 mVHz, which 
was significantly different from lead aVR and lead aVF (both pairwise tests p<0.001).
AMSA-values, precordial leads: Mean AMSA-values obtained from the precordial leads of the 
surface ECG are shown in Figure 2c. We observed significant differences between AMSA-
values of the precordial leads (ANOVA p<0.001). The highest AMSA-values were found in lead 
V3 and the lowest in lead V1 (20.5 ± 9.6 mVHz vs. 10.0 ± 4.7 mVHz, pairwise t-test p<0.001). 
Significant differences were found between all precordial leads (all p<0.001), except for lead 
pairs V1-V6 (p=0.08) and V2-V3 (p=0.52).
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FIGURE 2. MEAN AMSA-VALUES PER ECG-LEAD.
(a): AMSA of limb leads (means + standard deviation). Significant differences were found between AMSA-values 
(ANOVA p<0.001). Post-hoc pairwise comparisons revealed significant differences between all lead pairs (all 
t-tests p<0.001, p-for-significance after Bonferroni correction = 0.017). (b): AMSA of augmented leads. Significant 
differences were found between AMSA-values (ANOVA p<0.001). Post-hoc pairwise comparisons revealed significant 
differences between all lead pairs (all t-tests p<0.001, p-for-significance after Bonferroni correction = 0.017). (c): 
AMSA of precordial leads. Significant differences were found between AMSA-values (ANOVA p<0.001). Post-hoc 
pairwise comparisons revealed significant differences between all lead pairs, except from V1-V6 and V2-V3 (all other 
t-tests p<0.001, p-for-significance after Bonferroni correction = 0.008). AMSA = amplitude spectrum area.
IMPACT OF RECORDING DIRECTION: LEAD I VS. LEAD II
Figure 3a shows the Bland-Altman plot of AMSA-values of ECG-leads I (AMSAI) and II (AMSAII). 
The difference in AMSA between leads I and II (AMSAI – AMSAII) was -2.24 ± 4.3 mVHz, 
corresponding to a relative difference between these leads of -22%. Absolute and relative 
differences between AMSA-values of lead I and lead II varied per AMSA-category (Figure 3 
b-d). In case of a low AMSA in lead II (≤6.5mVHz), the mean AMSA was slightly higher in lead I 
than in lead II (0.4 ± 1.9 mVHz, +8%). For the intermediate and high AMSAII values, the mean 
AMSA was lower in lead I than in lead II. In case of an intermediate AMSAII (6.5-15.5 mVHz) 
the difference in AMSA was -1.8 ± 3.3 mVHz (-18%). In case of a high AMSAII (≥15.5 mVHz), the 
highest absolute and relative differences were found: -8.8 ± 5.2 mVHz (-44%).
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IMPACT ON CLASSIFICATION INTO AMSA-CATEGORIES
Of the 243 AMSA-values obtained from lead II, 53 (22%) were classified into the low, 157 
(65%) into the intermediate and 33 (13%) into the high AMSA-category (Figure 4). Of the 53 
patients with a high AMSA in lead II, 15% had a corresponding high AMSA when calculated 
from lead I, while 85% was classified as either intermediate (67%) or low AMSA (18%). Of the 
157 patients with an intermediate AMSA in lead II, 66% was also classified as intermediate 
with data from lead I. For the 33 patients with a low AMSA in lead II, 72% was also classified 
as low with data from lead I, Cohen’s kappa = 0.27.
FIGURE 3. BLAND-ALTMAN PLOTS OF AMPLITUDE SPECTRUM AREA (AMSA) VALUES.
AMSA values were simultaneously acquired by surface ECG lead I and lead II. Figure a: total population; Figure b: 
patients with a low AMSA in lead II (≤6.5 mVHz); Figure c: patients with an intermediate AMSA in lead II (6.5-15.5 
mVHz); Figure d: patients with a high AMSA in lead II (≥15.5 mVHz). ECG = electrocardiogram.
Discussion
In follow-up on VF-waveform studies that reported on shock success prediction, and clinical 
studies demonstrating the prognostic value of VF-waveform analysis, this experimental study 
was undertaken to provide additional information that may contribute to the further logistic 
development and optimal application of this promising technology. In this large series, we 
quantified the impact of ECG recording direction on AMSA over its entire spectrum of values. 
In relative terms, AMSA differed 20-30% when recorded in a more horizontal direction, with 
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an absolute 2.2 mVHz lower mean AMSA value in lead I than in lead II. Translated to clinical 
practice during OHCA, calculation of absolute AMSA-values by a smart defibrillator will be 
subject to electrode placement, resulting in a VF-guided defibrillation advice that will less 
likely direct towards immediate defibrillation, in case pads are placed more horizontally.
AMSA AND CARDIAC ARREST
In cardiac arrest, AMSA correlates with arrest duration and myocardial metabolic state.9, 
18 This has been regarded the underlying mechanism for AMSA to have moderate to 
good predictive ability for defibrillation success and favorable neurological outcome.4, 6, 7 
Of the potential applications of VF-waveform analysis, shock success prediction has been 
investigated most extensively.21-26 In a large OHCA-cohort, threshold values for AMSA to 
predict shock success have been derived, with classification of AMSA as either low (≤6.5 
mVHz), intermediate (6.5-15.5 mVHz) or high (≥15.5 mVHz).4, 5 Currently, a randomized trial 
investigates a new resuscitation protocol, based on real-time AMSA analysis by a ‘smart 
defibrillator’. Shock success with the new resuscitation protocol will be compared to that 
achieved with a standard CPR-protocol. In the new protocol, prompt defibrillation is only 
performed when AMSA is high, while the first shock is postponed for additional chest 
compressions if AMSA is classified as intermediate or low. Moreover, if AMSA reaches a value 
above 15.5 mVHz during subsequent 2-minute CPR-cycles, the protocol directs immediate 
defibrillation as well.
FIGUR 4. CATEGORIZATION OF AMSA WHEN USING VF-WAVEFORM INFORMATION OF LEAD I, COMPARED TO LEAD II. 
AMSA (Amplitude spectrum area, mVHz) is categorized as ‘low’ (≤ 6.5), ‘intermediate’ (6.5-15.5) or high 
(≥15.5). 
In the context of such new resuscitation protocols, applying cut-off values for AMSA, it is a key 
aspect to study reproducibility of AMSA-measurements. From studies with both laypersons 
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and professionals it is known that pad misplacement is common in clinical practice, resulting 
in variations in bipolar lead recording.12, 13, 27-29 In a previous investigation on the correctness 
of pad placement in a sample of 136 health care professionals whose duty was to perform 
defibrillation, only 25% of the subjects attached both pads within 5cm of the proposed 
range.29 Although misplacement was not further defined in terms of absolute angles, it was 
shown that pads were predominantly placed either too low (sternal pad) or too medial (apical 
pad), but variations were present in both vertical as well as horizontal directions. A previous 
small study (n=45) already suggested that such variations in recording direction could impact 
amplitude and frequency related VF-measures.14 
In this larger patient series we now provide a quantitative estimation of how AMSA-values 
differ in relation to recording direction, and we studied this aspect over a wide range of values, 
also including ECG-leads in the transverse plane. On average, we found absolute AMSA-
values to be markedly lower in lead I than in lead II (-2.2 ± 4.3 mVHz), with less pronounced 
differences in lower, and marked differences in higher AMSA values. While AMSA-values were 
observed to be almost equal in the low category (≤6.5 mVHz, absolute difference 0.4 mVHz, 
+8%), AMSA in lead I was markedly lower than in lead II in the high category (≥15.5 mVHz, 
absolute difference -8.8 mVHz, -44%). In relative terms, the observed average difference 
between lead I and lead II was 22%, which corroborates with the about 30% difference as 
reported previously.14 AMSA-measurements in the transverse plane resulted in clearly higher 
values than in the coronal plane, which may be related to the fact that leads are located much 
closer to the myocardial wall.
Translating these experimental findings into potential consequences in the field, we applied 
our findings to the currently used protocol of so-called ‘smart defibrillators’ during OHCA. In 
this protocol, prompt delivery of the first shock is advised in case of a high AMSA of ≥15.5 
mVHz.5 
We showed that 85% of the high AMSA-values based on lead II are classified as either 
‘intermediate’ or ‘low’ based on lead I. This classification difference shows the marked 
clinical impact of a more horizontal recording direction, resulting in a lower likelihood that 
a prompt first defibrillation will be advised. Moreover, in the AMSA-trial, the VF-guided 
defibrillation threshold of 15.5 mVHz is not restricted to the first, but applies to all shocks, 
and the placement issue therefore has implications for all subsequent CPR-cycles throughout 
the resuscitation attempt. 
IMPLICATIONS
The findings of our study provide important information for future directions of new 
resuscitation protocols with smart defibrillators. The key rationale of such protocols is that 
a high AMSA is associated with a high chance of shock success. Although the hypothesis to 
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perform early defibrillation in these patients and postpone defibrillations in others may be 
right, incorrect pad placement may affect AMSA-values. In turn, this may have implications 
for shock advice, which may ultimately impact trial outcomes. Our current findings may 
be of value to interpret trial outcomes in a more comprehensive context and provide an 
explanation why negative studies on such protocols may not necessarily mean that the initial 
concept can be refuted.
Moreover, from an electrophysiological point of view, this is one of the largest studies on 
12-lead VF registrations, providing detailed information on the VF-waveform in various 
recording directions. This information may contribute to future initiatives with a study design 
to specifically unravel the quantitative association between recording direction and AMSA 
assessment, as this may potentially contribute to further refinement of existing algorithms. 
We observed the highest AMSA-value in lead III of the coronal plane, and in lead V3 of the 
transverse plane. The fact that AMSA differs across limb leads, suggests that the locality of 
the VF rotors may contribute to the appearance of the VF-waveform in a certain direction. 
Previously, we demonstrated that the presence or absence of prior infarction also affects the 
VF-waveform, and that AMSA values are lower in the leads adjacent to the area of infarction.15 
In patients without infarction myocardial mass is another factor that plays a role.30
Additional OHCA-studies are warranted to further explore all different aspects involved that 
potentially affect VF-waveform measurements with smart defibrillators in the OHCA situation.31
LIMITATIONS  
In terms of inferences to the OHCA-setting, our data reflect early, induced VF. This may limit 
the generalizability of the observed magnitude of the absolute differences, but the direction 
of the observed differences will not change. In addition, we studied surface ECG-recordings, 
and not defibrillator pad registrations. However, from an electrophysiological point of view, 
the used limb lead registrations are bipolar, just like defibrillator ECG-registrations, which 
makes it reasonable to assume that the observed differences apply to other devices and in-
field VF as well.
Although we calculated AMSA-values in concordance with the key paper on this topic4, 
technical aspects (e.g. built-in device and filter settings) may have influenced absolute AMSA-
values in this study. Yet, for our current study question, addressing within-patient differences 
between lead I and lead II, this does not affect the main conclusions. 
Lastly, we studied the population of ICD-recipients as a whole, and did not stratify our 
analyses according to underlying cardiac disease. In sub-analyses on the effect of recording 
direction between patients with and without a previous myocardial infarction, we found 
uniform results in both subsets.




In this conceptual VF-waveform study with 12-lead surface ECG-recordings, we demonstrate 
that AMSA-values are markedly affected by ECG recording direction, with values that are lower 
in lead I than in lead II, in relative terms 20-30%. Appreciating the variability in pad placement 
during cardiac arrest, our findings indicate that a more horizontal recording direction leads to 
lower AMSA-values. For studies on new resuscitation protocols with ‘smart defibrillators’, this 
implies that the corresponding VF-guided defibrillation will less likely direct towards prompt 
administration of the first shock. In an era of studies on AMSA-guided defibrillation timing, 
our findings highlight important aspects for the full interpretation of such trials and may 
provide new directions for the optimal implementation of ‘smart defibrillators’ in the setting 
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Closing the gap between experimental 
studies and the clinical use of a “smart 
defibrillator”: A systematic review on 
calculation of the amplitude spectrum area 




BACKGROUND Ventricular fibrillation (VF) waveform characteristics can predict successful 
defibrillation and clinical outcome. The key VF-characteristic is the amplitude spectrum 
area (AMSA) and a randomized clinical trial investigates a protocol based on VF-waveform 
analysis, dictating defibrillation timing based on AMSA-thresholds. However, a uniform 
approach to assess AMSA is lacking and the impact of methodological variations is 
unknown. 
METHODS Systematic review on human VF-studies, with specific focus on key processes 
and related factors involved in AMSA-assessment: data acquisition (e.g., sampling 
frequency, SF), selection and processing (e.g., segment length, SL) and AMSA-calculation 
(e.g, AMSA-interval, AI). Moreover, we studied the impact of variations in these factors 
on absolute AMSA-values (mVHz) and AMSA-categorization (high: ≥15.5, intermediate: 
6.5-15.5, low: ≤6.5), using our available prospective VF cardiac arrest cohort.
RESULTS In 43 identified studies, SF, SL and AI were reported in 77%, 95% and 63%, 
respectively with a wide variation in AMSA-approaches. In our VF-cohort (n=139, 466 
VF-segments), variation in SL from 1 to 4s markedly affected mean AMSA-values (range 
6.5-12.1, pairwise p<0.001), for variations in AI and SF ranges were 5.7-8.7 mVHz and 
8.7-8.8 mVHz, respectively (both p<0.001). As for categorization, longer SL changed the 
proportion of high AMSA-values from 2% to 23%, while a wider AI changed this from 1% 
to 6% (both p-for-trend<0.001).
CONCLUSION AMSA-methodology in VF-waveform studies is often incompletely reported, 
varies greatly, and impacts absolute AMSA-values and its categorization, potentially 
affecting defibrillation advice. Given the increasing interest to incorporate AMSA in 
“smart defibrillators”, we emphasize the need for a uniform approach.




Ventricular fibrillation (VF) out-of-hospital cardiac arrest (OHCA) is a major health care 
problem, as it occurs frequently and carries a poor survival (20-25%).1, 2 Electrocardiographic 
analysis of the VF-waveform has increasingly been recognized as an easily obtainable tool, 
with the potential to gain patient-specific information in the earliest stages of the arrest.3-6 The 
key characteristic of interest is the amplitude spectrum area (AMSA), a measure combining 
amplitude and frequency characteristics of VF.
AMSA provides an indicator of the myocardial metabolic state and has shown predictive value 
for shock success and neurologically intact survival in clinical studies.7 5, 8-10 Based on the 
fact that high-quality chest compressions can improve the value of AMSA and the inherent 
chances of shock success8, 11, 12, a current randomized trial investigates whether AMSA-guided 
defibrillation may improve outcomes, compared to a conventional resuscitation protocol 
(NCT03237910). In this trial, a new resuscitation protocol is being studied with use of a ‘smart 
defibrillator, with a prompt shock strategy restricted to cases with a high AMSA (≥15.5 mVHz), 
and prolonged chest compressions and delayed defibrillation if AMSA is considered too low. 13
The abovementioned AMSA-trial distinguishes low (≤6.5 mVHz), intermediate (6.5-15.5 
mVHz) and high AMSA-values (≥15.5 mVHz), of which thresholds have been derived 
from large retrospective studies.5, 14 However, the method to obtain AMSA involves three 
different processes: acquisition of data using a certain device, selection and processing of 
VF-signals and calculation of AMSA.15 Each process contains different factors, which have 
interchangeably been used in current literature.4, 5, 16-19 As a potential result, reported AMSA-
values vary widely, ranging from a maximum of 10 in the one study, up to 100 mVHz in others. 
This hampers comparability and interpretation, and complicate the derivation of uniform 
AMSA-thresholds to be used in clinical practice. 
Although of potential importance, differences in AMSA-methodology have never been 
described and information on the impact on AMSA-values in real-world VF-patients is lacking. 
Therefore, we performed a systematic review on AMSA methodology, focusing on variations in 
the three important processes as described above. Second, we aimed to quantify the impact 
of key methodologic factors on the resulting absolute AMSA-value, as well as on classification 






The methodology and report of the present analyses are based on the recommendations of the 
Cochrane Collaboration, the PRISMA statement and the Moose group. A systematic electronic 
search was performed on PubMed, EMBASE and Web of Science. MeSH headings included: 
‘ventricular fibrillation’, ‘ventricular flutter’ and ‘ventricular tachycardia’. Further search terms 
such as “amplitude spectrum area”, “amplitude spectral area” and “AMSA” were added to 
identify relevant articles.  Exact search queries can be found in Supplement File 1. Moreover, a 
manual search was performed of citations from key primary articles (Snowball method).
INCLUSION AND EXCLUSION CRITERIA
We aimed to review original research articles describing the AMSA in human subjects. 
Duplicates were erased using EndNote (Version X9, Clarivate Analytics, Philadelphia, USA). 
Subsequently, we excluded the following articles: non-human studies, review articles, expert 
opinion articles, case reports and conference abstracts.
DATA EXTRACTION
Data was extracted from all included articles using a prespecified data extraction form 
(Supplement File 2) and performed separately by two investigators (JT, JN).  In case of 
discrepancies, data were extracted by a third reviewer (MB), whose judgement was decisive.
AMPLITUDE SPECTRUM AREA
Assessment of AMSA consists of three consecutive processes (Figure 1, Table 1). The first 
process is acquisition of VF-waveform signals using a certain device. An important factor in 
this process is the sampling frequency of the used device. The second process is selection and 
processing of the VF-signals. Key factors in this process are high-pass and low-pass filtering, 
choices with regard to the length of the selected VF-signal and the use of either artifact-
free segments or chest compression-corrupted VF-signals. Subsequently, the VF-signal is 
transformed to the frequency domain using a Fourier transform. The third and last step is 
AMSA-calculation. The AMSA (unity: mVHz) is defined as the sum of all individual products of 
the frequencies and corresponding amplitudes in the frequency spectrum. Key factor in this 
process is the frequency interval over which the calculation is performed.
In the largest VF-registry to date, threshold values of AMSA have been determined. Using 
these thresholds, AMSA can be categorized into either ‘low’ (≤6.5 mVHz), ‘intermediate’ (6.5-
15.5 mVHz) or ‘high’ (≥15.5mVHz). In that study, VF-segments are acquired with a sampling 
frequency of 250Hz. VF-waveform segments of 2s are selected and AMSA is calculated over 
a frequency interval of 2-48Hz. In the current study, we consider this approach (250Hz, 2s, 
2-48Hz) as our reference method.
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TABLE 1. OVERVIEW OF IMPORTANT PROCESSES AND FACTORS DURING ASSESSMENT OF THE AMPLITUDE SPECTRUM AREA (AMSA).
Process







- Device sample frequency
- Length of VF-segment





- Observed AMSA values
* see-through CPR or arterfact-free VF 
STUDY AIM
The aim of this systematic review was to provide an overview of all AMSA-approaches used in 
human VF-waveform studies. We sought to assess the proportions of studies that report on 
the abovementioned key factors: 1) sampling frequency, 2) VF-segment length and 3) AMSA 
frequency interval.
Moreover, we aimed to investigate the impact of different methodologic approaches on 
absolute values of AMSA, as well as on classification into predefined AMSA-categories, using 
VF-waveform data of our prospective OHCA-cohort. From each of the three processes of 
AMSA-methodology, we varied a key factor (Table 2) to assess the impact on (1) absolute 
AMSA-values and (2) classification into AMSA-categories.
AMSA-analyses on real-world VF-patients
PROCEDURE
We calculated AMSA-values from VF-waveform data of our prospective OHCA-cohort 
(Nijmegen, The Netherlands), of which details have been described previously.12, 20 In this 
cohort, all patients were treated with the same defibrillator (Lifepak 12, PhysioControl, 
Redmond, USA). For the present analyses, we studied artefact-free segments of VF prior to 
shock delivery.10
All signal analyses were performed using Matlab (R2014b, Mathworks, Natick, USA). VF-
signals were pre-processed with a fourth order Butterworth bandpass filter (1-48Hz). A 
discrete fast Fourier transform was performed on the filtered VF-segment xk for conversion 
to the frequency domain. In analogy to previous reports, AMSA was calculated from the 
obtained frequency spectrum, as the summed product of individual frequencies and their 
corresponding amplitudes over a certain frequency interval (Supplement File 3).
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IMPACT ON ABSOLUTE AMSA-VALUES AND CLASSIFICATION
First, we assessed AMSA-values while varying all methodologic opti ons (i.e. 64 methods in 
total). Second, we assessed absolute AMSA-values by varying only the factors of a single 
process, while keeping the other factors fi xed to the reference method (Table 2). Moreover, 
we assessed the impact on classifi cati on of AMSA into the categories ‘low’, ‘intermediate’ 
and ‘high’.
TABLE 2. KEY FACTORS OF AMSA-METHODOLOGY THAT WERE VARIED IN THE CURRENT STUDY,
Process Factor Variations used
Data acquisiti on Sample frequency 125Hz, 250Hz, 500Hz, 1000Hz*
Selecti on and processing Segment length 1s, 2s, 3s, 4s
AMSA calculati on AMSA frequency interval 2-20Hz, 1-26Hz, 4-48Hz, 2-48Hz
*using the functi on interp in Matlab
ANCILLARY ANALYSES ON SHOCK SUCCESS PREDICTION
To assess whether the predicti ve ability of AMSA diff ered with varying AMSA-methodology, 
we performed ancillary analyses on the ability of AMSA to discriminate between successful 
and unsuccessful shocks. Shock success was defi ned according to established criteria, as 
restorati on of organized rhythm with a rate ≥40/min, commencing within 60 seconds aft er 
defi brillati on.5 For these analyses, we used data prior to the fi rst three shocks of VF-pati ents 
in our OHCA-cohort, as we previously demonstrated that only AMSA prior to these shocks 
was associated with shock success. Analogous to previous methodology, threshold values 
for shock success were obtained at a balanced accuracy and positi ve predicti ve value; AMSA-
thresholds for defi brillati on failure were taken at a negati ve predicti ve value of 95%.5
STATISTICS
All stati sti cal analyses were performed with SPSS (Version 25, IBM, Armonk, USA). Categorical 
variables were reported as numbers (percentages), AMSA-values were reported as means 
± standard deviati ons. AMSA-values resulti ng from the diff erent methods were compared 
using pairwise testi ng, by a repeated measures ANOVA. Post-hoc pairwise comparisons 
were performed using paired t-tests with Bonferroni correcti on. Diff erences in proporti ons 
of AMSA-classifi cati on were tested with use of a Chi square test for trend. For all stati sti cal 
analyses, a p<0.05 was considered stati sti cally signifi cant. 
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1     DATA ACQUISITION 2  SELECTION & PROCESSING
LOW SAMPLE FREQUENCY WIDE AMSA INTERVALLONG VF-SEGMENT
HIGH SAMPLE FREQUENCY NARROW AMSA INTERVALSHORT VF-SEGMENT
AMSA ▲ AMSA ▲
AMSA ▼ AMSA ▼ AMSA ▼
AMSA ▲
3   AMSA CALCULATION
FIGURE 1. CENTRAL ILLUSTRATION – CALCULATION OF AMPLITUDE SPECTRUM AREA.
Schemati c view of the three consecuti ve processes of amplitude spectrum area (AMSA) assessment. Figure shows 
key factors that impact the absolute value of the AMSA of the VF-waveform, as calculated from a defi brillator 
electrocardiogram. A low sample frequency, long VF-segment and a wide AMSA-interval can increase the value of 
AMSA, while a high sample frequency, short VF-segment and narrow AMSA-interval can lead to lower AMSA-values. 
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FIGURE 2. PRISMA DIAGRAM
Results
ARTICLE SELECTION
In total, 507 records were identified by our search queries (PubMed: 89, EMBASE: 187, Web 
of Science: 231). After removal of duplicates (n=197) and exclusion by article type (n=112), 
198 unique full-text articles were screened. For the present analyses, we included 43 articles 
(Figure 2). 
STUDY DESCRIPTIONS
Study descriptions are reported in Table 3. Of the 43 included articles, the majority (67%) had 
a retrospective design. Studies mainly involved OHCA populations (84%), but combinations 
of both out-of-hospital and in-hospital cardiac arrest (7%) and implantable cardioverter 
defibrillator (ICD) patients (9%) were also present. The median number of patients per study 
was 190 (interquartile range 90-285). AMSA was mostly described as amplitude spectrum 
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area (56%), but other variants such as amplitude spectral area (19%), amplitude spectrum 
analysis (12%), amplitude spectrum relationship (5%) or multiple descriptions in one article 
(9%) were found.
REPORT OF AMSA METHODOLOGY
Data acquisition: With regard to data acquisition, the sample frequency of the used device 
was reported in 77% (33/43) of the studies. Most studies (15/33) reported 250 Hz, but 
observed sample frequencies ranged between 125-2000 Hz.
Selection and processing: The used segment length was reported in 95% (41/43) of all articles. 
The majority (38/41) used a fixed segment length, while 3 studies used variable segment 
lengths. The length of the VF-segment ranged from 1s to 10s, while a segment of 4.1s was 
most frequently observed (11/38). Eighty-four percent of the studies (36/43) mentioned the 
use of CPR-artefacts. Most studies (31/36) used artefact free VF-segments, while 5/36 studies 
reported on VF-segments through chest compressions. As for signal processing, only 58% 
(25/43) of the studies reported on the used filter settings, which showed a wide disparity. 
A 2-48 Hz filter range was most commonly used (5/25). In the other 20 studies, 13 different 
filter ranges were described. Windowing settings were reported in 19% (8/43) of the studies, 
most frequently involving a Hanning window (5/8).
AMSA-calculation: The frequency interval over which AMSA was calculated was reported in 
63% of the cases (27/43). The majority of the studies used 4-48 Hz (7/27), while six studies 
used an AMSA frequency interval of 2-48 Hz. Moreover, three studies used 1-26 Hz and three 
studies used 2-20 Hz. Other AMSA frequency intervals are reported in Table 3.
IMPACT ON ABSOLUTE AMSA-VALUES
In our OHCA-cohort of 139 patients (age 63 ± 14 years, 71% males), we calculated AMSA prior 
to 466 shocks. Mean AMSA-values of all approaches are shown in Figure 3. On average, the 
lowest AMSA-values were found with a sample frequency of 1000 Hz, a VF segment length of 
1s, and an AMSA frequency interval of 2-20 Hz (4.2 mVHz ± 2.3). Highest AMSA-values were 
found with a sample frequency of 125 Hz, a 4s VF-segment, and a AMSA frequency interval 
of 2-48 Hz (12.2 mVHz ± 6.0). 
When using the refence method, we observed a mean AMSA-value of 8.7 ± 4.3 mVHz (Figure 
4). When adjusting the sample frequency only, mean AMSA-values ranged from 8.7 to 8.8 
mVHz (p<0.001 for pairwise comparison, factor 1.01); adjusting the segment length resulted 
in a range of 6.5 to 12.1 mVHz (p<0.001, factor 1.87), and varying the frequency interval led 
to a range of 5.7 to 8.7 mVHz (p<0.001, factor 1.53). Post-hoc pairwise testing demonstrated 
significant differences between all described factors, except between sample frequencies of 
500 Hz and 1000Hz.
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FIGURE 3. INFLUENCE OF METHODOLOGICAL APPROACH ON ABSOLUTE AMSA VALUES.
Figure presenting mean AMSA values (z-axis) as obtained with different approaches based on variations in sampling 
frequency, sample length (both y-axis) and AMSA-interval (x-axis). AMSA = amplitude spectrum area; Hz = Hertz.
FIGURE 4. IMPACT OF INDIVIDUAL KEY FACTORS ON ABSOLUTE AMSA VALUES.
Values are presented as means and standard deviations. As reference method, the method of Ristagno et al was used 
(250Hz, 2s, 250Hz); AMSA = amplitude spectrum area.




Using the reference method, the total proportions of low, intermediate and high AMSA-
values were 164 (35.2%), 272 (58.4%) and 30 (6.4%) respectively. The impact of varying 
the sample frequency, segment length and AMSA frequency interval on AMSA classification 
is shown in Figure 5. No differences in AMSA classification were found for the different 
sample frequencies (p-for-trend = 0.99). When varying the segment length, the proportion 
of high AMSA-values increased from 2% to 23% with increasing segment lengths of 1s to 
4s respectively (p-for-trend < 0.001). As for the AMSA frequency interval, the amount of 
high AMSA-values increased with a broader AMSA frequency interval (1% to 6%, p-for-
trend<0.001).
ANCILLARY ANALYSES ON SHOCK SUCCESS PREDICTION
In total, 108/277 (39%) shocks with a known shock outcome were marked as successful. The 
reference method yielded an AUC of 0.71 (0.64-0.77), p<0.001, with a threshold value of 11.5 
mVHz for shock success, while the threshold for shock failure was 4.2 mVHz. No significant 
differences were found in shock success prediction between all methods. By varying the key 
factors of AMSA-methodology, we found threshold values for shock success ranging between 
7.8-16.4 mVHz and for failure between 2.3-5.8 mVHz (Supplement File 4).








 AMSA ≥ 15.5  AMSA 6.5 - 15.5  AMSA ≤ 6.5 
FIGURE 5. CLASSICIATION INTO AMSA CATEGORIES. 
Figure representing classification into AMSA-categories, using varying methodological options for AMSA (sample 
frequency: p-trend=0.98; segment length: p-trend<0.001; AMSA-frequency interval: p=trend<0.001). Black = high 
AMSA (≥15.5 mVHz); dark grey = intermediate AMSA (6.5-15.5 mVHz); light grey = low AMSA (≤6.5 mVHz). 
 
Discussion 
Given that the AMSA is under current investigation in a randomized trial to guide shock 
delivery during VF cardiac arrest, we performed a systematic review on its methodology. In 
this review, which included 43 studies describing the AMSA in human VF-patients, we 
observed that AMSA-methodology was often incompletely reported, i.e. data on at least 
one of the key factors (sample frequency, segment length, frequency interval) was missing 
in 49% of the studies. Moreover, we found a wide disparity of methodological approaches 
used for AMSA-assessment. In our analyses on the clinical impact of such methodological 
variations, we found that the used VF-segment length most markedly affected absolute 
AMSA-values, ranging from 6.5 to 12.1 mVHz while calculated on the same VF-cohort. 
Classification of AMSA-values using prevailing thresholds was also affected by VF-segment 
length, as well as by the used AMSA-frequency interval. Given the increasing interest to 
incorporate AMSA-analysis into “smart defibrillators”, we emphasize the need for a uniform 
FIGURE 5. CLASSICIATION INTO AMSA CATEGORIES.
Figure representing classification into AMSA-categories, using varying methodological options for AMSA (sample 
frequency: p-trend=0.98; segment length: p-trend<0.001; AMSA-frequency interval: p=trend<0.001). Black = high 
AMSA (≥15.5 mVHz); dark grey = intermediate AMSA (6.5-15.5 mVHz); light grey = low AMSA (≤6.5 mVHz).
Discu sion
Given that the AMSA is under current investigation in a randomized trial to guide shock 
delivery during VF cardiac arrest, we performed a systematic review on its methodology. 
In this review, which included 43 studies d scribing th  AMSA in hum n VF-patients, we 
observed that AMSA-methodology was often incompletely ported, i. . data on at least one 
of the key factors (sample frequency, segment length, frequency interval) was missing in 49% 
of the studies. Moreover, we found a wide disparity of methodological approaches used for 
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AMSA-assessment. In our analyses on the clinical impact of such methodological variations, 
we found that the used VF-segment length most markedly affected absolute AMSA-values, 
ranging from 6.5 to 12.1 mVHz while calculated on the same VF-cohort. Classification of 
AMSA-values using prevailing thresholds was also affected by VF-segment length, as well as 
by the used AMSA-frequency interval. Given the increasing interest to incorporate AMSA-
analysis into “smart defibrillators”, we emphasize the need for a uniform approach.
THE AMSA-TRIAL
Over the years, AMSA has become the key VF-waveform characteristic, given its predictive 
value for defibrillation success and neurologically intact survival after cardiac arrest.4, 5 21 Based 
on large observational OHCA-studies, threshold values have been derived to classify AMSA-
values into either “high”, “intermediate” or “low”.  A current randomized trial investigates 
a new resuscitation protocol with defibrillation timing based on real-time AMSA-analysis, 
versus a conventional shock-first strategy. In short, immediate defibrillation is only performed 
when AMSA is high (≥15.5 mVHz), while the first shock is being postponed for additional 
chest compressions if AMSA is considered intermediate (6.5-15.5 mVHz) or low (≤6.5 mVHz). 
Delivery of the second shock may be further delayed if AMSA persists ≤6.5 mVHz.
AMSA-METHODOLOGY
Given the use of AMSA in a randomized and its high potential to change treatment strategies 
in a near future, uniform assessment seems crucial. To assess AMSA from the VF-waveform, 
three consecutive processes are being followed: data acquisition, selection and processing 
and AMSA-calculation (Figure 1, central illustration). With regard to data acquisition, many 
different devices have been described, typically without specification of built-in signal 
processing characteristics, which may potentially cause important differences in the analysed 
“raw” signals. We observed that the majority of the analysed studies used artefact-free VF-
segments, i.e. without noise caused by chest compressions, from in-field ECG-registrations 
recorded by ambulance personnel. Pre-processing of these exported ECG-recordings mostly 
contained bandpass filtering of the VF-waveform over a certain frequency range. The 
subsequent calculation of AMSA is performed over the so-called “AMSA frequency interval”, 
which’ range is typically narrower than the applied filter range. A remarkable finding, observed 
in multiple studies, was that some frequencies of the AMSA-frequency interval process were 
already filtered out by a bandpass filter during the process of signal processing, which seems 
counterintuitive. The final step is calculation of the AMSA. This involves a summation of 
all products of individual frequencies and there corresponding amplitudes rather than the 
mathematical area under the curve. Therefore, we feel that the term amplitude spectrum 
analysis would be preferred above amplitude spectrum area.
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IMPACT ON AMSA VALUES
Importantly, using different approaches on one VF-segment, can result in different absolute 
AMSA-values, depending on methodologic choices. The marked differences in mean AMSA-
values that we observed among all publications is most likely the result of varying factors 
in the three main processes of AMSA-assessment. To study this issue, we systematically 
obtained ECG-tracings of VF-patients in our own OHCA-cohort and adjusted key factors in the 
assessment of AMSA: sampling frequency, VF-segment length and AMSA frequency interval. 
Using the reference method of Ristagno et al (250Hz, 2 seconds, 2-48Hz), the mean AMSA 
was 8.7 mVHz, a value that is in line with the results of that study.5 When combining these 
factors, we found AMSA-variations up to 300%, when calculated with different approaches.
In our analyses, the individual factors with the most apparent influence on absolute AMSA-
values were the length of the VF-segment and the AMSA frequency interval (Figure 3). 
Varying the VF-segment length from 1s to 4s led to an 87% difference in absolute values, and 
had also significant impact on classification into AMSA-categories. This may be explained by 
the fact that VF is not a stationary signal. In fact, VF has a varying appearance and is typically 
characterized by a rapidly fluctuating amplitude and frequency. It is more presumable for 
shorter than for longer VF-segments to be influenced by those fluctuations, potentially 
contributing to the observed differences between the used segment lengths. Another 
plausible explanation of the differences in AMSA-values according to the VF-segment length, 
might be that a Fourier transformed signal of a 4s VF-segment has a four times narrower 
frequency resolution (0.25 Hz) when compared to a 1s VF-segment (1Hz), causing differences 
in the frequency spectrum especially with regard to the height of the dominant peaks. It has 
previously been demonstrated that the predictive value of AMSA is maintained also with 
shorter VF-segments18, though our findings suggest that threshold values are influenced by 
the length of the VF-segment. Therefore, we recommend a fixed segment length to be used 
in future AMSA guided shock algorithms.
As for the frequency interval, it is reasonable that narrower frequency bands, with per 
definition fewer (high frequency) data points, cause lower AMSA values. Although the 
dominant peak of VF is commonly located around 5Hz, we observed that taking into account 
higher frequencies (up to 48Hz) significantly increased the AMSA-value, with differences up 
to 53%. Interestingly, higher frequency ranges have previously shown to contribute to the 
predictive value of the VF-waveform.22 Given that frequencies up to 48Hz are involved in all 
key papers, we recommend to include these higher frequencies for AMSA calculation.
Although the used sample frequency caused significant differences between AMSA-values, 
the impact was modest (2%) and classification to either high, intermediate or low AMSA-
values was not affected. The most plausible explanation for this modest impact is that – as 
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opposed to the segment length – the sampling frequency does not influence the frequency 
resolution of the Fourier transform.
As mentioned, varying the AMSA-methodology led to marked differences in classification into 
high, intermediate or low AMSA. The most marked differences were found for the segment 
length and AMSA frequency interval. A “low” AMSA was found in 59% of the cases when a 
VF-segment length of 1s was used, while this occurred only in 15% of cases when using a 4s 
VF-segment. These observations underscore that differences in absolute AMSA-values in fact 
impact classification, and thus potentially impact decisions on shock timing when used in 
clinical studies with “smart defibrillators”. 
IMPLICATIONS
Given the marked AMSA-differences observed in our study, our findings imply that variations 
in AMSA-methodology may potentially limit innovative resuscitative strategies with a “smart 
defibrillator”. The observation that AMSA could be classified as low when using a specific 
method, but as high when using another, suggests that threshold values acquired in one 
cohort, cannot be interchangeably used in other cohorts with other devices and AMSA-
methods.
 
Although we observed important AMSA-differences among the included articles, it should be 
noted that information from other strategies to calculate AMSA is still valuable. While some 
studies may follow a different approach to calculate AMSA, the reported differences observed 
in such a study still give insight into the VF-waveform from a more pathophysiological, 
research point of view. Our observations that the predictive ability for shock success persisted 
with the use of varying methodological approaches (Supplement 4), support this hypothesis. 
However, as AMSA-methodology impacted threshold values for shock success and failure, 
there are important clinical implications which should be accounted for in future studies 
on AMSA-guided resuscitation. From a clinical point of view, the varying AMSA-values limit 
generalizability to algorithms with absolute cut-off values to be used in clinical practice or 
with regard to data pooling. Importantly, for a better understanding and interpretation for 
AMSA-values in different studies, our findings underscore the importance of mentioning all 
steps of the mathematical process.
In follow up of this study, other factors that potentially affect the VF-waveform should be 
investigated. Such factors include more practical issues such as placement of the defibrillator 
pads, but also the influence of underlying etiology, which is known to affect VF-measures 
and, potentially, threshold values for shock success.




In order to classify AMSA-values to either a high, intermediate, or low category, we used 
thresholds based on previous studies. These threshold values are obtained from the largest 
registry to date, but may differ in our population. Given this limitation and the potential 
importance for AMSA-guided shock delivery, it seems plausible to validate threshold values 
per population, prior to implementation in clinical practice.
Although prospective in design, our VF-cohort is of modest sample size and restricted to 
patients with analyzable ECG recordings. Most of the analyzed studies were based on 
observational data from retrospective studies, with potential impact on the generalizability 
of AMSA-values in these selected populations. The lack of large prospective registries on 
VF-waveform analysis limits the comparability of AMSA thresholds and VF-waveform 
characteristics in general. Therefore, large prospective studies on this topic are highly 
warranted.
Conclusion
In current literature, there is a wide disparity in methodological characteristics to calculate 
AMSA from the VF-waveform. Key differences include the used devices and associated 
sample frequencies, the length of the used VF-segments and the frequency intervals over 
which AMSA is calculated. Importantly, in our OHCA-cohort, the used AMSA-method had 
significant impact on the AMSA-value, with up to 3-fold absolute differences when calculated 
from identical VF-segments. Moreover, AMSA-methodology impacted classification into 
established categories, which are under current investigation in a randomized trial. As such, 
variations in AMSA-methodology may affect the shock advice given by a ‘smart defibrillator’. In 
an era of increasing interest in AMSA-guided resuscitative strategies, we therefore emphasize 
the need for a uniform approach.
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TABLE 3. OVERVIEW OF AMSA METHODOLOGICAL CHARACTERISTICS AMONG THE INCLUDED STUDIES. 






2004 Eftestol11 77 OHCA Ambu Lifepak 12 125
2004 Young23 46 OHCA Ambu Forerunner AED 200
2005 Watson24 110 OHCA Ambu Heartstart 3000 -
2007 Li25 232 OHCA - Multiple -
2008 Gundersen26 221 OHCA+IHCA Ambu Heartstart 4000 SP 200
2008 Indik27 45 ICD 12 lead ECG BARD 2000
2008 Li28 258 OHCA Ambu - -
2008 Ristagno29 90 OHCA Ambu Multiple 250
2009 Olasveengen16 101 OHCA Ambu Lifepak 12 125
2010 Lederer30 9 OHCA Ambu PIC 50 defibrillator 500
2010 Lin31 155 OHCA Ambu ForeRunner AED 200
2011 Endoh32 152 OHCA Ambu Multiple 200
2011 Hall33 206 OHCA Ambu Multiple -
2012 Nakagawa34 83 OHCA Ambu Multiple 250
2012 Nowak35 197 OHCA Ambu Heartstart 4000 500
2012 Shandilya36 57 OHCA Ambu E-Series monitor/defibrillator 250
2012 Shanmugasundaram37 44 OHCA Ambu - 250
2013 Firoozabadi38 116 OHCA+IHCA Ambu Heartstart 4000 SP 200
2013 Lo39 150 OHCA Ambu ForeRunner AED 200
2013 Nakagawa40 81 OHCA Ambu Multiple 250
2013 Ristagno14 609 OHCA Ambu Multiple 250
2014 Howe41 41 OHCA+IHCA Ambu Samaritan AED 250
2014 Indik4 89 OHCA Ambu E series monitor/defibrillator 250
2014 Schoene8 390 OHCA Ambu - -
2015 Bonnes17 190 ICD 12 lead ECG BARD LabSystem 1000
2015 Indik10 140 OHCA Ambu E series monitor/defibrillator 250
2015 Ristagno5 1617 OHCA Ambu Multiple 250
2016 Coult18 442 OHCA Ambu HeartStart MRx 250
2016 He42 199 OHCA Ambu Multiple -
2016 Hidano43 430 OHCA Ambu Multiple -
2016 Shandilya44 153 OHCA Ambu - -
2017 Bonnes45 193 ICD 12 lead ECG BARD LabSystem 1000
2017 Hulleman46 716 OHCA Ambu + AED Multiple 125
2017 Jin47 257 OHCA Ambu CPR-D-padz 250
2017 Nakagawa19 285 OHCA - - 250
2018 Coult48 692 OHCA Ambu Multiple 250
2018 Salcido49 424 OHCA Ambu - -
2019 Dumas50 716 OHCA Ambu Multiple 250
2019 Thannhauser12 139 OHCA Ambu Lifepak 12 125
2019 Chicote51 214 OHCA Ambu MRx monitor defibrillator 250
2020 Hulleman52 990 OHCA Ambu + AED Multiple 125
2020 Thannhauser6 206 ICD 12 lead ECG BARD LabSystem 1000
2021 Frigerio53 112 OHCA Ambu Corpuls monitor/defibrillator -
Systematic review on AMSA-methodology 
111
6






AMSA frequency  
range (Hz)
Observed values  
(range)*
Artefact free 3.0 - - - 2-25 mVHz
- 3.0 - - 3-48 2-39 mVHz
Artefact free - - Hann 1-50 -
Both 10.0 1-30 - - -
Artefact free 4.0 0-30 - - -
Artefact free 4.1 - - 2-20 30-90 mVHz
Both 10.0 1-30 - 4-30 -
Artefact free 4.1 2-48 - 2-48 2-24 mVHz
Artefact free 1.0 - - - 3-50 mVHz
Both 10.0 - - - -
Artefact free 10.0 - - 3-48 1-15 mVHz
Artefact free 5.12 0.5-32 - - 2-32 mVHz
Artefact free 5.0 - - - 8-11 mVHz
- 4.1 1-40 Hanning Multiple 1-40 mVHz
Artefact free 2.5 3-40 - - -
- 7.8 - - - 1-21 mVHz
Artefact free 4.0 - - 2-48 3-67 mVHz
Artefact free 5.0 0.9-50 - 1-26 5-200 mVHz
Both 10.0 0.7-30 - 0.-7-30 2-17 mVHz
- 4.1 1-40 Hanning 4-48 0-44 mVHz
Artefact free 2.05 2-48 Tukey FFT 4-48 7-17 mVHz
Artefact free 4.1 1-40 Hanning 4-48 -
Artefact free 4.1 0-50 - 4-48 5-105 mVHz
Artefact free 5.0 - - - 9-10 mVHz
Artefact free 4.1 2-20 - 2-20 5-25 mVHz
Artefact free 4.1 - - 4-48 5-85 mVHz
Artefact free 2.05 2-48 Tukey FFT 2-48 1-25 mVHz
Artefact free Multiple - Hanning 1-26 1-90 mVHz
- 2.05 2-48 - - 0-34 mVHz
Artefact free 5.0 - - 4-24 7-14 mVHz
- - - - - -
Artefact free 4.1 2-20 - 2-20 5-22 mVHz
Artefact free Multiple 4-48 - - 4-23 mVHz
Artefact free 2.05 - - - 0-25 mVHz
Artefact free 4.1 - - 5-12 0-43 mVHz
Both 5.0 4-30 - 1-26 4-9 mVHz
- 3.0 - - - 0-20 mVHz
Artefact free 5.0 4-48 Hanning 4-48 0-16 mVHz
Artefact free 3.0 2-48 - 4-48 5-16 mVHz
Artefact free 2.0 0.5-30 - 2-48 0-40 mVHz
Artefact free Multiple 4-48 - - 1-28 mVHz
Artefact free 4.1 1-48 - 2-48 9-18 mVHz
Artefact free 2.0 0.5-30 - 2-48 1-38 mVHz
*if AMSA ranges were not specifically mentioned, ranges have either been extrapolated from described means and standard 
deviations, or estimated from graphs.
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Supplementary file 1 - Search queries
TABLE S1. AMSA REVIEW - SEARCH QUERIES AND RESULTS.
PUBMED (“Tachycardia, Ventricular”[Mesh] 
OR “Ventricular Fibrillation”[Mesh] 
OR “Ventricular Flutter”[Mesh] OR 
Ventricular fibrillation*[tiab] OR 
Ventricular flutter*[tiab] OR VF[tiab] OR 
PVT[tiab] OR (Polymorph*[tiab] AND 
ventricular tachycardia*[tiab]))
AND
(Amplitude spectr*[tiab] OR AMSA[tiab])
89
EMBASE (exp heart ventricle fibrillation/ or 
heart ventricle flutter/ or polymorphic 
ventricular tachycardia/ OR (Ventric* 
fibrillation* OR Ventric* flutter* OR 
VF OR PVT OR (Polymorph* ventric* 
tachycardia*)).ti,ab,kw.)
AND
(Amplitude spectral area/ OR (Amplitude 
spectr* OR AMSA).ti,ab,kw.)
187
Web Of Science (Ventric* fibrillation* OR Ventric* 
flutter* OR VF OR PVT OR Polymorph* 
ventric* tachycardia*)
AND
(Amplitude spectr* OR AMSA)
231
Last search performed on 22-Feb-2021
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Study design [  ] Prospective       







Device [  ]  Defibrillator paddles
[  ]   AED
[  ]  12 lead ECG leads:
[  ]  Other ………………
Device – name 
Device – manufacturer
Device – sampling rate (Hz)
VF analysis
VF - segments [  ] First shock
[  ] Subsequent shocks
[  ] First and subsequent shocks
[  ] Non shock-related segment (e.g. initial or CPR-free 
segments)
[  ] Other
VF – Segment options [  ]  Artefact free VF
[  ]   See-through chest compressions
[  ]  Both
[  ] Other
VF – segment length (seconds)
VF – number of samples
VF – filtering options
VF – windowing options
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AMSA – abbreviation [  ] Amplitude spectrum area
[  ] Amplitude spectral area
[  ] Other ………………
AMSA – mathematical description 
AMSA – frequency band (Hz)
AMSA range [  ]   < 10   mVHz
[  ]    < 30  mVHz
[  ]    < 100  mVHz
[  ]    > 100  mVHz
Study outcome
Primary outcome [  ]  Defibrillation success 
         [ ]   Termination of fibrillation
         [ ]   Organized rhythm
         [ ]   ROSC
[  ]   Survival 
         [ ]   hospital admission
         [ ]   hospital discharge
         [ ]   ……. days
[  ]  Neurologically intact survival
[  ]  Other   ………………..
Notes
Supplement File 2 (continued) – Data collection form 
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Supplement File 3 – AMSA formula
In the current study, AMSA was calculated following:
 AMSA = 
2
N
� |x ̂k ∙ fk |
N-1
k=0
in which x ̂k, k = 0,..,N - 1, represents the Fourier transformed VF-segment (mV) and fk , 
k = 0,..,N - 1 the corresponding frequencies (Hz). In this sum only those indices k are taken 
into account for which flow ≤ fk ≤  fhigh in which flow and fhigh represent respectively the lower and 
higher boundary of the frequency interval over which AMSA is calculated.12 
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Supplement File 4 – Ancillary analyses on shock success 
prediction with different AMSA methods





125 Hz 0.704 (0.642-0.766) <0.001 11.8 mVHz 4.3 mVHz
250 Hz 0.706 (0.644-0.767) <0.001 11.5 mVHz 4.2 mVHz
500 Hz 0.706 (0.644-0.768) <0.001 11.4 mVHz 4.2 mVHz
1000 Hz 0.706 (0.644-0.768) <0.001 11.4 mVHz 4.2 mVHz
Segment length
1s 0.698 (0.636-0.761) <0.001 8.9 mVHz 2.7 mVHz
2s 0.706 (0.644-0.767) <0.001 11.5 mVHz 4.2 mVHz
3s 0.707 (0.645-0.769) <0.001 14.8 mVHz 5.0 mVHz
4s 0.702 (0.640-0.764) <0.001 16.4 mVHz 5.8 mVHz
Frequency interval
2-20 Hz 0.697 (0.635-0.759) <0.001 7.8 mVHz 2.3 mVHz
1-26 Hz 0.700 (0.638-0.763) <0.001 9.1 mVHz 2.9 mVHz
4-48 Hz 0.705 (0.643-0.767) <0.001 11.1 mVHz 3.1 mVHz
2-48 Hz 0.706 (0.644-0.767) <0.001 11.5 mVHz 4.2 mVHz
Values are presented with area under the receiver operating characteristic curve (AUC) and 95% confidence 
intervals. The threshold for shock success is obtained at the balanced accuracy and positive predictive value for 
defibrillation success, while the threshold for defibrillation failure was taken at a negative predictive value of 95%. 
AMSA = amplitude spectrum area.
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Ventricular fibrillation 
waveform characteristics 
differ according to the presence 
of a previous myocardial infarction: 




BACKGROUND Characteristics of the ventricular fibrillation (VF) waveform reflect arrest 
duration and have been incorporated in studies on algorithms to guide resuscitative 
interventions. Findings in animals indicate that VF characteristics are also affected by the 
presence of a previous myocardial infarction (MI). As studies in humans are scarce, we 
assessed the impact of a previous MI on VF characteristics in ICD-patients. 
METHODS Prospective cohort of ICD-patients (n = 190) with defibrillation testing at the 
Radboudumc (2010–2013). VF characteristics of the 12-lead surface ECG were compared 
between three groups: patients without a history of MI (n = 88), with a previous anterior 
(n = 47) and a previous inferior MI (n = 55). 
RESULTS As compared to each of the other groups, the mean amplitude and amplitude 
spectrum area were lower, for an anterior MI in lead V3, and for an inferior MI in leads II 
and aVF. Across the three groups, the bandwidth was broader in the leads corresponding 
with the infarct localization. In contrast, the dominant and median frequencies only 
differed between previous anterior MI and no history of MI, being lower in the former. 
CONCLUSION The VF waveform is affected by the presence of a previous MI. Amplitude-
related measures were lower and VF was less organized in the ECG-lead(s) adjacent to 
the area of infarction. Although VF characteristics of the surface ECG have so far primarily 
been considered a proxy for arrest duration and metabolic state, our findings question 
this paradigm and may provide additional insights into the future potential of VF-guided 
resuscitative interventions.




Ventricular fibrillation (VF) is the first observed cardiac rhythm in about 30% of out-of-hospital 
cardiac arrests (OHCAs).1 As a potential strategy to improve the rather poor outcomes, the VF 
signal itself has become subject of study.2–4 
It has been demonstrated that the VF waveform can be related to survival and favorable 
neurological outcome.5–7 Given that the VF waveform reflects arrest duration and myocardial 
metabolic state, VF characteristics have also been studied to predict shock success, and may 
be used to guide the decision whether to opt for a strategy of immediate defibrillation or 
CPR first.2–5 Based on this idea, a randomized trial was designed in which first shock delivery 
was guided by a VF-based algorithm incorporated into an automatic external defibrillator.8 
This strategy did not result in improved outcomes. The basis for this study was derived from 
many observational studies that suggested a positive association between VF waveform 
characteristics and shock success, albeit generally with modest predictive values.2–5,9,10 
In view of the above, there is room for improvement. The observed results may be explained 
by the fact that the appearance of the VF waveform does not merely reflect time delay or 
metabolic state, but is influenced by other factors as well. Observations in animals indicate that 
the presence of a myocardial infarction (MI) is associated with less coarse VF.11,12 Accordingly, 
it may be difficult to differentiate whether fine VF reflects a longer arrest duration – with a 
lower chance of successful defibrillation – or is related to a short arrest duration in an animal 
with an MI. Evidence on this topic in humans is scarce, although there are studies using 
intracardiac recordings that demonstrate that the VF waveform is affected by the presence 
of a previous MI.13,14 
Therefore, we studied a large series of patients who underwent defibrillation testing after 
implantable cardioverter defibrillator (ICD) implantation and assessed the impact of a previous 
MI and its localization on VF waveform characteristics of the surface electrocardiogram (ECG). 
Methods
PATIENT POPULATION
We identified all first ICD implantations with defibrillation testing at the Radboud University 
Medical Center from June 2010 till December 2013. For the present analysis, we studied 
patients with a previous anterior MI, a previous inferior MI and those without a history of MI. 
Exclusion criteria were the following: age <18 years, congenital heart disease, right-sided ICD 
implants, no analysable12-lead ECG-recording of the induced VF. In addition, patients were 
excluded in case of a history of MI that did not involve the anterior or inferior wall. Patients 
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with both anterior and inferior wall infarctions were excluded as well. Given the observational 
design of the study, written informed consent was not necessary to obtain according to the 
Dutch Act on Medical Research involving Human Subjects. 
ICD IMPLANTATION AND TESTING
The devices implanted were Medtronic® (Minneapolis, MN,USA), St Jude Medical® (St. 
Paul, MN, USA) or Biotronik® (Berlin, Germany) ICD or cardiac resynchronization therapy 
defibrillator systems with transvenous single coil leads. Routine defibrillation testing was 
performed after ICD implantation to test the ability of the implanted device to sense, detect 
and terminate VF appropriately. After sedation with propofol, VF was induced using T-wave 
shock, direct current pulses or 50 Hz burst pacing. The presence of VF, defined as a rapid 
(around 300 bpm) grossly irregular ventricular rhythm with marked variability in QRS cycle 
length, morphology, and amplitude, was confirmed on surface ECG-recordings.15 Sequential 
shocks were delivered (15–25–35 joule) until VF was terminated. In case of persisting VF after 
the third shock, an external defibrillation shock was delivered. 
DATA ACQUISITION
Demographic, clinical and echocardiographic parameters were collected from patient 
records. During defibrillation testing, a standard 12-lead ECG of the induced VF was recorded 
(sampling frequency 1000 Hz; 16-bit A/D converter) with BARD® LabSystem (Lowell, MA, 
USA). Lead I, II, aVF,V1, V3 and V6 were selected for VF analysis, as these represent the main 
electrical vectors and include uni- and bipolar leads.
VF-WAVEFORM ANALYSIS
VF waveform characteristics were determined using a time segment of 4.1 s prior to first shock 
delivery (4096 time-points). The signal was pre-processed with a 2 Hz high-pass filter and a 20 
Hz low-pass filter. To study different aspects of the VF waveform, we analyzed several previously 
studied VF characteristics.4,16,17 From the ECG-signal in the time domain, we determined the 
mean absolute amplitude. Subsequently, the signal was converted to the frequency domain 
by using a fast Fourier transform to visualize the frequencies and corresponding amplitudes 
which the sampled VF signal contains.4 From the amplitude frequency spectrum, the amplitude 
spectrum area (AMSA) was calculated as the summed product of individual frequencies and 
their corresponding amplitudes over an interval of 2–20 Hz.16,17 From the power spectrum, we 
determined the dominant frequency, which is the frequency where the power spectrum attains 
its maximum.4 In addition, we determined the median frequency, i.e. the frequency for which 
the integrated signal power was one half of the total integrated power. Finally, we calculated the 
bandwidth, which is the difference in frequency corresponding to the first and third quartile of 
the total power, providing a measure of the spread in frequencies.17 Definitions of the analyzed 
VF characteristics are described in detail in the Appendix. Calculations were performed using 
Matlab (version 2011a, Mathworks, Natick, MA, USA).
Impact of prior MI on the VF-waveform
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OUTCOME MEASURES AND STUDY GROUPS 
The outcome measures are the ECG-characteristics of the VF waveform as described above. 
These were compared between three study groups: patients with a previous anterior MI, 
a previous inferior MI and without a history of MI. Evidence for the presence or absence 
of a previous MI was based on reports in the medical charts. MI was defined according to 
the ESC criteria.18 Infarct localization was based on a combination of information obtained 
from ECGs (e.g. area with ST-elevation or pathological Q waves) and coronary angiographies, 
and was confirmed by imaging reports.18,19 Imaging was performed and analyzed as part of 
daily clinical practice following the recommendations of the ACC/AHA/ESC guidelines for ICD 
therapy and was not part of a particular study protocol.18,20 In short, for MRI the presence of 
delayed enhancement, regional wall motion abnormalities and information on myocardial 
thick-ness and thickening were used in the diagnosis and localization of the MI. In case of 
echocardiography, information on regional differences in wall motion, myocardial thickness 
and thickening were used. For nuclear imaging, the combination of a persistent perfusion 
defect and wall motion abnormalities were used as indicators. For all modalities, wall motion 
abnormalities had to be present in at least two corresponding segments. 
STATISTICAL ANALYSIS
Statistical analysis was performed with IBM SPSS statistics software version 20 (IBM 
Corp., Armonk, NY, USA). Baseline variables and the VF waveform characteristics were 
compared between the three study groups. Categorical data were expressed as frequencies 
(percentages) and analyzed using the Chi square test. Continuous baseline variables were 
reported as means ± standard deviations and compared using the analysis of variance 
analysis (ANOVA). The VF waveform characteristics were reported as medians (interquartile 
ranges) and compared between the three study groups with the Kruskal–Wallis test. Post hoc 
pairwise comparisons were performed using Mann–Whitney U with Bonferroni correction. A 
p-value of <0.05 was considered statistically significant. 
Results
STUDY GROUP
In total, 337 eligible patients underwent a first ICD implantation with defibrillation testing. 
Twelve-lead ECG-recordings of VF inductions were available in 214 patients; the ECG could 
not be analyzed in 8 patients due to artefacts. Sixteen patients with a previous MI were 
excluded, because they had evidence of infarction of (1) both the anterior and the inferior 
wall (n = 15) or (2) the posterior wall only (n = 1). Accordingly, a total of 190 patients were 
included in the present analysis. Baseline characteristics did not differ between the in- and 




The mean age was 63 years ± 13 and 75% (143/190) were male. In 35% (67/190) of patients, 
ICDs were implanted for secondary prevention. The mean left ventricular ejection fraction 
(LVEF) was 36% ± 14. In 46% (88/190) of patients, there was no evidence of a previous 
MI. A previous anterior MI was present in 25% (47/190) and a previous inferior MI in 29% 
(55/190). Of the subset without a history of MI, left ventricular dysfunction was caused by 
cardiomyopathies, hypertensive or valvular heart diseases in 88% (77/88), while 5% (4/88) 
had a cardiac channelopathy and in 8% (7/88) the cause of the ventricular arrhythmias was 
unknown. Baseline characteristics of the study groups are presented in Table 1.
VF-WAVEFORM CHARACTERISTICS
Study groups: In Figs. 1 and 2, we present the medians with interquartile ranges of the analyzed 
VF characteristics for the study groups. The only lead without between-group differences in 
VF characteristics was V1. The exact numerical values can be found in Supplementary Table 2. 
Previous anterior MI: We observed a lower mean amplitude and AMSA and a broader 
bandwidth for patients with a previous anterior MI in lead V3 than for patients with a 
previous inferior MI and those without a history of MI, respectively. When compared with the 
latter, the mean amplitude and AMSA were lower in lead V6 for a previous anterior MI. The 
dominant and median frequencies were lower for patients with an anterior MI in leads V3, I 
and V6 when compared with those without a history of MI. The adjusted p-values of pairwise 
comparisons are presented in Supplementary Table 3. 
Previous inferior MI: We observed a lower mean amplitude and AMSA and a broader 
bandwidth for patients with a previous inferior MI in leads II and aVF than for patients with a 
previous anterior MI or those without a history of MI, respectively. When compared with the 
latter, the mean amplitude and AMSA were lower and the bandwidth was broader in lead V6. 
The dominant and median frequencies did not differ from those of the other study groups in 
all leads. The adjusted p-values of the pairwise comparisons can be found in Supplementary 
Table 3. 
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TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION.
No previous MI 
n = 88





Age (yrs) 58 ± 14 64 ± 12 68 ± 9 <0.001
Male gender 57 (65) 35 (75) 51 (93) 0.001
Hypertension 30 (34) 18 (38) 23 (43) 0.59
Diabetes 17 (19) 13 (28) 13 (24) 0.53
Atrial fibrillation 26 (30) 11 (23) 20 (36) 0.36
Secondary prevention 24 (27) 16 (34) 27 (49) 0.03
CRT-D 33 (38) 14 (30) 12 (22) 0.14
BMI (kg/m2) 26 ± 4 27 ± 4 28 ± 4 0.13
LVEF (%) 37 ± 16 31 ± 11 38 ± 14 0.09
LVIDd-index (cm/m2) 3.1 ± 0.6 3.2 ± 0.4 3.0 ± 0.4 0.52
QRS duration (ms) 126 ± 31 116 ± 25 125 ± 28 0.16
Creatinine (μmol/l) 109 ± 151 99 ± 66 100 ± 35 0.85
Beta blocker 76 (86) 45 (96) 48 (89) 0.24
ACE inhibitor/ARB 73 (83) 41 (87) 49 (91) 0.41
Aldosterone blocker 31 (35) 28 (60) 15 (28) 0.003
Diuretics 41 (47) 29 (62) 21 (39) 0.07
Antiplatelet 33 (38) 34 (72) 44 (82) <0.001
Anticoagulation 35 (40) 21 (45) 20 (37) 0.73
Cholesterol reducer 35 (40) 41 (87) 48 (89) <0.001
Amiodarone 9 (10) 5 (11) 9 (17) 0.49
Values are n (%) or means ± standard deviations. ACE inhibitor: angiotensin converting enzyme inhibitor, ARB: 
angiotensin receptor blocker, BMI: body mass index, CRT-D: cardiac resynchronization therapy-defibrillator, LVEF: left 
ventricular ejection fraction, LVIDd: left ventricular internal diastolic diameter, MI: myocardial infarction.
Discussion
To our knowledge, this is the largest surface ECG study in humans analyzing the impact of 
the presence of a previous MI and its localization on characteristics of the VF waveform. 
Amplitude-related characteristics of the induced VF waveform were markedly lower in the 
leads adjacent to the area of infarction, i.e. in lead V3 for an anterior MI, and in leads II and 
aVF for an inferior MI. In the leads corresponding with the infarct localization, the bandwidth 
was broader as well, indicating less organized VF. The dominant and median frequencies of 
VF were affected in case of an anterior MI only. Our observations challenge the currently used 
concept that fine VF is a mere proxy for a longer arrest duration and myocardial metabolic 
state, and indicate that the underlying etiology also plays an important role in the appearance 
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FIGURE 1. AMPLITUDE-RELATED VF WAVEFORM CHARACTERISTICS IN THE ANALYZED SURFACE ECG-LEADS.
VF waveform characteristics are presented as medians with interquartile ranges.**p-Value <0.001 for comparisons 
between the three study groups. AMSA: amplitude spectrum area, Hz: hertz, MI: myocardial infarction, mV: millivolt. 
Pairwise comparisons showed significant differences between the following study groups: Mean amplitude: Lead II: 
inferior vs. anterior MI (p < 0.001); inferior vs. no MI (p < 0.001). Lead aVF: inferior vs. anterior MI (p < 0.001); inferior 
vs. no MI (p < 0.001). Lead V3: anterior vs. inferior MI (p = 0.001); anterior vs. no MI (p < 0.001). Lead V6: anterior vs. 
no MI (p = 0.001);inferior vs. no MI (p < 0.001). AMSA: Lead II: inferior vs. anterior MI (p = 0.001); inferior vs. no MI 
(p < 0.001). Lead aVF: inferior vs. anterior MI (p = 0.001); inferior vs. no MI(p < 0.001). Lead V3: anterior vs. inferior 
MI (p < 0.001); anterior vs. no MI (p < 0.001). Lead V6: anterior vs. no MI (p = 0.001); inferior vs. no MI (p = 0.001).
ANIMAL STUDIES
Animal studies primarily investigated the impact of a previous anterior wall infarction, 
induced by ligation of the left anterior descending artery and reported lower VF frequency 
characteristics for this subset when compared to controls.21,22 We observed lower dominant 
and median frequencies in patients with a previous anterior MI as well, but not in case of a 
previous inferior MI. While we focused on early, short-duration, induced VF, animal studies 
analyzed the VF signal at different time points during the arrest.21–23 In these studies, it has 
also been demonstrated that – when compared to arrests in animals with a previous MI – VF 
in the setting of an acute, ongoing MI seems to have even lower frequency characteristics.21,23 
Impact of prior MI on the VF-waveform
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Mapping studies in animals provided insight into the potential electrophysiological background 
of the observed lower frequency characteristics. In dog hearts with a previous MI, it was 
observed that during VF the mean size of activation wavefronts was larger than in controls. 
Larger wavefronts have been associated with lower dominant frequencies on the ECG.24,25
With regard to the amplitude-related VF characteristics, observations in animals were less 
uniform.11,12,21,22,26 This may be related to the fact that some studies analyzed paddle ECGs 
or recordings from needle electrodes (y-axis) – more or less corresponding to lead II of the 
surface ECG – while the localization of the (previous) MI was not in the inferior but in the 
anterior wall.12,21,26 Hypothetically, an effect on amplitude-related characteristics may have 
gone undetected in these studies due to the lack of chest leads.
HUMAN STUDIES
OHCA-setting: Studies on the impact of an MI on VF characteristics in OHCA-patients are 
hampered by a lack of information on the exact underlying etiology, especially in the non-
surviving patients. Nonetheless, for patients with VF in the setting of a suspected acute MI, 
the waveform showed significant differences when compared to patients without acute MI, 
including lower AMSA values.27 In a study on shock success prediction, it was described that 
patients with a prior MI demonstrated a lower median frequency, but not a lower AMSA.5 
However, in the absence of data on the actual arrest etiology, it remains uncertain to what 
extent the baseline characteristics, on the one hand, and the actual underlying etiology, on 
the other, were the primary drivers behind the observed differences in the VF waveform. 
Defibrillation testing: In the above-described context, VF induction during defibrillation testing 
provides a unique setting to study the VF waveform under controlled conditions.13,14,17 As for 
the impact of a previous MI, a small study analyzing limb leads reported a trend towards 
lower VF frequencies in ischemic than in nonischemic heart disease.17 With regard to infarct 
localization, a study of intracardiac recorded VF reported a higher fraction of energy in the 
low frequency region for patients with a previous inferior MI than for an anterior MI.13 
In follow-up of our previous intracardiac ECG study that demonstrated differences in the VF 
waveform related to the history of a previous MI, we now conducted a comprehensive 12-
lead surface ECG study to expand the current knowledge on the impact of an MI and its 
localization on the VF waveform.14 We found that amplitude characteristics were lower in 
V3 for an anterior MI and in II and aVF for an inferior MI, i.e. in the leads adjacent to the 
area of infarction. In contrast, the dominant and median frequencies were lower only in the 
presence of a previous anterior MI (I, V3, V6). An explanation for this finding could be that the 
patients with anterior MIs had larger infarctions, which may have affected the VF waveform to 
a greater extent than the smaller inferior infarctions. This hypothesis is supported by fact that 
the LVEF was slightly lower in the subset with a previous anterior MI than in the other study 
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groups. In lead V6, we observed lower amplitudes and less organized VF both for patients 
with a previous anterior and inferior MI when compared to the subset without an MI. This 
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FIGURE 2. FREQUENCY-RELATED VF WAVEFORM CHARACTERISTICS IN THE ANALYZED SURFACE ECG-LEADS. 
VF waveform characteristics are presented as medians with interquartile ranges. *p-Value <0.05 for comparisons 
between the three study groups. Hz: hertz, MI: myocardial infarction. Pairwise comparisons showed significant 
differences between the following study groups: Dominant frequency: Lead I: anterior vs. no MI (p = 0.026). Lead 
V3: anterior vs. no MI (p = 0.015). Lead V6: anterior vs. no MI (p = 0.009). Median frequency: Lead I: anterior vs. no 
MI (p = 0.019). Lead V3: anterior vs. no MI (p = 0.013). Lead V6: anterior vs. no MI (p = 0.021). Bandwidth: Lead II: 
inferior vs. anterior MI(p = 0.054); inferior vs. no MI (p = 0.012). Lead aVF: inferior vs. anterior MI (p = 0.063); inferior 
vs. no MI (p = 0.017). Lead V3: anterior vs. inferior MI (p = 0.017); anterior vs. no MI (p = 0.001). Lead V6: inferior 
vs. no MI (p = 0.031).




Our findings that both amplitude and frequency characteristics of early VF are affected by a 
prior MI and its localization warrant a more comprehensive concept of the VF waveform that 
goes beyond an indicator of arrest duration. In addition, previous studies have shown that 
the VF waveform has promising predictive value for longer-term clinical outcomes.5–7
The first implication of our findings is that fine VF during OHCA does not necessarily reflect 
longer arrest duration, with a low chance of successful defibrillation, but may be influenced 
by the underlying etiology as well. For example, in patients with a previous inferior MI, a low 
AMSA at the paddle ECG (corresponding to limb lead II) may be the result of the previous MI 
rather than a long arrest duration. The issue may be overcome with the use of multiple leads, 
reflecting different recording directions, but the potential benefit of such an approach needs 
further study.
As lead V1 does not seem to be influenced by the presence of a prior MI, one might 
hypothesize that VF characteristics in that lead are more reliable indicators of arrest duration 
and less affected by left ventricular disease. In the context that the number and choice of 
leads affects study findings, the use of only one lead during OHCA seems a complicating 
factor. 
Further study is warranted to see whether our findings on short-duration, electrically induced 
VF apply to the OHCA-setting. Signal differences between spontaneous and induced VF have 
been described, but animal studies and an OHCA cohort have reported that a previous MI 
affects the VF waveform in the acute setting as well.11,12,21,22,27–29 
Appreciating that other factors than time affect the VF waveform, the modest prediction in 
earlier OHCA studies on shock success could possibly be optimized. More comprehensive 
studies on VF characteristics are warranted to unravel the future potential of VF-guided 
resuscitative interventions.
LIMITATIONS
This study describes the impact of a previous infarction in patients with short-duration, 
electrically induced VF. This may limit inferences to the OHCA-setting with spontaneous VF 
of longer duration. Second, about a third of patients was excluded, as digital 12-lead ECG-
recordings were not available. Given the similar baseline characteristics (Supplementary Table 
1), it is unlikely that this selection has affected our findings. Third, for an even more academic 
approach, the use of a single imaging technique (MRI), including systematic quantification of 




In the present study on VF characteristics in a large series of patients undergoing ICD testing, 
we observed that a previous MI and its localization affect the VF waveform on the surface 
ECG. Amplitude-related characteristics were significantly lower and VF was less organized in 
the leads adjacent to the area of infarction, i.e.in lead V3 for an anterior MI and in leads II and 
aVF for an inferior MI. Frequency characteristics were lower in case of an anterior MI only. 
Although VF characteristics have so far primarily been considered a proxy for arrest duration 
and myocardial metabolic state, our findings warrant more comprehensive studies on VF 
to re-evaluate this paradigm and to study the future potential of VF-guided resuscitative 
interventions.
SUPPLEMENTARY DATA
Supplementary material related to this article can be found in the online version (https://
www.resuscitationjournal.com/article/S0300-9572(15)00387-1/fulltext). 
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BACKGROUND Despite a promising association between ventricular fibrillation (VF) waveform 
characteristics and prognosis after resuscitation, studies with VF-guided treatment have 
so far not improved outcomes. While driven by the idea that the VF waveform reflects 
arrest duration, increasing evidence suggests that pre-existent disease-related changes 
of the myocardium affect ECG-characteristics of VF as well. In this context, we studied 
the impact of the left ventricular (LV) diameter and mass. 
METHODS Cohort of 193 ICD-patients with defibrillation testing at the Radboudumc 
(2010–2014). Surface ECG-recordings (leads I, II, aVF, V1, V3, V6) were analyzed to study 
amplitude and frequency characteristics of the induced VF. Both for LV diameter and 
mass, patients were categorized in two groups, using echocardiographic data (ASE-
guidelines). 
RESULTS In all ECG-leads, dominant and median frequencies were significantly lower in 
patients with (n = 40) than in patients without (n = 151) an increased LV diameter. The 
mean amplitude and amplitude spectrum area (AMSA) did not differ. In contrast, we 
observed no differences in frequency characteristics in relation to the LV mass, whereas 
mean amplitude (I, aVF, V3) and AMSA (I, V3) were significantly higher in patients with (n 
= 57) than in patients without (n = 120) an increased LV mass. 
CONCLUSION Frequency characteristics of VF were consistently lower in case of an 
increased LV diameter. Whereas LV mass does not affect the frequency of the VF 
waveform, amplitudes seem higher with increasing mass. These findings add to the 
current knowledge of factors that modulate VF characteristics of the surface ECG and 
provide insight into factors which may be accounted for in future studies on VF-guided 
resuscitative interventions.




Over the years, various initiatives have been taken to improve outcome after out-of-hospital 
cardiac arrest (OHCA)1,2 For patients with ventricular fibrillation (VF), one of the proposed 
strategies involves guidance of chest compressions and shock deliveries based on analysis of 
the VF waveform.2-5
This idea was based on early observations that the VF waveform of the electrocardiogram 
(ECG) reflects arrest duration, and evolves from coarse to fine with worsening of the 
myocardial metabolic state.6 In this context, it has been thought that patients with longer 
arrest durations may benefit from a chest compression-first strategy, instead of immediate 
shock therapy, to improve myocardial readiness for defibrillation.3-5,7 However, randomized 
studies comparing these strategies in the OHCA setting, whether or not guided by VF analysis, 
could not substantiate survival benefit.8,9 
More recent evidence indicates that the appearance of the VF waveform of the surface ECG 
not only reflects arrest duration, but is also affected by the underlying cardiac disease.10-12 
In animals, VF frequency characteristics have consistently been shown to be lower in the 
presence than in the absence of an acute myocardial infarction (MI).10-11 In contrast, studies 
in OHCA-patients yielded inconsistent results with regard to the impact of an acute MI.13-15 
Besides acute factors, there is robust evidence in both patients and animals that pre-existent 
cardiac disease affects VF characteristics as well.12,16-18 Previous studies primarily investigated 
the impact of infarction, while there is scarcity of data on the effect of other pre-existent 
disease-related changes of the myocardium on VF characteristics.16-18
Improved understanding of factors that influence the appearance of the VF waveform 
of the surface ECG may help to unravel whether and how VF analysis could be helpful to 
guide resuscitative interventions. In this context, we studied induced VF characteristics of 
the surface ECG in relation to the left ventricular (LV) diameter and mass in patients who 
underwent implantable cardioverter defibrillator (ICD) implantation. 
Methods
PATIENT POPULATION
From a registry of first ICD implantations at the Radboud University Medical Center, we 
identified all patients who underwent defibrillation testing from June 2010-January 2014. 
We included patients for whom the following was available: 1) A 12-lead surface ECG of the 
induced VF; 2) A complete echocardiographic assessment prior to ICD implantation. Exclusion 
criteria were: age <18 years, congenital heart disease and right-sided ICD implants. Given the 
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observational design of the study, written informed consent was not necessary to obtain 
according to the Dutch Act on Medical Research involving Human Subjects. 
ICD IMPLANTATION AND TESTING
The devices implanted were Medtronic® (Minneapolis, Minn, USA), St Jude Medical® (St. 
Paul, Minn, USA) or Biotronik® (Berlin, Germany) ICD or cardiac resynchronization therapy-
defibrillator systems with transvenous single coil leads. Routine defibrillation testing was 
performed after ICD implantation to test the ability of the implanted device to sense, detect 
and terminate VF appropriately. After sedation with propofol, VF was induced using T-wave 
shock, direct current pulses or 50 Hz burst pacing. The presence of VF, defined as a rapid 
(around 300 bpm) grossly irregular ventricular rhythm with marked variability in QRS cycle 
length, morphology and amplitude, was confirmed on surface ECG recordings.19 The ICD was 
programmed to deliver sequential shocks (15–25–35 J) until VF was terminated. In case of 
persisting VF after the third shock, an external defibrillation shock was delivered.
CLINICAL AND ECHOCARDIOGRAPHIC PARAMETERS 
Data regarding demographics and medical histories were collected from patient records. 
The underlying cardiac etiology was determined using patient charts. In the presence of a 
previous MI, we crosschecked the MI localization using ECGs and imaging reports (i.e. echo, 
nuclear scan, MRI), as described previously.18 
LV DIAMETER AND MASS
Echocardiographic measurements of the LV internal diastolic diameter (LVIDd) and mass 
were collected from imaging reports. Both measurements had been done as part of the 
work-up for ICD implantation according to local standards. Measurements were indexed to 
body surface area and categorized using gender-specific thresholds as recommended by the 
American Society of Echocardiography.20 Echocardiography had to be performed within one 
year before ICD implantation and without intercurrent cardiac events. 
VF WAVEFORM CHARACTERISTICS
ECG recordings: During defibrillation testing, a standard 12-lead ECG of the induced VF was 
recorded (sampling frequency 1000 Hz; 16-bit A/D converter) with BARD LabSystem Pro 
(Lowell, Massachusetts, USA). Lead I, II, aVF, V1, V3 and V6 were selected for VF analysis, as 
these represent the main electrical vectors and include uni- and bipolar leads. 
VF waveform analysis: VF waveform characteristics were determined using a time segment 
of 4.1 s prior to first shock delivery (4096 time-points). The signal was pre-processed with 
a 2 Hz high-pass filter and a 20 Hz low-pass filter. We analyzed several previously studied 
VF characteristics.5,21,22 From the ECG-signal in the time domain, we determined the mean 
absolute amplitude. Subsequently, the signal was converted to the frequency domain by using 
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a fast Fourier transform to visualize the frequencies and corresponding amplitudes, which 
the sampled VF signal contains.5 From the amplitude frequency spectrum, the amplitude 
spectrum area (AMSA) was calculated as the summed product of individual frequencies and 
their corresponding amplitudes over an interval of 2–20 Hz.21,22 From the power spectrum, 
we determined the dominant frequency, which is the frequency where the power spectrum 
attains its maximum.5 In addition, we determined the median frequency, i.e. the frequency 
for which the integrated signal power was one half of the total integrated power. Finally, we 
calculated the bandwidth, which is the difference in frequency corresponding to the first 
and third quartile of the total power, providing a measure of the spread in frequencies.22 
Definitions of the analyzed VF characteristics are described in detail in the Appendix. 
Calculations were performed using Matlab (version 2011a, Math-works, Natick, MA, USA). 
OUTCOME MEASURES AND DEFINITION OF STUDY GROUPS 
Outcome measures are the VF waveform characteristics as described above. For analyses 
on the LV diameter, we compared two groups: 1) patients with normal LV diameters or with 
LV diameters that indicated mild dilatation versus 2) patients with moderate to severely 
increased LV diameters [study groups: normal vs. increased LV diameters (≥3.5 cm/m2)]. 
For analyses on the LV mass, we compared two groups as well: 1) patients with normal LV 
masses or with masses that indicated mild hypertrophy versus 2) patients with moderate to 
severely increased LV masses [study groups: normal vs. increased LV masses (males: ≥132 g/
m2; females: ≥109 g/m2)]. 
STATISTICAL ANALYSIS
Statistical analyses were performed with IBM SPSS statistics software (version 22, IBM Corp., 
Armonk, NY, USA). Categorical data are expressed as numbers (percentages). Continuous 
baseline variables are expressed as means ± standard deviations. The VF waveform 
characteristics are presented as medians (interquartile ranges (IQRs)) and were compared 
using the Mann Whitney U test. A p-value of <0.05 was considered statistically significant. 
To provide an indication whether the effect of the LV diameter and mass on the outcomes 
measures was independent of other factors, we performed multivariate linear regression 
analyses using data of surface ECG-lead I. This lead was chosen in view of the similarity 
with the paddle-ECG recorded during resuscitations. The mean amplitude and AMSA were 
log-transformed to approximate a normal distribution. All confounding variables as well as 
variables which have previously been associated with the outcome measure of interest were 





A total of 337 adults underwent a first left-sided ICD implantation with defibrillation testing 
during the study period. In total, 144 patients were excluded for the following reasons: 
no analyzable 12-lead ECG of the induced VF (n = 131), missing echocardiographic data (n 
= 13). Accordingly, a total of 193 patients were included in the present analysis. Baseline 
characteristics did not differ between the in- and excluded patient groups (Supplementary 
Table 1).
PATIENT CHARACTERISTICS
The mean age of the included patients was 63 years ± 13 and 76% (146/193) was male. Mean 
left ventricular ejection fraction (LVEF) was 36% ± 14. In total 58% (111/193) of patients had 
a previous MI, of which 41% (46/111) was located in the anterior wall and 45% (50/111) 
in the inferior wall. Of the patients without infarction (n = 82), LV dysfunction was caused 
by cardiomyopathies, hypertension or valvular heart diseases in 89% (73/82). Four percent 
(3/82) had a cardiac channelopathy and 7% (6/82) could not be classified. Further clinical 
characteristics are summarized in Tables 1 and 2. 
VF CHARACTERISTICS IN RELATION TO THE LV DIAMETER 
Measurements of the LV diameter were available for 191 patients. In total, 79% (151/191) 
had a normal to mildly abnormal indexed LV diameter, with a mean of 2.8 ± 0.3 cm/m2. In the 
21%(40/191) with a moderate to severely abnormal LV diameter, the mean LVIDd index was 
0.8 ± 0.3 cm/m2. Baseline characteristics are presented in Table 1. 
Frequency characteristics: In patients with an increased LV diameter, the dominant and 
median frequencies were significantly lower when compared to the subset with a normal 
diameter in all analyzed ECG-leads (Fig. 1). The bandwidth did not differ between study 
groups.
Amplitude characteristics: The mean VF amplitude and AMSA did not differ between patients 
with normal and increased LV diameters. This held true for all analyzed ECG-leads (Figure 1).
Multivariate analysis: After correction for the LV mass, amiodarone and a previous MI, we 
found an independent association between the LV diameter and the dominant and median 
frequencies of VF [β -0.324 (95%CI -0.565 to -0.083), p = 0.009]; β -0.291 (95%CI -0.513 to 
-0.069), p=0.010].
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TABLE 1. CLINICAL CHARACTERISTICS OF PATIENTS WITH NORMAL AND INCREASED LV DIAMETERS.





Age (years) 63 ± 12 62 ± 14 0.663
Male gender 123 (82) 22 (55) 0.001
Hypertension 61 (41) 14 (35) 0.515
Diabetes 36 (24) 9 (23) 0.843
Atrial fibrillation 50 (33) 10 (25) 0.326
Previous MI 89 (59) 22 (55) 0.653
BMI (kg/m2) 27 ± 4 25 ± 4 0.039
Secondary prevention 59 (39) 4 (10) 0.001
CRT-D 44 (29) 17 (43) 0.107
LVEF (%) 38 ± 14 28 ± 9 <0.001
LVIDd-index (cm/m2) 2.8 ± 0.3 3.8 ± 0.3 <0.001
LV mass index (g/m2) 110 ± 29 132 ± 30 <0.001
QRS duration (ms)* 112 (94-122) 111 (102-125) 0.374
QTC duration (ms)* 455 (423-483) 455 (423-480) 0.968
Creatinine 97 ± 54 137 ± 211 0.249
Beta blocker 137 (91) 37 (93) 1.000
ACE inhibitor 129 (86) 38 (95) 0.173
Aldosterone blocker 59 (39) 20 (50) 0.224
Diuretics 69 (46) 28 (70) 0.007
Antiplatelet 91 (61) 20 (50) 0.224
Anticoagulation 66 (44) 16 (40) 0.650
Cholesterol reducer 100 (67) 28 (70) 0.690
Amiodarone 20 (13) 3 (8) 0.419
*In the absence of a typical bundle branch block. Values are n (%), means ± standard deviations or medians (IQRs). 
ACE inhibitor: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index, 
CRT-D: cardiac resynchronization therapy defibrillator, LV: left ventricular, LVEF: left ventricular ejection fraction, 





















































































Moderate to severely increased
LV diameter (n=40)
Normal LV diameter or mild
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FIGURE 1. IMPACT OF THE LV DIAMETER ON VF WAVEFORM CHARACTERISTICS OF THE SURFACE ECG.
VF waveform characteristics are presented as medians with interquartile ranges. * P-value < 0.05. The dominant and 
median frequencies were significantly lower in patients with an increased LV diameter when compared to those with 
a normal LV diameter. P-values dominant frequency: lead I: 0.006, lead II: 0.010, lead aVF 0.019, lead V1: 0.028,lead 
V3: 0.050, lead V6: 0.009. P-values median frequency: lead I: 0.008, lead II: 0.028, lead aVF: 0.032, lead V1: 0.027, 
lead V3: 0.017, lead V6: 0.006. The mean amplitude, AMSA and bandwidth did not differ significantly between 
patients with increased and normal LV diameters, in all leads (p-values > 0.05). AMSA: Amplitude Spectrum Area, Hz: 
Hertz, LV: left ventricular, mV: millivolt.
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VF CHARACTERISTICS IN RELATION TO THE LV MASS
Measurements of the LV mass were available for 177 patients. In total, 68% (120/177) had 
a normal to mildly abnormal indexed LV mass, with a mean of 98 ± 19 g/m2. In the 32% 
(57/177) of patients with a moderate to severely abnormal LV mass, the mean mass index 
was 147 ± 23 g/m2. Baseline characteristics are presented in Table 2.
Frequency characteristics: The dominant and median frequencies did not differ between 
study groups, with the exception of a significantly lower dominant frequency in lead V3 in 
the subset with an increased LV mass compared to those with a normal LV mass (Fig. 2). The 
bandwidth did not differ between study groups in any lead either.
Amplitude characteristics: In patients with an increased LV mass, the mean VF amplitude 
was significantly higher in leads I, aVF and V3 when compared to the subset with a normal 
LV mass (Fig. 2). In leads II and V6, the mean amplitude was slightly higher as well (p < 0.1), 
but this did not reach statistical significance. No difference was observed in lead V1. In case 
of an increased LV mass, the AMSA was significantly higher in leads I and V3 as well. In leads 
II an d aVF, the AMSA was also slightly higher (p < 0.1). No difference was observed in lead 
V1 and V6. 
Multivariate analysis: After correction for a previous MI, gender and the LVEF, we observed 
an independent association between the LV mass and the log-transformed mean amplitude 
and AMSA [β 0.095 (95%CI 0.027–0.163), p = 0.006; β 0.065 (95%CI 0.008–0.122) p = 0.026].
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TABLE 2. CLINICAL CHARACTERISTICS OF PATIENTS WITH NORMAL AND INCREASED LV MASSES.
Normal LV mass index 
n = 120
Increased LV mass index
n = 57
p-value
Age (years) 62 ± 13 63 ± 13 0.618
Male gender 96 (80) 37 (65) 0.030
Hypertension 47 (40) 25 (44) 0.582
Diabetes 29 (24) 13 (23) 0.820
Atrial fibrillation 34 (28) 22 (39) 0.170
Previous MI 71 (59) 31 (54) 0.548
BMI (kg/m2) 27 ± 5 27 ± 3 0.975
Secondary prevention 46 (38) 13 (23) 0.041
CRT-D 32 (27) 23 (40) 0.066
LVEF (%) 38 ± 13 33 ± 13 0.018
LVIDd-index (cm/m2) 2.9 ± 0.4 3.3 ± 0.5 <0.001
LV mass index (g/m2) 98 ± 19 147 ± 23 <0.001
QRS duration (ms)* 112 (94-124) 108 (101-123) 0.769
QTC duration (ms)* 450 (421-480) 466 (445-502) 0.010
Creatinine 91 ± 38 127 ± 178 0.149
Beta blocker 108 (91) 52 (91) 0.919
ACE inhibitor 105 (88) 52 (91) 0.549
Aldosterone blocker 52 (44) 26 (46) 0.811
Diuretics 59 (50) 33 (58) 0.301
Antiplatelet 74 (62) 28 (49) 0.100
Anticoagulation 50 (42) 25 (44) 0.817
Cholesterol reducer 78 (66) 37 (65) 0.934
Amiodarone 13 (11) 7 (12) 0.791
*In the absence of a typical bundle branch block. Values are n (%), means ± standard deviations or medians (IQRs). 
ACE inhibitor: angiotensin converting enzyme inhibitor, ARB: angiotensin receptor blocker, BMI: body mass index, 
CRT-D: cardiac resynchronization therapy defibrillator, LV: left ventricular, LVEF: left ventricular ejection fraction, 
LVIDd: left ventricular internal diastolic diameter, MI: myocardial infarction.
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FIGURE 2. IMPACT OF THE LV MASS ON VF WAVEFORM CHARACTERISTICS OF THE SURFACE ECG.
VF waveform characteristics are presented as medians with interquartile ranges. * P-value < 0.05. The dominant and 
median frequencies as well as the bandwidth did not differ between study groups, in all leads (p-values > 0.05), with 
the exception of the dominant frequency in lead V3 (p = 0.047). The mean amplitude and AMSA were significantly 
higher in patients with an increased LV mass compared to those with a normal LV mass in leads I, aVF and V3 and 
leads I and V3, respectively. P-values mean amplitude: lead I: 0.021, lead II: 0.050, lead aVF: 0.031, lead V1: 0.451, 
lead V3: 0.014, lead V6: 0.092. P-values AMSA: lead I: 0.047, lead II, 0.084; lead aVF: 0.060, lead V1: 0.282, leadV3: 




Frequency characteristics of initial VF varied according to the LV diameter, with consistently 
lower values in all ECG-leads in patients with marked LV dilatation. Amplitude characteristics 
were not related to the LV diameter. In contrast, VF frequency was not related to the LV mass. 
While amplitude characteristics seemed higher in case of an increased LV mass, this was 
not consistent across all the different ECG-leads. These findings add to the growing body of 
evidence indicating that the VF waveform of the surface ECG is altered by pre-existent disease-
related changes of the myocardium, including abnormal geometrics and infarcted areas.17-18 
In this light, a more comprehensive concept of VF characteristics seems warranted, which 
may contribute to renewed insights into the potential of VF analysis to guide resuscitative 
interventions.
DETERMINANTS OF THE VF WAVEFORM
Animal studies: Studies in animals have generated a valuable amount of information on 
determinants of the VF waveform.5,10-12,23-26 Initial studies primarily focused on the relation 
with markers of the metabolic state, e.g. arrest duration or coronary perfusion pressure.23-26 
More recent studies showed that the presence of an acute MI also results in less coarse 
VF.10,11 For a history of a previous myocardial infarction, thus for pre-existent infarction as 
well, it has been demonstrated that the course of the VF waveform differs when compared to 
VF in a structurally normal heart.11,12 
Human studies: In Table 3, we provide an overview of our current knowledge on patient-related 
factors that influence the electrocardiographic appearance of the VF waveform. Among the 
different studies on the impact of a previous MI, data are consistent, demonstrating lower 
VF amplitude characteristics in the leads adjacent to the area of infarction.13,16-18 In contrast, 
results of the studies on acute MI yielded contrasting findings in the setting of OHCA.13-15 
Despite the frequent occurrence of LV dilatation and hypertrophy, and the associated 
increased risk of sudden cardiac death, the impact of the LV diameter and mass on VF 
characteristics has so far only scarcely been studied.27 
IMPACT OF THE LV DIAMETER
The dominant and median frequencies were consistently lower in all analyzed ECG-leads in 
case of an increased LV diameter. This effect was seen in both patients with and without 
pre-existent infarctions and was independent of other variables that are known to lower 
VF frequency characteristics (Table 3), as for example amiodarone and beta blocker use.28 
The dominant frequency roughly corresponds to the number of fibrillation cycles per second 
and to the reciprocal of the cycle length.29 In animal hearts, it has been demonstrated 
that acute ventricular stretching results in shortening of the action potential duration and 
refractory period, leading to higher dominant frequencies.30,31 This seems contrasting with 
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our observations. However, acute stretching may not mimic the human situation in which 
LV remodelling is often multifactorial and results from longstanding adaptation to cardiac 
overload. In animal hearts, it has been demonstrated that in case of heart failure remodelling, 
the VF rate decreases.31 The latter is in concordance with our observations and corresponds 
to the characteristics of our study population, which mainly consists of heart failure patients. 
A mapping study in explanted hearts from transplant recipients with dilated cardiomyopathy 
provides further insight in the potential underlying mechanism of the altered VF frequency 
characteristics.32 In this study, it was observed that areas of fibrosis on histopathologic 
examination corresponded with areas of conduction block during VF. 
TABLE 3. IMPACT OF PATIENT-RELATED FACTORS ON ECG CHARACTERISTICS OF THE VF WAVEFORM.
Measures related to  
VF cycle length
Measures related to  
VF amplitude
Acute myocardial infarction13-15 = ↓/=
Previous myocardial infarction13,16-18,22 ↓/= ↓
Increased LV diameter17 ↓ =
Increased LV mass = ↑/=
Low LV ejection fraction33 ↓ Unk
Beta blockers28 ↓ Unk 
Class III anti-arrhythmic drugs17 ↓ =
Longer arrest duration34,35 ↓ ↓
CPR36,37 ↑ ↑
In this table, we provide an overview of the currently available knowledge on associations between myocardial 
disease, medication and arrest variables on the one hand and VF waveform characteristics (i.e. amplitude, 
frequency) on the other hand from studies with patients. CPR: cardiopulmonary resuscitation, LV: left ventricular, 
Unk: unknown, VF: ventricular fibrillation.
LV MASS
Observations regarding the LV mass were less consistent, although it seems that an increased 
LV mass is associated with higher VF amplitudes. Previously, we have shown that in the 
presence of pre-existent infarction, and thus with a loss of depolarizing mass, VF amplitude 
characteristics were lower in the adjacent leads.18 The present observations seem in line with 
these findings as with an increased cell mass amplitude characteristics were generally higher, 
although findings were not as robust and consistent as observed for the correlation between 
LV dilatation and the VF waveform. This may relate to local differences in wall thickness 
adjacent to the various ECG leads. Unfortunately, our imaging information was limited to 
echocardiography and lacks an advanced technique like MRI. This could have provided 
important information on the complex alterations in ventricular architecture that occur with 




The present study further completes the current picture with regard to the impact of pre-
existent myocardial disease on characteristics of the VF waveform. It needs to be determined 
whether our findings on short-duration electrically-induced VF also apply to the OHCA setting. 
If this is the case, our findings may have important implications. First, pre-existent myocardial 
changes may then complicate the use of the VF waveform as a mere proxy of arrest duration 
or actual metabolic state. As such, it may influence the predictive ability for shock success 
and outcome. For example, low amplitude, low frequency VF could represent someone with 
a long arrest duration, but could also be indicative of pre-existent myocardial pathology 
(prior infarction, LV dilatation etc.). Second, it could explain the contrasting observations in 
studies that reported on the impact of acute infarction on the VF waveform. In these studies, 
factors like previous infarction, LV mass or diameter were not accounted for. Third, it should 
be noticed that the observed interplay between the VF waveform on the one hand, and pre-
existent and acute myocardial pathology on the other, is dependent on the ECG-recording 
direction. Concluding, our findings support the idea that the appearance of the VF waveform 
on the surface ECG depends on multiple factors. In this light, more comprehensive studies on 
VF characteristics are warranted to investigate if and how VF-guided resuscitation strategies 
might improve outcome after cardiac arrest. 
LIMITATIONS 
First, although the present study question was retrospectively defined, data are part 
of a prospective study project on VF waveform analysis.18 This explains the lack of 
echocardiographic data in 13 cases, which resulted in exclusion for this paper. Our project is 
performed in a specialized research electrophysiology lab, which accounts for the fact that 
this study represents only about half of our total of ICD implantations. However, as baseline 
characteristics of the other half of patients did not differ (Supplementary Table 1), it is 
unlikely that exclusion of patients has affected our main findings. Second, in view of the low 
number of patients with an increased LV mass, we were unable to perform in-depth analysis 
on a potential gender-dependent relation between LV mass and VF waveform characteristics. 
In this context, we used a guideline-defined categorization, and corrected for gender in 
multivariate analysis. Finally, in- and exclusion of patients with channelopathies did not result 
in different study findings. 




Frequency characteristics of the VF waveform were consistently lower across all ECG-leads in 
case of an increased LV diameter, with no effect on amplitude characteristics. In contrast, VF 
frequencies did not vary according to the LV mass. Although less uniform, amplitude-related 
measures were slightly higher in case of an increased LV mass. Further study on pre-existent 
disease-related myocardial characteristics that modulate the VF waveform is warranted to 
improve our insights into factors which should be accounted for in future studies on VF-
guided resuscitative interventions. 
SUPPLEMENTARY MATERIAL
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CHAP T ER  9
Computerized analysis of the ventricular 
fibrillation waveform allows identification 
of myocardial infarction: A proof-of-concept 





BACKGROUND In cardiac arrest, computerized analysis of the ventricular fibrillation (VF) wa-
veform provides prognostic information, while its diagnostic potential is subject of study. 
Animal studies suggest that VF morphology is affected by prior myocardial infarction 
(MI), and even more by acute MI. This experimental in-human study reports on the dis-
criminative value of VF waveform analysis to identify a prior MI. Outcomes may provide 
support for in-field studies on acute MI.
METHODS We conducted a prospective registry of implantable cardioverter defibrillator 
recipients with defibrillation testing (2010–2014). From 12-lead surface ECG VF 
recordings, we calculated 10 VF waveform characteristics. First, we studied detection of 
prior MI with lead II, using one key VF characteristic (amplitude spectrum area, AMSA). 
Subsequently, we constructed diagnostic machine learning models: (A) lead II, all VF 
characteristics; (B) 12-lead, AMSA only; and (C) 12-lead, all VF characteristics.
RESULTS Prior MI was present in 58% (119/206) of patients. The approach using the AMSA 
of lead II demonstrated a C-statistic of 0.61 (95% CI, 0.54–0.68). Model A performance 
was not significantly better: 0.66 (95% CI, 0.59–0.73), P=0.09 versus AMSA lead II. Model 
B yielded a higher C-statistic: 0.75 (95% CI, 0.68–0.81), P<0.001 versus AMSA lead II. 
Model C did not improve this further: 0.74 (95% CI, 0.67–0.80), P=0.66 versus model B.
CONCLUSION This proof-of-concept study provides the first in-human evidence that MI 
detection seems feasible using VF waveform analysis. Information from multiple ECG 
leads rather than from multiple VF characteristics may improve diagnostic accuracy. 
These results require additional experimental studies and may serve as pilot data for 
in-field smart defibrillator studies, to try and identify acute MI in the earliest stages of 
cardiac arrest.




Ventricular fibrillation (VF) is the presenting heart rhythm in about 30% of out-of-hospital 
cardiac arrests (OHCAs), with dismal survival despite improvements in the chain of care1, 2 
With the emerging applications of artificial intelligence, new strategies have been suggested 
to try and improve cardiac arrest care, involving computerized VF-waveform analysis of the 
paddle electrocardiogram (ECG).3
The amplitude spectrum area (AMSA) of the VF-waveform has become the key characteristic 
of interest in prognostic studies on defibrillation success and neurological outcome.3-6 
Moreover, a current international randomized trial studies the impact of a smart defibrillator 
that provides real-time AMSA-analysis and guides defibrillation timing, with the aim to 
improve outcomes.7
Another application of the VF-waveform could be identification of the underlying arrest cause. 
With the introduction of advanced resuscitative therapies (e.g. mechanical cardiopulmonary 
resuscitation (CPR), extracorporeal life support) early transportation and intervention has 
become possible.8 Such “early invasive” strategies may in particular be beneficial for patients 
with an underlying acute myocardial infarction (MI).9-11
For such strategies, very early recognition of acute MI is crucial, while at present the diagnosis 
of acute MI is restricted to patients who (eventually) achieve return of spontaneous circulation 
(ROSC).12, 13 Studies in animals have shown that the appearance of the VF-waveform is affected 
by ischemia and by prior MI, and that changes are even more impressive in acute MI.14-16 In 
human studies in the setting of OHCA, it has been shown that AMSA-values were lower in 
patients with than without ST-elevation MI.17, 18
In follow-up on these observed associations, we sought to assess whether VF-waveform 
analysis of the surface ECG may also facilitate detection of an MI. Given the logistical 
challenges of an in-field study on the diagnostic performance of acute MI, we designed a 
proof-of-concept study in the setting of defibrillation testing after implantable cardioverter 
defibrillator (ICD) implantations and focused on detection of a prior MI.15, 19, 20 First, we 
assessed the feasibility of MI-identification using the AMSA of lead II, which has been used in 
previous VF-waveform studies as a proxy for the ECG-signal of the paddle ECG.21-23 Moreover, 
we investigated whether the diagnostic accuracy could be improved by combinations of VF-






From our prospective registry of first ICD-implantations at the Radboud University Medical 
Center (Nijmegen, The Netherlands), we identified all patients who underwent defibrillation 
testing between 2010-2014, which was the hospital protocol during that period. For the 
present analyses, we included patients with an analyzable 12-lead surface ECG of induced 
VF. Exclusion criteria were: age <18 years, congenital heart disease, right-sided ICDs, and 
subcutaneous ICDs. In line with our previous publication, patients were excluded in case of 
a history of MI that did not involve the anterior or inferior wall.20 Given the observational 
design of the study written informed consent was not necessary to obtain according to the 
Dutch Act on Medical Research involving Human Subjects.
ICD IMPLANTATION AND TESTING
The devices implanted were Medtronic® (Minneapolis, USA), St Jude Medical® (St. Paul, 
USA) or Biotronik® (Berlin, Germany) ICD, or cardiac resynchronization therapy-defibrillator 
(CRT-D) systems with transvenous single coil leads. Defibrillation testing was performed after 
ICD implantation to test the ability of the implanted device to sense, detect, and terminate 
VF appropriately. Following our hospital protocol, patients were sedated with propofol, after 
which VF was induced using T-wave shock, direct current pulses or 50 Hz burst pacing. The 
presence of VF, defined as a rapid (around 300 bpm) grossly irregular ventricular rhythm 
with marked variability in QRS cycle length, morphology, and amplitude, was confirmed on 
surface ECG recordings. ICDs were programmed to deliver sequential shocks (15-25-35 joule) 
until VF was terminated. In case of persisting VF after three shocks, external defibrillation was 
performed.
AIM OF THE STUDY
The primary aim of this study was to discriminate between patients with and without a prior 
MI with VF-waveform information from lead II, using either an AMSA-only approach or a 
combination of VF-features. Subsequently, we assessed and compared the discriminative 
performance of VF-waveform analysis with data input of 12 ECG-leads, using either the AMSA 
or combined VF-features.
STUDY GROUPS
Patients were divided in two groups, either with or without a history of MI. For the present 
analyses we used the study groups as reported previously.20 In short, MI was defined according 
to the criteria of the European Society of Cardiology.24 Evidence for the presence or absence 
of a prior MI was based on reports in the medical charts.20, 24 Infarct localization was based 
on information obtained from ECGs (e.g. area with ST-elevation or pathological Q waves) 
and coronary angiographies, and confirmed by imaging reports.24, 25 Imaging was performed 
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and analyzed as part of daily clinical practice, following recommendations of the prevailing 
guidelines for ICD-therapy.20, 26
VF WAVEFORM ANALYSIS
ECG recordings: During defibrillation testing a standard 12-lead surface ECG was recorded 
(sampling frequency 1000 Hz; 16-bit A/D converter) with BARD LabSystem (Lowell, USA). 
VF-waveform characteristics: All definitions, mathematical descriptions, and VF-waveform 
calculations are described in more detail in Supplement File 1. Signal analysis was performed 
using Matlab (version R2018a, The Mathworks Inc, Natick, USA). A VF-segment of 4.1 seconds 
(4096 samples) directly prior to the first ICD-shock was selected for waveform analysis. 
Signals were pre-processed with a fourth-order Butterworth 1-48 Hz bandpass filter, after 
which VF-waveform characteristics were calculated. We analyzed ten different VF-waveform 
characteristics, which can be categorized into time domain characteristics, frequency domain 
characteristics and signal organization characteristics. 
• Time domain: From the filtered ECG-segment in the time domain we determined the 
amplitude of the VF signal27, more specifically defined as the mean absolute amplitude 
(MAA).20 Moreover, we calculated the median slope (MDS)28, which can be regarded as a 
measure of the overall steepness of the VF-signal.
• Frequency domain: After conversion of the ECG-segment to the frequency domain using 
a Fast Fourier Transform, the amplitude spectrum area (AMSA)29 was calculated as the 
summed product of individual frequencies and their corresponding amplitudes over 
an interval of 2-48 Hz, a frequency range which is also used in the key AMSA-paper.3 
Subsequently, the power spectrum was obtained from which the power spectrum area 
(PSA)28 was calculated. Moreover, we determined the dominant frequency (DF)30, which 
is the frequency where the power spectrum attains its maximum, and the median 
frequency (MDF)31, i.e. the frequency for which the integrated power was half of the total 
integrated power. Finally, we calculated the bandwidth (BW), defined as the frequency 
difference between the first and third quartile of the total power, providing a measure of 
the spread in frequencies.32
• Signal organization: The organization index (OI)33 was calculated as the sum of the 
power of the dominant frequency and its harmonics, divided by the total power of the 
signal, over an interval of 2-48 Hz (Supplement Figure 1.4.1).19 Furthermore, detrended 
fluctuation analysis (DFA)34 was performed as a measure of the complexity of the VF-
signal. In the current study, we report on two DFA scaling exponents, in small and larger 




We used the following stepwise protocol to discriminate between the two study groups, 
using four different approaches (Table 1):
• Approach 1: Lead II, single VF-characteristic
In the setting of OHCA anterolateral direction of the defibrillator paddles is the most standard 
and recommended method. Therefore, we used ECG information of lead II. First, we assessed 
the diagnostic performance of an approach using the AMSA of lead II only, to discriminate 
between patients with and without a prior MI. Subsequently, the same procedure was 
followed for all other individual characteristics of lead II, and their diagnostic yield was 
compared with that of the AMSA.
• Approach 2: Lead II, 10 VF-characteristics (machine learning model A)
To investigate the additional value of the input of more VF-features, the entire set of VF-
waveform characteristics from lead II was used as input for a support vector machine (SVM) 
classifier, resulting in a model with 10 input features. The SVM process is explained in more 
detail in Table 1 and Supplement File 2 (Figures 2.2.1 and 2.2.2). The discriminative ability 
of the constructed SVM-model (model A) was compared with the performance of the prior 
approach (lead II, AMSA only).
• Approach 3: 12 ECG-leads, single VF-characteristic (machine learning model B)
To investigate the additional value of information from more recording directions, AMSA-data 
of all 12 ECG-leads were used as input features for an SVM model. Previous work showed 
that the VF-waveform in lead V1 seems unaffected by the presence or absence of an MI.20 
Therefore, we calculated differences with the AMSA of V1 and added these as extra input 
features, resulting in a model with 23 input features (Table 1, Supplement File 2.2). The 
discriminative performance of this model (model B) was compared with that of the approach 
with the AMSA of lead II only. The same procedure (i.e. lead II vs. all leads) was followed for 
all other individual VF-characteristics.
• Approach 4: 12 ECG-leads, 10 VF-characteristics (machine learning model C)
To investigate the impact of the input of additional VF-characteristics in a 12-lead model, the 
entire set of 10 VF-characteristics from all ECG-leads was used, as well as their differences 
with V1, resulting in an SVM-model with 230 input features (Table 1, Supplement File 2.2). 
The discriminative performance of this approach (model C) was compared with model B.
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1 Lead II AMSA 1 variable
2 Lead II Entire set of VF-
characteristics
SVM-model with 10 input featuresa
(model A)
3 12 ECG-leads AMSA SVM-model with 23 input featuresb
(model B)
4 12 ECG-leads Entire set of VF-
characteristics
SVM-model with 230 input featuresc
(model C)
Four approaches were used to discriminate between patients with and without a myocardial infarction (MI). In 
approach 1, the amplitude spectrum area (AMSA) was used as a single variable predictor. Approach 2, 3 and 4 
represent support vector machine (SVM) discriminative models. Receiver operating characteristic analysis was 
performed to assess diagnostic accuracy. For approach 1 and 3, the same procedure as the AMSA was performed for 
all other individual VF-characteristics. ECG, electrocardiogram; VF, ventricular fibrillation. 
a: The entire set of 10 VF-characteristics, derived from lead II (10x1=10 input features).
b: The AMSA derived from all 12 ECG-leads (1x12=12 input features) plus the difference of these AMSA-values with 
the AMSA-value of lead V1 (1x11 input features), resulting in 23 input features. 
c: The entire set of 10 VF-characteristics derived from all 12 ECG-leads (10x12=120 input features) plus the difference 




ANCILLARY ANALYSES – INFARCT LOCALIZATION
Previously, we have shown that VF-waveform differences associated with underlying etiology 
are best observed in the ECG leads adjacent to the affected myocardial region.20, 36 In follow 
up, we performed ancillary analyses to assess the discriminative ability of the SVM-models 
to detect the localization of the prior MI. We used the patient subset with a prior MI and 
assessed the ability of two SVM-models, with all VF-waveform characteristics from either 
lead II or 12 ECG-leads. C-statistics were assessed for discrimination between patients with a 
prior inferior or anterior MI. Patients with both involvement of the anterior and inferior wall 
were excluded.
STATISTICS
Categorical variables were reported as numbers (percentages) and compared between 
groups using a χ2-test or a Fisher’s exact test, whichever appropriate. Continuous variables 
were analyzed for Gaussian distribution and reported as means ± standard deviations (SD) or 
medians (interquartile ranges, IQR), whichever appropriate. Comparisons between groups 
were performed accordingly, with either a Student t-test or a Mann Whitney U test. Descriptive 
and comparative statistics were performed with SPSS (Version 25, IBM, Armonk, USA). 
Receiver operating characteristic (ROC) analysis was performed to assess the discriminative 
performances of the models (MedCalc Version 19.1.3, MedCalc Software bv, Ostend, 
Belgium). C-statistics (95% confidence interval) were compared using the DeLong method.37 
Moreover, the positive predictive value (PPV) was obtained at the threshold value where 
Youden’s J-statistic (J=sensitivity + specificity -1) reaches his maximum, which was considered 
as the optimal cut-off point of the discriminative model.38 For all statistical analysis, a p-value 




We studied 206 patients with a median age of 64 (57-72) years, of whom 150 were male 
(73%). Thirty-two percent (67/206) of the implanted ICDs were for secondary prevention and 
32% (66/206) were CRT-D devices. In total, 42% (87/206) of the patients had no evidence of a 
prior MI. A prior anterior MI was present in 23% (47/206) of the cases, a prior inferior MI was 
present in 27% (56/206), and 8% (16/206) of the patients had an MI that involved both the 
inferior and the anterior myocardial wall. Baseline characteristics are reported in Table 2. A 
representative example of VF induction and termination by an ICD shock is shown in Figure 1.
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MI IDENTIFICATION, LEAD II 
Approach 1, single VF-characteristic: The AMSA in lead II was lower in patients with than 
without a prior MI (10.7 mVHz [IQR 8.7-13.4] vs 12.7 mVHz [IQR 9.7-17.7], p=0.006). The 
discriminative ability of an approach using the AMSA of lead II demonstrated a C-statistic of 
0.61 (0.54-0.69), with a PPV of 69% (Table 3).
As for the other individual VF-characteristics, we found differences according to the presence 
or absence of prior MI, as well as a significant ability to discriminate between the study 
groups, for the MAA, MDS, OI and PSA (Figure 2 blue graphs, Supplement Table 3.1.1). None 
of these characteristics had a diagnostic performance that was significantly different from 
the AMSA.
Approach 2, entire set of VF-characteristics: The single lead SVM-model with all 10 VF-
characteristics of lead II as input features (model A), resulted in a C-statistic of 0.66 (0.59-0.73) 
with a PPV of 71% (Figure 3, Supplement Table 3.3.1). The discriminative value of this model 
with the entire set of VF-characteristics did not significantly differ from the performance of 
the approach using only the AMSA in lead II (p=0.09, Table 3).
MI IDENTIFICATION, 12 ECG-LEADS
Approach 3, single VF-characteristic: The SVM-model with as input features the AMSA data 
of all 12 ECG-leads (model B), yielded a C-statistic of 0.75 (0.68-0.81), Figure 3. This was 
significantly higher than the C-statistic of the approach with the AMSA of lead II only (p<0.001, 
Table 3). The PPV of this model was 77%. None of the other 12-lead SVM-models with input 
from a single VF-characteristic demonstrated a significantly better diagnostic performance 
than the approach of using the AMSA data of all 12 ECG leads. The performance of the 12-
lead AMSA model was superior to those which contained 12-lead information of the BW, 
DFAα1 and DFAα2 (Figure 2, red graphs, Supplement Table 3.2.1).
Approach 4, entire set of VF-characteristics: The 12-lead SVM-model, with information of all 
VF-characteristics from all 12 ECG-leads (model C) demonstrated a C-statistic of 0.74 (0.67-
0.80) with a PPV of 71% (Figure 3, Supplement Table 3.3.1). The discriminative ability was not 
significantly different compared to the performance of model B (p=0.66, Table 3).
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Age 64 (57-72) 67 (61-75) 59 (48-68) <0.001
Male gender 150 (73%) 100 (84%) 56 (64%) 0.001
Secondary prevention 67 (33%) 44 (37%) 23 (26%) 0.111
CRT-D 66 (32%) 33 (28%) 33 (38%) 0.121
BMI (kg/m2) 25.9 (23.9-28.9) 26.4 (24.5-29.2) 25.1 (23.0-28.6) 0.034
LVEF (%) 34 (27-45) 33 (27-44) 34 (27-46) 0.539
LVIDd index (cm/m2) 3 (2.7-3.3) 3 (2.7-3.3) 3 (2.7-3.3) 0.965
LV mass index (g/m2) 113 (94-134) 111 (96-134) 113 (87-136) 0.635
QRS duration (ms) 119 (102-142) 116 (102-138) 122 (102-150) 0.319
Infarct localization
Anterior infarction 47 (23%) 47 (39%) - - 
Inferior infarction 56 (27%) 56 (47%) - -
Both 16 (8%) 16 (13%) - -
Medication
Beta blocker 185 (90%) 110 (93%) 75 (86%) 0.094
Amiodarone 27 (13%) 18 (15%) 9 (10%) 0.304
BMI: body mass index; CRT-D: cardiac resynchronization therapy defibrillator; ICD: implantable cardioverter 
defibrillator; LV: left ventricle; LVEF: left ventricular ejection fraction; LVIDd: left ventricular internal diastolic 
diameter; MI: myocardial infarction; VF: ventricular fibrillation.
INFARCT LOCALIZATION
In total, 39% (47/119) patients had a prior anterior, and 47% (56/119) a prior inferior MI. 
An SVM-model with all VF-waveform characteristics of lead II demonstrated a C-statistic of 
0.77 (0.67-0.85) for identification of the infarcted area, with a PPV of 74% for detection of 
an inferior MI. A machine learning model combining all VF-waveform characteristics from 12 
ECG-leads demonstrated a C-statistic of 0.89 (0.81-0.94) and a PPV of 83% for identification 
of an inferior MI (p-for-comparison = 0.01, Supplement Figure 4.1). 









































































































































































































































































































FIGURE 3. IDENTIFICATION OF AN MI, FOUR DIFFERENT APPROACHES.
ROC-curves for MI-identification, using either the AMSA of a single lead II (approach 1, blue dashed line), an SVM-
model with combined VF-characteristics of lead II (approach 2, blue solid line), an SVM-model with the AMSA of 
all 12 ECG-leads (approach 3, red dashed line) or an SVM-model with combined VF-characteristics of all 12 ECG-
leads (approach 4, red solid line). The positive predictive value is obtained at the threshold value where Youden’s 
J-statistic (J=sensitivity + specificity -1) reaches his maximum. AMSA: amplitude spectrum area; char: characteristics; 
ECG: electrocardiogram; MI: myocardial infarction; ROC: receiver operating characteristic; Sens: sensitivity; Spec: 
specificity; SVM: support vector machine; VF: ventricular fibrillation.
TABLE 3. RESULTS OF THE PRIMARY ANALYSIS.
Approach SVM-model C-statistic* PPV
1 – lead II, AMSA only - 0.61 (0.54-0.69) 69%
2 – lead II, all VF-characteristics A 0.66 (0.59-0.73)§ 71%
3 – 12 leads. AMSA only B 0.74 (0.68-0.80)§§ 77%
4 – 12 leads, all VF-characteristics C 0.73 (0.66-0.79)¶ 71%
Model performances of the different approaches are presented by the area under the receiver operating 
characteristic curve (C-statistic). The positive predictive value is obtained at the threshold value where Youden’s 
J-statistic (J=sensitivity + specificity -1) reaches his maximum. AMSA: Amplitude spectrum area; PPV: positive 
predictive value; SVM: Support vector machine; VF: Ventricular fibrillation. *p<0.017 was considered statistically 
significant after Bonferroni correction; §  non-significant (p=0.09) compared to approach 1; §§ significantly different 
(p<0.001) compared to approach 1; ¶  non-significant (p=0.66) compared to approach 3.




In follow-up on studies that showed associations between the VF waveform and underlying 
etiology, we now present the first study in humans with focus on diagnostic performance, 
and demonstrate that computerized VF waveform analysis may have the potential to 
actually detect an MI using a single ECG lead (lead II). Data from diagnostic machine learning 
approaches showed that additional input from a combination of VF characteristics rather 
than from a single VF feature did not improve discriminative ability, whereas input from all 
12 ECG leads resulted in a significantly higher diagnostic accuracy. These findings warrant 
additional confirmative experimental studies. Appreciating that VF morphology may be even 
more affected in case of acute MIs15, 17, 18, our findings on prior MI can be considered as pilot 
data for future in-field initiatives to study the diagnostic performance of an acute MI, which 
could pave the way toward very early triage and treatment of patients with cardiac arrest.
THE VF-WAVEFORM AND CARDIAC ARREST
Over the years, analysis of the VF-waveform has become a new instrument in cardiac arrest 
research, as it is easily obtainable, with the potential to provide information in the very 
early, prehospital phase of resuscitation.3, 39, 40 The AMSA is the key characteristic of interest 
in most of the studies and has been shown to reflect myocardial metabolic state.41 Several 
studies have demonstrated associations between the AMSA and cardiac arrest outcomes 
(defibrillation success, neurologic survival).4, 42, 43 In follow-up, the first initiatives to study 
the predictive value of the VF-waveform have been published, with promising results using 
machine learning approaches with input of a wide variety of VF-characteristics.3-6 As a next 
step, a randomized trial has been initiated to investigate defibrillation success with a standard 
CPR protocol, compared to a protocol with a smart defibrillator that provides real-time AMSA-
analysis and guides defibrillation timing.7
Another potential application of VF-waveform analysis could be detection of underlying heart 
disease, such as an MI. Infarct model studies have shown markedly different VF-waveform 
characteristics in case of a prior MI, with even more pronounced changes during acute 
coronary occlusion. More specifically, these animal studies demonstrated that ischemia 
results in VF-waveform changes early after initiation of VF and that differences between 
prior and acute MI seem to increase with longer arrest duration.14-16 As of yet, human studies 
have been contradictory. While retrospective cohort studies in OHCA-patients with STEMI 
have reported associations with lower AMSA-values17, 18, others did not observe significant 
VF waveform differences between patients with ST-segment–elevation MI, non–ST-segment–
elevation MI and nonischemic OHCA.44
In follow-up on these studies describing associations, and as a first step towards potential 
future studies on identification of acute MI, we performed this experimental study on the 
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diagnostic ability of VF waveform analysis to detect a prior MI. From an electrophysiological 
perspective, this study adds to the current knowledge that computerized VF-waveform 
analysis may allow for identification of underlying disease, in this case a prior MI. Our current 
findings can be considered as pilot data for OHCA-studies on acute MI.
DETECTION OF MI USING THE VF-WAVEFORM
Initially, we studied the diagnostic performance achieved with VF-waveform information 
from lead II, as a proxy for the paddle ECG. We demonstrated that with the AMSA of lead II 
only, it was feasible to detect a prior MI. Discriminative performance was moderate, without 
significant impact of input from a combination of VF-characteristics rather than a single VF-
feature. With use of input from all 12 ECG-leads, diagnostic accuracy significantly improved 
compared to the single lead approach, again without additional yield from a combination of 
VF-characteristics.
Our observations that machine learning techniques with combined information from 
multiple ECG-leads resulted in marked improvements in discriminative performance, is in line 
with previous observations on the importance of recording direction of VF.20, 45 In previous 
work, we observed differences in VF-waveform characteristics in patients with and without a 
prior MI, especially in the leads adjacent to the infarcted area.20 These differences were not 
present in lead V1. As such, V1 may serve as individual reference electrode, which is why we 
used VF-waveform differences from each electrode with V1 data as additional input features.
Building on the hypothesis that infarcted myocardium results in regional VF-waveform 
differences, we performed ancillary analyses on the subset with either anterior or inferior MI, 
in order to determine the diagnostic accuracy in terms of infarct localization. Machine learning 
models combining information from 12 ECG-leads were very accurate in the identification of 
the infarcted area (C-statistic 0.89), which was superior to a single lead approach (C-statistic 
0.77). In short, these collective findings support the concept of regional ECG-differences in 
VF-characteristics in patients with MI. Appreciating that VF-waveform changes have been 
reported to be more apparent in acute than in prior MI, this paves the way for future work on 
the detection of acute MI with use of computerized VF-waveform analysis.
IMPLICATIONS
Our observation that identification of a prior MI is feasible with computerized analysis of 
the VF-waveform, calls for further experimental and clinical studies. Given the challenging 
conditions of in-field cardiac arrest research, additional work is needed before undertaking 
an out-of-hospital cardiac arrest study with a smart defibrillator, aiming at detection of acute 
MI with VF-waveform analysis.
Experimental studies will have to focus on further exploration and optimization of the SVM-
models in terms of tuning parameters and input features, with primary focus on an approach 
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using a single lead II, which most closely reflects current daily practice with defibrillator pads. 
From a scientific point of view, more data is needed on the optimal number and positions of 
the ECG-electrodes, as well as on quantification of the potential additional diagnostic yield 
of these options. 
In terms of clinical studies, prospective cardiac arrest registries with systematically collected 
ECG-data and coronary angiography information can help answer whether VF-waveform 
information from the paddle-ECG can contribute to identification of an acute MI. Potentially, 
a smart defibrillator with an analysis algorithm on the VF-waveform may help to identify 
patients with an acute MI in a much earlier stage of cardiac arrest. As of yet, the diagnosis of 
acute MI is restricted to the selection of patients who (eventually) achieve ROSC. Especially in 
patients with refractory VF, there is a high burden of coronary artery disease.9, 10 Identification 
of acute MI as underlying, treatable cause would be a first step towards research on 
more individualized resuscitation strategies. In an era of upcoming treatment options like 
transport with mechanical resuscitation and extracorporeal membrane oxygenation, a smart 
defibrillator may provide important input on shock success, prognosis, and possibly, the 
underlying cause to guide triage and decision making.3, 10, 11, 40, 46
LIMITATIONS
In this experimental setting we investigated induced, short-duration VF, which has previously 
been reported to be more organized than in-field VF.47, 48 Moreover, the current rhythm 
recordings reflect very early VF, in an earlier stage than observed during OHCA. This may 
limit generalizability to VF in the OHCA setting. Appreciating the logistic challenge of a 
prospective in-field study with VF-waveform analysis, we opted to firstly investigate the 
feasibility of detecting underlying etiology under controlled conditions, including multiple 
ECG-leads. During cardiac arrest, the appearance of the VF-waveform develops over time, 
and morphology also depends on the quality of administered CPR, factors that were not 
addressed in this experimental model, but could contribute to improve discriminative ability 
in the field.43, 49, 50
Finally, despite the fact that we report on the largest VF-cohort to date with 12-lead ECG-
recordings, the amount of input features is relatively small for machine learning purposes. In 




This proof-of-concept study provides the first evidence that computerized VF-waveform 
analysis allows for actual detection of a prior MI. During ongoing VF, MI-identification is 
modestly feasible with use of the AMSA of lead II. Machine learning approaches suggest 
that information from multiple ECG-recording directions rather than input of multiple VF-
characteristics results in superior discriminative performances. Appreciating that previous 
studies have indicated that VF-waveform changes are even more pronounced in acute MI, 
our findings fuel the concept that VF-analysis may contribute to the detection of an acute MI. 
This calls for additional studies that may ultimately pave the way towards more individualized 
cardiac arrest care with assistance of a ‘smart defibrillator’.
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INTRODUCTION Shock-resistant ventricular fibrillation (VF) poses a therapeutic challenge 
during out-of-hospital cardiac arrest (OHCA). For these patients, new treatment strategies 
are under active investigation, yet underlying trigger(s) and substrate(s) have been poorly 
characterized, and evidence on coronary angiography (CAG) data is often limited to 
studies without a control group. 
METHODS In our OHCA-registry, we studied CAG-findings in OHCA-patients with VF who 
underwent CAG after hospital arrival. We compared baseline demographics, arrest 
characteristics, CAG-findings and outcomes between patients with VF that was shock-
resistant (defined as >3 shocks) or not shock-resistant (≤3 shocks).
RESULTS Baseline demographics, arrest location, bystander resuscitation and AED-use 
did not differ between 105 patients with and 196 patients without shock-resistant VF. 
Shock-resistant VF-patients required more shocks, with higher proportions endotracheal 
intubation, mechanical CPR, amiodaron and epinephrine. In both groups, significant 
coronary artery disease (≥1 stenosis >70%) was highly prevalent (78% vs. 77%, p=0.76). 
Acute coronary occlusions (ACOs) were more prevalent in shock-resistant VF-patients 
(41% vs. 26%, p=0.006). Chronic total occlusions did not differ between groups (29% 
vs. 33%, p=0.47). There was an association between increasing numbers of shocks and 
a higher likelihood of ACO. Shock-resistant VF-patients had lower proportions 24-hour 
survival (75% vs. 93%, p<0.001) and survival to discharge (61% vs. 78%, p=0.002).
CONCLUSION In this cohort of OHCA-patients with VF and CAG after transport, acute 
coronary occlusions were more prevalent in patients with shock-resistant VF compared 
to VF that was not shock-resistant, and their clinical outcome was worse. Confirmative 
studies are warranted for this potentially reversible therapeutic target.




Ventricular fibrillation (VF) is frequently observed as initial rhythm in out-of-hospital cardiac 
arrest (OHCA).1 An important subset of these patients have VF that is resistant to multiple 
defibrillation attempts, i.e. VF that persists or recurs despite shock delivery. This so-called 
shock-resistant VF is most commonly defined as requiring >3 shocks.2-4 These patients with 
prolonged arrest duration are at high risk of mortality and poor neurologic outcome, and have 
gained increasing interest in recent years.5, 6
A wide range of treatment strategies has been studied for shock-resistant VF, ranging from 
experimental studies to a pilot randomized trial on dual sequential defibrillation and a large 
randomized trial on amiodarone.4, 7, 8 Recently, more invasive protocols such as early coronary 
angiography and extra-corporeal life support have gained attention.2, 9-11 As of yet, only the 
use of anti-arrhythmic drugs has been incorporated in cardiopulmonary resuscitation (CPR) 
guidelines as routine treatment.12 However, despite the growing interest in the optimal 
therapeutic strategy for these patients, the underlying myocardial substrate has scarcely 
been described. Importantly, detailed analyses on underlying etiology may reveal potential 
therapeutic targets.
One recently published study investigated a treatment strategy with immediate coronary 
angiography (CAG) in patients with VF that was refractory to >3 shocks without intermittent 
return of spontaneous circulation (ROSC).2 This study revealed that significant coronary artery 
disease (CAD) was present in 82% of the patients with refractory VF, with acute thrombotic 
lesions in 64%. However, that study was limited in patient numbers (n=55) and there was no 
description of CAG-findings in a control group.
Given the high prevalence of coronary artery disease in VF-patients in general, additional 
study is warranted to identify coronary substrate that is specific for shock-resistant VF.13-
15 Such analyses may provide impetus for further study on treatment specifically targeted 
towards this substrate, which in turn may contribute to improved outcomes in these high-risk 
patients. Therefore, we studied coronary angiography findings in cardiac arrest patients with 





We studied patients from the Nijmegen area OHCA-cohort (Gelderland-Zuid, the 
Netherlands).16 We included patients ≥18 years with a non-traumatic OHCA and a shockable 
first observed rhythm (defined as either an ECG-confirmed initial rhythm of VF or pulseless 
ventricular tachycardia, or a shockable rhythm as indicated by the automated external 
defibrillator [AED] if the first shock was administered by the AED), resuscitated between 
1 January 2013 and 1 July 2018, transported to our tertiary hospital and undergoing CAG. 
Appreciating the non-interventional study design, written informed consent was not 
necessary to obtain (Dutch Act on Medical Research involving Human Subjects).17
EMERGENCY MEDICAL SERVICES
Gelderland-Zuid (population 530,000 residents, 1040 square kilometers) includes (sub)urban 
and rural areas. The emergency medical service (EMS) system is activated by calling 112. 
Paramedics will give instructions to the caller to initiate CPR, and usually two ambulances are 
dispatched to the OHCA-location. Ambulances are staffed by a driver and a paramedic, who is 
professionally trained to perform advanced life support. CPR was performed according to the 
prevailing European Resuscitation Council guidelines at the time of the OHCA.12
DATA ACQUISITION
Baseline characteristics and outcome data were collected using EMS-records, hospital records 
and data from municipal registries, following Utstein style definitions.18
CORONARY ANGIOGRAPHY
A dedicated angiography committee (1 senior, 1 fellow interventional cardiologist) reviewed 
all CAG-images specifically for research purposes, using a predefined template including the 
angiographic parameters of interest.19, 20 A random sample of 20% of all evaluated CAGs was 
used to calculate inter-observer agreement. In concordance with previous studies, a kappa 
of > 0.80 was used as a cut-off to decide whether the initial evaluations would be used for 
final reporting, or if a systematic evaluation of all CAGs by a third reader would be required.21 
It was hospital policy to perform CAG in all patients with VF that regained ROSC and had no 
contraindication for CAG, but the final decision to perform CAG was left to the discretion 
of the treating physician. From January 2017 we participated in the Coronary Angiography 
after Cardiac Arrest (COACT) trial, in which patients with ROSC after shockable cardiac arrest 
without ST-elevation were randomized to immediate or delayed CAG.15 Patients that were 
randomized in the COACT study were also included in the present study.
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In accordance with previous studies we used the following definitions: 
• Significant stenosis: stenosis >70%.2
• Significant coronary artery disease: at least one stenosis >70%.2
• Acute coronary occlusion: a presumably new obstructive lesion (i.e. the ability to pass a 
guidewire easily through the occlusion if angioplasty was attempted) with TIMI 0-I flow.14, 20
• Chronic total occlusion (CTO): complete occlusion of one of the main coronary artery 
branches, deemed >3 months old.22
STUDY GROUPS
Patients were categorized as having either shock-resistant VF or VF that was not shock-
resistant. In line with previous studies and an American Heart Association consensus 
document, we used a cut-off of >3 shocks.2, 3 Patients with >3 shocks were categorized as 
shock-resistant VF, whereas patients with VF requiring ≤3 shocks were categorized as patients 
with VF that was not shock-resistant. For this categorization, both AED and EMS shocks were 
taken into account.4 
OUTCOME MEASURE
Primary outcome measures were CAG-findings as described above. Secondarily, we calculated 
the proportions of ROSC, 24-hour survival and survival to discharge. 
STATISTICAL ANALYSIS
Categorical data were expressed as frequencies (percentages) and compared using Chi-
squared tests. Continuous data were tested for normal distribution and reported as means 
(standard deviations) or medians (interquartile ranges) and compared using student t-tests or 
Mann-Whitney U tests, whichever appropriate. A p-value <0.05 was considered statistically 
significant. Analyses were performed using SPSS (Version 25, IBM Corp., USA).
Results
Entire population
BASELINE AND ARREST CHARACTERISTICS
During the study period, 571 patients were transported to our hospital with OHCA. A 
total of 301 patients was included in the present analysis, with exclusion mainly related to 
presentation with a non-shockable rhythm (Supplement 1).  The majority was male (82%) and 
median age was 63 (53-70) years (Table 1). Of all arrests, 58% occurred at a public location 
and 88% was witnessed, of which 8% by the EMS. Bystander CPR was performed in 79% of 
the non EMS-witnessed cases. AED use before EMS-arrival occurred in 54% of the patients. 




The blinded secondary review resulted in an inter-observer agreement of 93% for acute 
coronary occlusion, of 93% for no acute coronary occlusion and a kappa of 0.83. Given this 
high level of agreement, we report on the CAG-reviews of the first observer in all cases. 
Of all patients, 77% had significant coronary artery disease, with 40% of all patients having 
1-vessel disease and 37% having ≥ 2-vessel disease (Table 2). An acute coronary occlusion 
was present in 31% of all patients. The localization of these acute occlusions can be found in 
Table 2. Of all patients, 31% had a chronic total occlusion (CTO), of which the localization can 
be found in Table 2. 
OUTCOMES
Of all patients, 83% was transported with sustained ROSC, 87% survived for at least 24h and 
72% survived to hospital discharge. 
TABLE 1. CLINICAL AND BASELINE VARIABLES. 
Shock resistant VF
Overall Yes (>3 shocks) 
N = 105
No (≤3 shocks ) 
N = 196
p-value
Male 246 (82%) 89 (85%) 157 (80%) 0.32
Age 63 (53-70) 63 (54-71) 63 (53-70) 0.72
Prior MI (n=288) 66 (23%) 23 (24%) 43 (23%) 0.82
Previous cardiac disease 125 (43%) 43 (43%) 82 (43%) 0.88
Arrest characteristics
Public location 166 (58%) 56 (54%) 110 (60%) 0.32
Witnessed 249 (88%) 89 (86%) 160 (88%) 0.62
   Bystander 226 (80%) 83 (81%) 143 (79%)
0.53
   EMS 23 (8%) 6 (6%) 17 (9%)
Bystander CPR* 215 (79%) 75 (78%) 140 (80%) 0.72
AED used before EMS arrival* 151 (54%) 57 (57%) 94 (52%) 0.42
EMS response time (min) 7 (5-10) 9 (5-15) 6 (5-10) 0.08
Shocks by EMS 220 (73%) 98 (93%) 122 (62%) <0.001
Total nr of shocks 2 (1-4) 5 (4-8) 2 (1-2) <0.001
Autopulse used 45 (16%) 27 (28%) 18 (10%) <0.001
Endotracheal intubation 166 (60%) 68 (72%) 98 (54%) 0.006
Amiodarone 96 (33%) 70 (70%) 26 (15%) <0.001
Epinephrine 120 (42%) 74 (74%) 46 (25%) <0.001
ST-elevation on ECG 170 (60%) 66 (71%) 104 (55%) 0.009
Clinical and baseline characteristics in patients with and without shock-resistant VF. * Of all cases not witnessed by the 
EMS. VF = Ventricular fibrillation, MI = Myocardial infarction; CPR = Cardiopulmonary resuscitation; AED = Automated 
external defibrillator; EMS = Emergency medical services; ECG = Electrocardiogram.
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Comparison between study groups
Of all patients, 105 (35%) received >3 shocks and were thus classified as shock-resistant 
VF, while the remaining 196 (65%) patients were classified as patients with VF that was not 
shock-resistant.
BASELINE AND ARREST CHARACTERISTICS
Baseline demographics did not differ between the two groups (Table 1). There were no 
differences in arrest location, bystander CPR and AED use. Patients with shock-resistant VF 
more often received shocks by the EMS, more often underwent endotracheal intubation, 
and more frequently received epinephrine and amiodarone. There was a significantly higher 
proportion of ST-segment elevation on the post-arrest ECG among patients with shock-
resistant VF (71% vs. 55%, p=0.009). 
CORONARY ANGIOGRAPHY FINDINGS
Comparisons between both study groups are shown in Table 2. The proportion with immediate 
CAG (i.e. immediately after admission) was high, and significantly higher in patients with than 
without shock-resistant VF (97% vs. 89%, p=0.02). There was no difference in the occurrence 
of significant CAD between the two groups (78% vs. 77%, p=0.76). 
An acute coronary occlusion occurred significantly more often in patients with compared to 
those without shock-resistant VF (41% vs. 26%, p=0.006). There was a statistically significant 
association between the number of shocks and the proportion of patients with an acute 
coronary occlusion (Figure 1). There was a trend towards a higher proportion of acute 
occlusions in the LAD and a significantly higher proportion of acute occlusions in the RCA in 
patients with shock-resistant VF. 
There was no difference in the occurrence of CTOs between patients with vs. without shock-
resistant VF (29% vs. 33%, p=0.47), and a trend towards a higher proportion of patients 
undergoing PCI in the shock-resistant VF group (63% vs. 53%, p=0.09). Lesions in patients 
undergoing PCI are described in Supplement 2.
OUTCOMES
Proportions of sustained ROSC, 24-hour survival and survival to discharge were lower in 
patients with compared to patients without shock-resistant VF (Figure 2). 
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TABLE 2. CORONARY ANGIOGRAPHY FINDINGS. 
Shock resistant VF
Overall
Yes (>3 shocks) 
N = 105
No (≤3 shocks ) 
N = 196
p-value
Immediate CAG 277 (92%) 102 (97%) 175 (89%) 0.02
Coronary artery disease
Significant CAD 232 (77%) 82 (78%) 150 (77%) 0.76
  1 vessel 119 (40%) 50 (48%) 69 (35%)
0.17  2 vessel 64 (21%) 19 (18%) 45 (23%)
  3 vessel 49 (16%) 13 (12%) 36 (18%)
Location of significant stenosis
LM 21 (7%) 6 (6%) 15 (8%) 0.53
LAD 142 (47%) 49 (47%) 93 (47%) 0.90
RCx 115 (38%) 33 (31%) 82 (42%) 0.08
RCA 132 (44%) 44 (42%) 88 (45%) 0.67
Acute coronary occlusion
≥1 ACO 93 (31%) 43 (41%) 50 (26%) 0.006
  ACO LAD 47 (16%) 22 (21%) 25 (13%) 0.06
  ACO RCx 27 (9%) 9 (9%) 18 (9%) 0.86
  ACO RCA 26 (9%) 15 (14%) 11 (6%) 0.01
Chronic total occlusion
≥1 CTO 94 (31%) 30 (29%) 64 (33%) 0.47
  CTO LAD 22 (7%) 4 (4%) 18 (9%) 0.09
  CTO RCx 38 (13%) 11 (11%) 27 (14%) 0.42
  CTO RCA 68 (23%) 23 (22%) 45 (23%) 0.85
Percutaneous coronary intervention
≥1 lesion treated with PCI 169 (56%) 66 (63%) 103 (53%) 0.09
  LM 12 (4%) 5 (5%) 7 (4%) 0.62
  LAD 83 (28%) 33 (31%) 50 (26%) 0.27
  RCx 50 (17%) 18 (17%) 32 (16%) 0.86
  RCA 56 (19%) 24 (23%) 32 (16%) 0.15
Coronary angiography findings in patients with and without shock-resistant VF. VF = Ventricular fibrillation; CAG = 
Coronary angiography; CAD = Coronary artery disease; LM = Left main; LAD = Left anterior descending artery; RCx = 
Ramus circumflex; RCA = Right coronary artery; ACO = Acute coronary occlusion; CTO = Chronic total occlusion; PCI = 
Percutaneous coronary intervention.
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FIGURE 1. THE ASSOCIATION BETWEEN THE NUMBER OF SHOCKS AND OCCURRENCE OF AN ACUTE CORONARY OCCLUSION.
Figure demonstrating the association between the number of shocks and occurrence of an acute coronary occlusion 
(ACO). 
FIGURE 2. OUTCOMES IN PATIENTS WITH AND WITHOUT SHOCK-RESISTANT VF. 
Outcomes in shock-resistant vs. non- shock-resistant VF. These are all patients that were transported to the hospital. 




We compared coronary angiography findings between cardiac arrest patients with VF that 
was shock-resistant (>3 shocks) compared to VF that was not shock-resistant (≤3 shocks), and 
found that significant coronary artery disease was present in >75% of patients in both groups. 
Notably, we found 1.5 times as many acute coronary occlusions among shock-resistant VF-
patients and a significant association between the number of shocks and the proportion of 
acute coronary occlusions. Outcomes were also poorer in case of shock-resistant VF. Larger 
registries that confirm our angiographic and clinical outcome data could provide impetus 
randomized controlled studies on the potential benefit of an early invasive approach in 
patients with shock-resistant VF.
CORONARY ANGIOGRAPHY FINDINGS
We found significant CAD (≥1 stenosis >70%) in 78% of patients with shock-resistant VF, which 
is comparable to findings reported in a previous study with 55 patients with VF refractory to 
>3 shocks, without intermittent ROSC.2 However, as in that report a control group without 
refractory VF was lacking, it was unclear whether those findings were exclusive to VF requiring 
multiple shocks, particularly given the high prevalence of CAD in VF-patients in general.13-15, 23
We now demonstrate that significant CAD is also often present in VF that is not shock-resistant 
(77%). The extent of CAD, in terms of number of vessels affected, was also similar between 
both groups. We did, however, find a higher proportion of acute coronary occlusions in the 
group of patients with shock-resistant VF. This is in line with the fact that we also found more 
ST-elevation in this group, as ST-elevation is a strong predictor for ACO.24 Our observations 
could indicate that an ACO in itself may be a trigger or a sustaining substrate of shock-resistant 
VF. 
It could also be hypothesized that an ACO triggers VF, and that VF becomes shock-resistant 
in case of a persisting acute occlusion, while VF that is not shock-resistant occurs in case of 
reperfusion before CAG. Studies on primary PCI show that reperfusion before PCI occurs in 
15-30% of patients.25 Our findings also corroborate with animal studies, which show that VF 
induced by a persistent acute coronary occlusion on average requires more shocks before 
regaining ROSC than VF without persistent coronary occlusion.26, 27 
In terms of PCI-performance, Table 1 shows that there is a significant difference in acute 
coronary occlusions but not in the proportion of patients undergoing a PCI, implying that 
there are relatively many patients without shock-resistant VF group with lesions that are not 
persistently occluded, but in whom PCI has been performed. 
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Regarding the infarct related artery, acute occlusion of the RCA was significantly more frequent 
in case of shock-resistant VF. Based on mechanistic studies, there is a complex interplay 
between the extent of ischemia, the presence of prior infarction, genetic predisposition and 
conduction disturbances in the initiation of ventricular arrhythmias.28-30 As for CTOs, data 
in OHCA-patients is scarce.31 Our findings indicate no association between CTO and shock-
resistant VF. It should be noted that patients with CTO form a heterogeneous group, where 
in some the CTO is related to prior infarction, whereas in others there may be no signs of 
myocardial scar. Importantly, previous studies did not specifically study the role of CTOs in 
shock-resistant VF, and to our knowledge we describe the first study on CAG-findings in this 
patient category with a control group without shock-resistant VF. 
BASELINES, ARREST CHARACTERISTICS AND OUTCOMES
Baseline characteristics and key prognostic arrest characteristics (e.g. public location, 
bystander CPR, AED use) did not differ between both study groups. This provides additional 
support to the hypothesis that the underlying substrate is a major contributing factor to the 
shock-resistancy of VF. To further explore this, we studied and confirmed the association 
between increasing numbers of required defibrillation attempts and a higher likelihood of an 
acute coronary occlusion (Figure 1). 
We found a trend towards a longer response time in shock-resistant VF-patients, which might 
have contributed to VF becoming shock-resistant, given the association between longer VF-
duration and lower shock success.5, 6 In an exploratory post-hoc logistic regression analysis we 
corrected for response time, and the association of an acute coronary occlusion with shock-
resistant VF remained significant (adjusted odds ratio 2.20, p=0.045). However, this analysis 
should be considered hypothesis generating as our study was not designed to identify 
predictors of shock-resistant VF.
In the current cohort, overall survival is high, which could have several reasons. First, we 
selected only VF-patients transported to the hospital and undergoing routine CAG. In a 
previous report from our registry, we studied all, non-selected OHCA-cases and found survival 
to discharge rate of 15%.32 Importantly, the present data corroborate with previous studies 
using similar inclusion criteria.33, 34 Second, we defined shock-resistant VF according to the 
number of defibrillation shocks, in line with previous studies.35 As such, included patients 
may have had intermittent organized rhythm or output between shocks. Other studies, such 
as Yannopoulos et al., exclusively focused on patients with refractory VF without intermittent 
ROSC, with poorer outcomes.2, 11 Third, we found a markedly high proportion of bystander 
AED-use, which is common in the Dutch setting.36  In the Netherlands, AED-use has been 





The high proportion of acute coronary occlusions in shock-resistant VF implies that these 
may be a trigger or substrate for difficult-to-defibrillate VF. In the context of these findings, 
and the current possibilities of transport with mechanical resuscitation and extracorporeal 
membrane oxygenation programs, our data support future initiatives to investigate the impact 
of immediate catheterization in patients with shock-resistant VF.3, 9, 11 Two recently published 
randomized trials (COACT and PEARL) found that early CAG is not beneficial for patients without 
ST-elevation and without ongoing resuscitation. The present study focusses on all VF-patients 
transported to the hospital and undergoing CAG, regardless of the ECG-pattern and whether 
or not ROSC is reached before CAG, and can therefore be interpreted as complementary to 
COACT and PEARL.15, 37 Our findings implicate that the need for multiple shocks might indicate 
a high likelihood of acute coronary occlusion. Whether or not such patients benefit from early 
invasive strategies is an interesting topic for further study. Prerequisite for future intervention 
studies is that our angiographic and clinical outcomes are corroborated by additional studies. 
Importantly, previous reports indeed demonstrated favorable outcomes in case of early 
transportation to the catheterization lab in patients with refractory VF, both in observational 
as well as in pilot randomized studies.2, 11 
The downside of an early-invasive strategy for shock-resistant VF is that several shocks have to 
be awaited before deciding to transport the patient, as the patient only then fulfils the criteria 
for shock-resistant VF. Longer VF- duration is associated with worse outcomes.5, 6 Thus, it would 
be helpful to either predict the chance of VF becoming shock-resistant, or identify a coronary 
occlusion earlier, i.e. at the moment of arrival at the patient. With regard to the former, 
we found no baseline characteristics associated with shock-resistant VF, which precludes 
predicting of the occurrence of shock-resistant VF using such characteristics. Regarding the 
latter, experimental studies suggest that there may be a role for analysis of the morphology of 
the VF-waveform itself in early identification of acute coronary occlusions.38 Animal and human 
studies demonstrate that the VF-signal is markedly altered in case of an underlying coronary 
occlusion.27, 34 This should be investigated further, preferably using prospective studies, which 
are currently lacking.
LIMITATIONS
As stated, we used a cut-off of >3 shocks for defining shock-resistant VF, in accordance with 
the scientific statement of the American Heart Association and previous studies..2, 3 This does 
not necessarily mean that VF has actually persisted through all shocks as we cannot exclude 
the possibility of intermittent return of organized rhythm and VF-recurrence. This is a problem 
frequently encountered in studies on VF requiring multiple shocks, as defibrillator read-out 
is not routinely performed.35 This hampers comparing (outcome) data between different 
cohorts. Future studies should aim for a more uniform methodology to define shock-resistant 
VF, as we previously demonstrated that the type of VF (recurrent or persisting) may impact 
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patient outcomes.39 Although selection bias cannot be excluded, during the study period it 
was hospital policy to perform immediate CAG in all resuscitated VF patients that regained 
ROSC. Arguments not to perform catheterization are shown in Supplement 2: no ROSC at 
any point during CPR was the main reason (67%). Exclusion of the 8% with delayed (i.e. not 
immediately after presentation at the emergency room, but still during the same hospital 
admission) CAG did not alter the results, as can be seen in Supplement 3. Importantly, the 
present study was designed to assess CAG-findings and not to provide in-depth analyses on 
outcome. As such, those findings should be considered hypothesis generating.
Conclusions
In VF-cardiac arrest patients transported to our hospital and undergoing coronary 
angiography, we found significantly more acute coronary occlusions in case VF was shock-
resistant (>3 shocks) compared to when VF was not shock-resistant (≤3 shocks). Shock-
resistant VF-patients had adverse outcome. Larger confirmative registries are warranted and 
the collective evidence may provide impetus for randomized controlled trials on the potential 
benefit of an early invasive approach in patients with shock-resistant VF.
SUPPLEMENTARY MATERIAL
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IMPORTANCE In out-of-hospital cardiac arrest (OHCA), early, on-scene detection of an acute 
coronary occlusion (ACO) during ventricular fibrillation (VF) may facilitate timely triage and 
treatment. Currently, this is restricted to patients with restored organized rhythm. Recent 
experimental data indicates that VF-waveform analysis can detect myocardial infarction 
(MI). This is the first clinical series on its diagnostic performance during cardiac arrest.
OBJECTIVE To investigate the diagnostic potential of VF-waveform analysis to discriminate 
between OHCA-patients with and without an underlying acute MI due to an ACO, using 
single-variable predictors as well as machine learning models combining multiple VF-
characteristics. 
DESIGN, SETTING AND PARTICIPANTS From our prospective OHCA-registry we studied patients 
presenting with VF, transported to a tertiary hospital (Radboudumc, Nijmegen, The 
Netherlands). VF-waveform segments prior to the first defibrillation attempt were used 
to calculate various amplitude and frequency related VF-characteristics. Changes in 
characteristics from the first till second shock were also studied (Δ-characteristics). Presence 
or absence of ACO was determined using 12-lead electrocardiogram, coronary angiography 
and/or autopsy data.
MAIN OUTCOMES AND MEASURES Diagnostic performance of a single-variable model was the 
primary outcome, using the AMSA before the first shock (amplitude spectrum area, a 
key VF-characteristic). In addition, we constructed machine learning models combining 
AMSA and ΔAMSA. Moreover, we explored algorithms that combined various VF-
characteristics. Main outcome measure is the C-statistic (95% confidence interval) of the 
receiver operating characteristic curve. 
RESULTS In total, 111 VF-patients were studied (median age 62 years [51-71], 71% men), of 
which 67 had an ACO. Using only the AMSA prior to the first shock, discrimination between 
ACO and non-ACO patients was feasible (C-statistic 0.66; 0.56-0.75). The machine learning 
model using AMSA+ΔAMSA yielded a C-statistic of 0.80 (0.69-0.88), whereas combinations 
of various VF-characteristics did not further improve algorithm performances.
CONCLUSION AND RELEVANCE This clinical case series of cardiac arrest patients provides the 
first evidence that detection of acute MI due to an ACO seems feasible with use of VF-
waveform analysis, particularly with additional input on VF-waveform changes between 
defibrillation attempts. These findings fuel the concept of patient-tailored treatment 
guided by “smart” defibrillators, and call for further confirmation in larger series. 




Ventricular fibrillation (VF) out-of-hospital cardiac arrest (OHCA) occurs frequently and carries 
a poor prognosis.1 In many cases, the cause of VF is acute coronary occlusion (ACO), for which 
early coronary angiography (CAG) and intervention might be beneficial.2 An important barrier 
for such etiology-directed treatment approaches is that identification of ACO is difficult, and 
currently restricted to the subset of patients regaining organized rhythm.3
A potential tool for earlier detection of an ACO may be analysis of the VF-waveform of the 
defibrillator-derived electrocardiogram (ECG). VF-waveform characteristics, particularly the 
amplitude spectrum area (AMSA), are increasingly recognized as predictors of defibrillation 
success and survival.4, 5 As such, VF-analysis has been incorporated in “smart” defibrillators to 
provide real-time AMSA-quantification, an innovative technique under active investigation in 
a randomized trial to provide guidance on shock delivery (NCT03237910). 
Importantly, several studies have shown associations between myocardial infarction (MI), 
VF-signal characteristics, and changes in VF-morphology during the course of the arrest.6-8 
In terms of diagnostic potential, the first in-human experimental data has recently been 
published that MI can be detected using VF-characteristics, supporting the concept of a 
diagnostic defibrillator with use of machine learning techniques.9 However, a clinical study 
on the diagnostic performance of this new technology has yet to be performed. To provide 
first insights, we present a clinical case series in which we studied VF-waveform based 
discriminative models to detect acute MI due to ACO in a real-world VF-cohort. 
Methods
STUDY POPULATION
From our prospective OHCA-registry10, we studied adult VF-patients transported to the 
Radboudumc (Nijmegen, The Netherlands). We excluded patients without (analyzable) 
defibrillator ECG-recordings or sufficient information to determine the presence/absence 
of ACO. The need for informed consent of this non-interventional observational study was 
waived by the local Medical Ethics Review Board.
DATA ACQUISITION
Collection of baseline characteristics (EMS and hospital records) was done following Utstein 
recommendations. ECG-signals (sampling frequency 125Hz) were obtained with defibrillator 
pads (Lifepak12, PhysioControl). Signal analyses (Matlab 2020a, Mathworks) were performed 
on three-second, artefact-free VF-segments prior to the first shock for calculation of 
AMSA (frequency interval 2-48Hz) and a series of other VF-characteristics.4, 9 Moreover, in 
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patients with >1 shock, we calculated relative changes between the first and second shock 
(Δ-characteristics).
STUDY AIM
Primary aim was to assess the performance of a single-variable approach to distinguish ACO 
from non-ACO patients, using AMSA prior to the first defibrillation attempt. Secondarily, we 
studied the discriminative ability of machine learning based models combining AMSA and 
ΔAMSA-measures. Finally, we explored models combining various VF-characteristics.
GROUP DEFINITION
ACO-classification was based on previously reported methodology: patients that met the 
universal definition of MI and had regional ST-elevation and/or an obstructive acute lesion on 
CAG or autopsy were categorized as ACO. All other patients were categorized as non-ACO.3, 11
DISCRIMINATIVE APPROACHES
For the primary aim (single-variable approach), AMSA was used as continuous test variable 
(Table 1). For multiple-variable approaches, machine learning techniques were used, with 
the construction of support vector machine (SVM) models, adhering to previously reported 
methodology (Supplement 1).9
TABLE 1. THE DIFFERENT APPROACHES USED IN THIS STUDY FOR DETECTION OF ACUTE CORONARY OCCLUSION WITH USE OF VF WAVEFORM ANALYSIS.
Approach Method VF-waveform information Input features
Primary aim: AMSA-only
#1 Single predictor AMSA-only AMSA
Secondary aim: AMSA+ΔAMSA
#2 SVM model AMSA-only and AMSA-course AMSA, ΔAMSA
Exploratory analyses: Additional VF-characteristics
#3 SVM model Entire set of VF-characteristics AMSA, MAA, DF and OI
#4 SVM model Entire set of VF-characteristics  
and their course
AMSA, MAA, DF, OI,  
ΔAMSA, ΔMAA, ΔDF 
and ΔOI
Table showing the four different approaches for constructing discriminative models. Approaches #2 and #4 only 
apply to patients receiving >1 shock. ACO = acute coronary occlusion; AMSA = Amplitude spectrum area;, DF = 
Dominant frequency;  MAA = Mean absolute amplitude; OI = Organization index; SVM = support vector machine; VF 
= Ventricular fibrillation;  Δ = relative changes in VF-characteristics between shock 1 and 2.
STATISTICS
Continuous variables were described as medians (interquartile ranges) and compared using 
Mann Whitney U-tests. Categorical variables were presented as numbers (percentages) and 
compared using χ2-tests (SPSS 25, IBM). Receiver operating characteristic (ROC) analysis was 
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performed (MedCalc 19.1.3, MedCalc Software) for assessment of discriminative ability. 
C-statistics (95% CI) were considered the main outcome measure for model performances, 
and compared using DeLong’s method. P<0.05 was considered statistically significant.
Results
BASELINE CHARACTERISTICS
Of the 111 patients (Supplement 2), median age was 62 years [51-71], 71% were men and 
ACO was present in 60% (67/111). Baseline characteristics were similar, except for a trend 
towards higher response times in the ACO than in the non-ACO group (8 vs 7 minutes, 
p=0.05). Seventy-five patients (68%) received more than one shock (Table 2).
IDENTIFICATION OF ACO
Discrimination between ACO and non-ACO patients using only AMSA prior to the first shock, 
resulted in a C-statistic of 0.66 (0.56-0.75), Figure 1a. The SVM-model using AMSA and 
ΔAMSA resulted in a C-statistic of 0.80 (0.69-0.88), Figure 1b. Models that combined various 
VF-characteristics did not improve diagnostic performance (Supplement 3). 
Discussion 
In the setting of cardiac arrest, we present the first clinical series on the diagnostic 
performance of VF-waveform analysis of defibrillator-derived ECG-measures, providing 
supportive evidence for the future development of a diagnostic ‘smart defibrillator’ with 
built-in signal analysis techniques to detect acute MI while patients are in ventricular 
fibrillation. We found that AMSA was moderately able to detect patients with an ACO, while 
incorporation of ΔAMSA-measures tended to improve diagnostic performance. These pilot-
data require further confirmation, as this innovative technology may eventually contribute to 
earlier diagnosis and timely triage of OHCA-victims with a treatable underlying cause.
Animal and human studies demonstrated that VF due to MI has distinct ECG characteristics, 
i.e. low voltages and lower frequency content, with a more marked effect in acute MI than in 
prior MI.7, 12 In an animal study, acute MI could be diagnosed with a single-variable approach, 
using the AMSA (C-statistic 0.85).12 Recently, the first in-human proof of concept study was 
published, demonstrating the feasibility of detection of prior MI in an experimental setting 
(C-statistic 0.61).9 The present real-world OHCA-study builds on these findings, and provides 




Applying machine learning techniques combining AMSA with ΔAMSA, discriminative ability 
tended to improve (C-statistic 0.80 vs. 0.66, p=0.07) in the subgroup with >1 shock. Changes 
in AMSA may reflect changes in myocardial perfusion and myocardial metabolic state, with 
improvement after chest compressions.13 Although, on a group level, univariate comparisons 
showed no difference in Δ-characteristics between groups (Table 2), it was with machine 
learning algorithms that we identified the potential distinctive ability of ΔAMSA (Supplement 
4). In line with our previous study, machine learning algorithms that combined various VF-
characteristics did not improve model performances.9
Our main implication is that VF-analysis might facilitate earlier detection of MI due to an acute 
occlusion, a major cause of difficult-to-defibrillate VF.14 Current diagnostics are limited to the 
subset of patients that regain organized rhythm, often in a later phase of the arrest.3 VF-
analysis is possible in all patients, and in a very early phase of the arrest, potentially shortening 
the delay-to-diagnosis, and facilitating early, etiology-directed hospital transportation and 
prompt angiography. Especially this group with a treatable underlying cause may constitute 
a target population for early hospital transportation in case of refractory VF, with support of 
a mechanical resuscitation devices or ECMO.15
The present study is limited in sample size and requires additional, larger studies in terms of 
confirmation and generalizability. Moreover, with larger datasets, machine learning models 
can reach full potential, and may yield superior approaches than presented here. 
Appreciating that currently studied “smart” defibrillators already possess the technology for 
real-time AMSA assessment, our findings support further developments towards a diagnostic 
application that may be tested in search of new strategies to improve outcome after cardiac 
arrest.
Conclusion
This clinical series of OHCA-patients provides the first evidence that detection of MI due to an 
acute coronary occlusion seems feasible with use of VF-waveform analysis, particularly with 
input on VF-changes from the first to second shock. These findings fuel the concept of smart 
diagnostic defibrillators and call for further confirmation in larger studies. 
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Age (years) 62 (51-71) 60 (49-71) 62 (54-62) 0.45
Male sex 79 (71) 49 (73) 30 (68) 0.57
Arrest characteristics
Public arrest 49 (44) 30 (45) 19 (43) 0.87
Witnessed arrest (n=108) 93 (86) 57 (88) 36 (84) 0.56
Bystander CPR (n=108) 72 (77) 44 (68) 28 (65) 0.78
AED shock (n=108) 9 (8) 5 (8) 4 (9) 0.49
Response time (min) (n=101) 8 (6-10) 8 (6-11) 7 (5-9) 0.05
Number of EMS shocks 3 (1-6) 4 (1-6) 3 (1-5) 0.27
≥ 2 EMS shocks 75 (68) 47 (70) 28 (64) 0.47
Clinical outcome










































Table showing baseline characteristics in all patients (first column), patients with an underlying ACO (second 
column) and patients without an underlying ACO (third column). P-values represent comparisons between ACO 
and non-ACO patients. ACO = Acute coronary occlusion, CPR = Cardiopulmonary resuscitation, AED = Automated 
external defibrillator, EMS = Emergency medical services, AMSA = Amplitude spectrum area, MAA = Mean absolute 
amplitude, DF = Dominant frequency, OI = Organization index, Δ= relative change in VF-characteristics between 
shock 1 and 2 (e.g., ΔAMSA = AMSA2/AMSA1). 
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FIGURE 1. ROC-CURVES FOR DETECTION OF ACUTE CORONARY OCCLUSION WITH USE OF VF-WAVEFORM ANALYSIS.
Figure showing ROC-curves of diff erent approaches to discriminate ACO from non-ACO pati ents. [a] AMSA-only, 
prior to the fi rst shock att empt, based on the total study populati on (n=111); [b] light blue represents AMSA-
only, prior to the fi rst shock att empt, based on the subset with >1 shock (n=75); dark blue represents a support 
vector machine model with the AMSA prior to the fi rst shock and the relati ve AMSA-change with the second shock 
(ΔAMSA), based on the subset of >1 shocks (n=75). ACO = Acute coronary occlusion, AMSA = Amplitude spectrum 
area, ROC = receiver operati ng characteristi c, VF = Ventricular fi brillati on, Δ = relati ve change in VF-characteristi cs 
between shock 1 and 2.
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Supplement File 1. Support vector machine process
Support vector machine (SVM) is a machine learning technique which enables discrimination 
between two classes by an algorithm that maximizes the distance between these classes, 
using a prespecified amount of input features. The mathematical function that gives 
the optimal separation between the classes is called the hyperplane, which allows for 
discrimination between the two classes. SVMs have been used in multiple VF-studies to 
combine VF-waveform characteristics and predict defibrillation success, clinical outcome 
measures and underlying heart disease (Howe et al, Resuscitation 2014, Coult et al, Circ 
Arrhythm Electrophysiol 2019; Thannhauser et al, JAHA 2020).
For construction of the SVM-models in the current study, we used Matlab (version 2020a, 
The Mathworks, Natick, MA, USA).
INPUT FEATURES
The input feature matrix consists of N x M elements, with N the number of patients and M 
the number of input features. The value of M is determined by the amount of VF-waveform 
characteristics used (either an approach with the amplitude spectrum area (AMSA) only, 
or a combination the following VF-characteristics: AMSA, mean absolute amplitude (MAA), 
dominant frequency (DF) and organization index (OI)), and whether or not the so-called 
Δ-characteristics were added to the model. These Δ-characteristics represent the relative 
change of the abovementioned VF-characteristics between the first and the second shock 
delivery. The value of N and M in the different approaches is presented in Table S1.
TABLE S1: INPUT FEATURES OF DIFFERENT SVM APPROACHES IN THIS STUDY.
Approach SVM-model Input features N x M
Approach 1 No SVM-model N/A N/A
Approach 2 SVM-model 1 AMSA, DF, MAA, OI 111 x 4
Approach 3 SVM-model 2 AMSA, ΔAMSA 75 x 2
Approach 4 SVM-model 3 AMSA, ΔAMSA, MAA, ΔMAA, DF, ΔDF, OI, ΔOI 75 x 8
AMSA = amplitude spectrum area; DF = dominant frequency; MAA = mean absolute amplitude; M = number of input 




All SVM-models were created using the Matlab function fitcsvm. Identical SVM settings were 
used for all models: the box constraint was set to 1, a Gaussian kernel function was used 
with a kernel scale of 1 and the option Standardize was set to “true”. An overview of all SVM-
settings is provided in Table S2.
TRAINING AND VALIDATION SETS
The SVM-models were subjected to five-fold cross-validation using the crossval function in 
Matlab. This was done according to a cross-validation partition created with the function 
cvpartition, with the option Stratify set to “true”. As such, each of the five training sets and 
corresponding validation sets had a fixed 60/40 ratio of ACO and non-ACO cases. For example, 
of the 111 patients one fold may consist of a training set with 89 cases (80%), of which 54 
(60%) had ACO, and a validation set with 22 cases (20%) of which 13 (60%) had ACO. The 
cross-validated model was used as input for the kfoldPredict function in Matlab, as a means 
to calculate the classification scores of all the cases, to be used in the ROC-analysis.
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Supplement File 2. Patient flowchart
* Of these 40 patients, 36 did not have return of spontaneous circulation upon arrival at the emergency department 
and none survived until 24 hours after admission. ACO = Acute coronary occlusion; ECG = electrocardiogram; OHCA 
= Out-of-hospital cardiac arrest, VF = Ventricular fibrillation.
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Supplement File 3. Discriminative performances of the 
different approaches to distinguish ACO from non-ACO 
patients with use of the VF-waveform.
Figure showing C-statistics of the four discriminative models and their 95% confidence intervals. Model 1: AMSA-
only, prior to the first shock attempt; Model 2: Support vector machine (SVM) model with the entire set of VF-
characteristics prior to the first shock, p=0.52 vs Model 1; Model 3: SVM model with AMSA prior to the first shock 
and the relative change of AMSA between the first two shocks (ΔAMSA). Model 4: SVM-model with all VF-waveform 
characteristics prior to the first shock and their relative changes with the second shock (Δ-characteristics), p=0.92 vs 
Model 3. ACO = Acute coronary occlusion, AMSA = Amplitude spectrum area; VF = Ventricular fibrillation.
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Supplement 4. Scatter plot of AMSA1 and ΔAMSA
Figure showing a scatter plot of the subset of patient with ≥ shocks, with on the horizontal axis the AMSA prior to 
the first shock (AMSA1) and on the vertical axis the relative change in AMSA between the first two shocks (∆AMSA 
= AMSA2 / AMSA1). The yellow areas illustrate the decision boundaries of the discriminative model, which was the 
result of one representative iteration of the 5-fold cross validation in the SVM-process. Although baseline values of 
∆AMSA did not differ between the groups, this figure illustrates how nonlinear machine learning approaches may 
have value  in the distinction  between ACO and non-ACO-patients. In this figure, a cluster of ACO-patients is visible 
in whom AMSA prior to shock 1 is low, and ∆ is typically lower than 1.5. ACO = acute coronary occlusion; AMSA = 
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In this thesis, we studied promising technological innovations which have been investigated 
to try and improve treatment and outcomes of out-of-hospital cardiac arrest (OHCA). 
THE IMPORTANCE OF BYSTANDER CARE
OHCA is a unique medical emergency, of which the outcome is importantly determined by 
adequate prehospital care, defined by a well-coordinated “chain of survival”; a complex 
infrastructure involving (trained) bystanders, strategically placed automated external 
defibrillators (AEDs) and rapid activation of emergency medical services (EMS).1 With the 
ubiquitous use of smartphones, the network of trained civilians has increased over the 
years.2 Together with the increased availability and use of AEDs, OHCA-survival has improved 
to about 25%.3 Our national text message system (HartslagNu) has importantly contributed 
to timely care for OHCA-victims.4, 5 However, to reach the full potential of this network, more 
awareness and registration of trained citizens and AEDs is essential.
Crucial factors in this process are recognition of cardiac arrest by bystanders, and subsequent 
high-quality basic life support (BLS) and early defibrillation. Current resuscitation guidelines 
highlight the urge for community initiatives to promote bystander awareness, as unrecognized 
cardiac arrest can result in unnecessarily delay to the start of cardiac massage and availability 
of an AED.6-8 Importantly, focus should not only lie on typical signs (i.e. non-responding and 
non-breathing or agonal breathing) but also on atypical signs (e.g. gasping, uncontrolled 
movements) as these may even be missed by health professionals, for example in young 
athletes with sudden cardiac arrest during a sports match.9
To improve arrest recognition and the quality of bystander cardiopulmonary resuscitation 
(CPR), current American Heart Association (AHA) guidelines highlight the importance 
of effective education as an important contributor to OHCA-survival.6 In the area of CPR-
training, new tools such as virtual reality (VR) applications have evolved.10 Such modalities 
have the potential to provide incomprehensive, low-cost CPR-training, where and whenever 
convenient, in a more realistic environment than CPR-training with standard manikins. 
Experts in the field consider VR as one of the most promising tools in medical training in 
general and CPR training in particular.11, 12 In this thesis, we demonstrated that CPR-training 
with a VR-app resulted in similar chest compression rate, but inferior chest compression 
depth when compared to conventional face-to-face training.13 Although VR may result in 
more widely disseminated CPR training, our results indicated that further development of 
such applications is needed to achieve sufficient skills with regard to the quality of chest 
compressions. On the other hand, we observed that at least half of the participants in the 
VR-group met the guideline-endorsed depth or rate requirements. Interestingly, results 
from subanalyses revealed a significant interaction between previous CPR-training and 
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chest compression depth, with smaller differences in depth in participants with previous 
CPR-training. This indicates that VR-training may serve as a good retraining alternative for 
individuals who were initially trained using the standard approach, which requires further 
study. All in all, VR-applications seem a promising modality to improve public awareness, 
arrest recognition and CPR-quality in the future.
TOWARDS AN OPTIMIZED AED NETWORK
Over recent years, bystander care has improved in our region, a factor that has contributed 
to increased OHCA survival rates, especially in patients with shockable initial rhythms.14, 15 In a 
previous study on a series of patients transported to the Radboudumc, we demonstrated this 
increase in survival (Figure 1).14 While characteristics of transported OHCA-victims remained 
similar between the two periods  (mean age 66 years, 75% males, 79% witnessed arrests) we 
observed a marked increase in bystander CPR and AED use between 2008-2011 and 2013-2016.
FIGURE 1. BYSTANDER CARE IN THE REGION OF NIJMEGEN.
Figure representing cardiac arrest victims transported to the Radboudumc, Nijmegen, The Netherlands in two 
cohorts. AED = automated external defibrillator; CPR = cardiopulmonary resuscitation. Data: Nas et al, Neth Heart 
J, 2018.14
To further improve these promising numbers, in particular AED availability and use, the 
Dutch Heart Foundation and our national text-message alert system HartslagNu stimulate 
registration of trained civilians and AEDs. With use of an interactive online map, civilians 
can find the optimal location to attach their registered AEDi. As such, the aim is to move 
towards a national optimal AED infrastructure, to ensure that OHCA-victims in the future can 
be reached within the crucial 6 minutes.
i    https://www.hartstichting.nl/aed 




In a later phase, when the emergency medical services (EMS) have arrived, innovations 
in advanced cardiac arrest care have improved the treatment options of EMS-personnel. 
Technical developments such as mechanical chest compression devices and extracorporeal 
life support may facilitate more individualized treatment strategies of cardiac arrest victims, 
with the potential to improve outcomes.16
The main focus point of the presented articles in this thesis was the potential incorporation 
of VF-waveform analysis into ‘smart’ defibrillators, as a new method to provide patient-
specific information in the earliest stages of cardiac arrest, as a means to improve triage 
and treatment of OHCA-patients. Potential applications of this technique are 1) prediction of 
prognosis, 2) guidance of defibrillation and 3) identification of underlying heart disease, in 
particular a myocardial infarction (MI).
THE RISE OF THE AMPLITUDE SPECTRUM AREA IN CARDIAC ARREST RESEARCH
Clinical research on the VF-waveform goes back to the 1980s, when Weaver and colleagues 
demonstrated an association between VF-amplitude and survival from cardiac arrest.17 In 
2000, Povoas and Bisera introduced a new VF-waveform characteristic: the amplitude 
spectrum area (AMSA, Figure 2).18 In a porcine model, they stated that AMSA could predict 
return of spontaneous circulation (ROSC) and, more importantly, had a very high negative 
predictive value (96%) to predict that a shock would fail to reestablish spontaneous circulation. 
They concluded that AMSA could have the potential to guide optimal defibrillation timing.
Now, in the 2020s, numerous animal and human studies have confirmed the potential of VF-
waveform characteristics as a marker for myocardial state, and a predictor of shock success 
and prognosis.19-22 In the largest VF-waveform registry to date, comprising a total of 1617 
OHCA-patients, threshold values for AMSA have been determined for shock success (≥15.5 
mVHz) and failure (≤6.5 mVHz).21 These cut-offs are currently being used in an international 
randomized trial, studying a new defibrillation protocol for its potential to improve shock 
success and OHCA-outcomes.23
Appreciating that a current randomized trial investigates the potential of AMSA to adjust 
the optimal timing of defibrillation, we appear to be on the cusp of a new phase in cardiac 




FIGURE 2. FIRST DESCRIPTION OF THE AMPLITUDE SPECTRUM AREA (AMSA). 
Figure reprinted from the article of Povoas and Bisera, Crit Care Med, 2000, with permission.18 
Before such new VF-waveform guided algorithms are clinically applicable, some important 
issues have to be investigated. In this context, we studied clinical and technical aspects 
of the VF-waveform, in particular the AMSA. Moreover, besides optimal shock timing, we 
introduced a potential new application of VF-waveform analysis: identification of MI as the 
underlying cause of the arrest.
It has to be noted that most information on AMSA, including the abovementioned registry 
from which AMSA threshold values have been derived, stems from resuscitation attempts 
with a relatively short duration, i.e. with an average of 2 shocks per patient.21 Appreciating 
that 40-50% of all OHCA-patients need more than three defibrillation attempts, we sought 
to assess whether associations between AMSA and shock success persisted beyond the first 
shocks, and applied for later phases of resuscitation as well.24 As we observed in Chapter 4 
of this thesis, AMSA-values become lower over the course of resuscitation, which is plausible 
from a physiological point of view, as the myocardial metabolic state deteriorates over time.25 
Importantly, we showed that associations of AMSA with shock success differed between early 
and late phases of resuscitation. While we found strong associations between AMSA and 
shock success in the early phase (shocks 1-3), these were less consistent in later shocks (4-8). 
Although the exact mechanisms of lowering AMSA values over the course of resuscitation 
require further investigation, the observed differences between early and late phases may 
have pragmatic implications for the use of AMSA-guided shock delivery. First, we recommend 
for future studies to further investigate until what time point the association between AMSA 
and shock success is still present. Second, it seems important to improve our knowledge 
and define characteristics of those patients who reach this “late” phase of resuscitation, in 
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relation to patients who regain organized rhythm in the early phase of resuscitation. Given 
that prolonged resuscitation is associated with a worse prognosis, this patient subset may 
be a target group for other resuscitative strategies.6, 26 Moreover, it cannot be ruled out 
that threshold values of AMSA derived from registries with relatively short resuscitations, 
may change over the course of the arrest in patients with prolonged VF. If we want to take 
this promising new technique to larger scale clinical studies, it seems important to improve 
our understanding on AMSA and its behavior over time, as well as the potential effects on 
threshold values for shock success.
TOWARDS A UNIFORM METHODOLOGY FOR AMSA DERIVATION
Besides clinical factors such as the course of AMSA over time, reproducibility of AMSA-
values is also essential when using this technique for clinical decision making. Previous 
studies demonstrated that positioning of the defibrillator electrodes may vary greatly in 
clinical practice.27-29 In Chapter 5 we observed that the used electrocardiographic recording 
direction markedly affects the resulting AMSA-value, with 20-30% lower AMSA-values when 
the ECG was recorded in a more horizontal direction.30 This underestimation of AMSA mostly 
influenced the advice for prompt defibrillation, when using the threshold of 15.5 mVHz 
for a high AMSA. Translated to the OHCA setting, calculation of absolute AMSA-values by a 
smart defibrillator may therefore be subject to pad placement and consequently influence 
the shock advice given by a defibrillator. These findings underscore the urge of standardized 
electrode placement while implementing VF-waveform analyses in clinical practice.
In addition to ECG recording direction, we demonstrated that the procedure to calculate 
AMSA is important for the resulting AMSA-value. As for AMSA-assessment, one can 
distinguish three consecutive processes: acquisition of the ECG-signals, data selection 
and processing, and calculation of AMSA using a certain mathematical formula. In current 
literature, AMSA-values vary markedly, ranging from a maximum of 10 mVHz in the one, to 
about 100 mVHz in other studies.31 This may be caused by the fact that choices with regard 
to the three abovementioned processes also vary among studies. As we demonstrated in 
Chapter 6, the resulting AMSA-value importantly depends on methodological factors in the 
process. We observed up to 3-fold differences in absolute AMSA-values calculated on the 
same cohort, while varying the sample frequency, VF-segment length and AMSA frequency 
interval of the AMSA process. Especially the segment length had a marked impact on AMSA, 
with up to 87% differences in absolute AMSA-values while obtained on the same VF-cohort. 
Moreover, although the predictive ability for shock success remained present with varying 
AMSA-methodology, we observed a clear impact on threshold values for shock success 
and -failure.  These findings implicate that from a research point of view, studies on AMSA 
are useful as they provide mechanistic information and give insight in pathophysiological 
processes related to the VF-waveform. However, the observed differences in absolute AMSA 
values complicate interpretation of studies and the inherent derivation of absolute threshold 
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values to be used in clinical practice. Moreover, they limit the possibility of data pooling. 
All-in all, if AMSA is being used for future smart defibrillator applications, a more uniform 
approach seems required. Factors with regard to data acquisition (placement of defibrillator 
pads, characteristics of exported, raw, VF-signals) in the first place, and signal processing 
and AMSA-calculation in the second, should be protocolized as much as possible. Notably, 
information on each of the three processes was lacking in many studies (Table 1). Therefore, 
to improve our understanding and interpretation of AMSA-values, we feel that it is important 
to describe the used methodology in future AMSA studies, especially if the used method 
deviates from the gold standard. 
THE VF WAVEFORM AND UNDERLYING HEART DISEASE
The first descriptions on the association between VF-waveform characteristics and underlying 
heart disease date from the early 2000s. Animal studies demonstrated an effect of both 
previous and acute myocardial infarction (MI) on VF-morphology (i.e. amplitude, frequency), 
as well as on the evolution of such VF-characteristics over time.32-34
In human studies on the relation between the VF-waveform and underlying etiology, it has 
been shown that factors such as a low left ventricular (LV) ejection fraction, an increased LV-
diameter and the use of antiarrhythmic drugs (betablockers, amiodarone) are associated with 
decreased VF-frequencies.35-37 In part III of this thesis, we provided evidence that previous MI is 
associated with lowered amplitude- and frequency VF-characteristics in humans as well.38 
In experimental studies on 12-lead registrations of induced VF on the catheterization lab, we 
observed that the VF-waveform was affected by the presence of a previous MI, especially in leads 
adjacent to the area of infarction. Moreover, we found that increased left ventricular (LV) mass led 
to regionally higher VF-amplitudes.39 As opposed to these localized VF-waveform differences, we 
observed that an increased LV-diameter resulted in higher VF-frequencies among all ECG-leads.39 
These findings implicate that factors involving the whole left ventricle rather than a specific area, 
seem to cause diffuse lowered VF-frequency, while a previous MI – which can be regarded a more 
localized problem – seems to cause regional differences on the ECG. 
Altogether, our observations have two important implications. The first is that “fine” VF 
during cardiac arrest may not necessarily reflect long arrest duration and a  low chance of a 
successful defibrillation, but could also indicate the presence of underlying MI. For example, 
in an OHCA patient with a previous MI, a low AMSA measured with the defibrillator ECG 
might be the result of a previous inferior MI rather than the time-in-VF. On the other hand, 
factors such as LV hypertrophy may cause an overestimation of the AMSA, resulting in 
relatively high AMSAs in patients with a prolonged arrest duration. Hence, our observations 
may subsequently impact the predictive ability of AMSA and inherent threshold values for 
shock success. As such, this may have impacted results of trials on VF-guided resuscitative 
strategies.23, 40
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TABLE 1. KEY ELEMENTS OF AMSA METHODOLOGY AS DESCRIBED IN CURRENT LITERATURE.
Methodologic element Specified in studies
N=43
Data acquisition
Sampling frequency 33 (77%)
Device type 41 (95%)
Device brand 37 (86%)
Selection and processing
Length of VF-segment 40 (93%)
Type of VF-segment 36 (84%)
Filtering options 27 (63%)
AMSA calculation
AMSA frequency interval 27 (63%)
AMSA description/formula 36 (84%)
Second, given the localized effect of an MI on VF-waveform characteristics, the use of multiple 
leads may provide additional, patient-specific information. Interestingly, we observed that 
amplitude characteristics in lead V1 were never affected by underlying left ventricular heart 
disease, indicating that this lead reflects the “true” VF-waveform and may therefore serve as 
a more reliable indicator of arrest duration and defibrillation success.
THE VF WAVEFORM AS A DIAGNOSTIC TOOL
In follow up on studies on associations between the VF-waveform and underlying heart 
disease, we investigated a novel application of VF-analysis in this thesis: identification of 
underlying MI.
As a first step, we designed a proof-of-concept study on identification of patients with a 
previous MI in the population of ICD-recipients with induced VF in the electrophysiology 
lab.41 In this study, we provided the first evidence that detection of MI seems feasible with 
VF-waveform based models. Although the discriminative ability was modest for the AMSA of 
ECG-lead II (which can be regarded as a surrogate for the recording direction of defibrillator 
pads) as a single variable predictor, we found moderate to good discrimination abilities when 
adding information of multiple leads with use of machine learning models. We assume that 
this increase in discriminative ability is caused by the regional ECG-differences in case of  an 
MI, which can better be detected when using multiple ECG-leads. This hypothesis is supported 
by our observations that machine learning models combining information from 12 ECG-leads 
were very accurate in the identification of the infarcted area in patients with a previous MI 
(C-statistic 0.89), which was superior to a single lead approach (C-statistic 0.77, Figure 3).
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The promising results of our experimental proof-of-concept study raised the question whether 
the VF-waveform could also contribute to diagnosis of an acute MI in the out-of-hospital 
setting. It is known from previous investigations that an acute MI based on an acute coronary 
occlusion (ACO) is a major cause of difficult-to-defibrillate VF.42, 43 This is supported by our 
observations in Chapter 10, in which we demonstrated that in patients who needed more 
than three shocks during out-of-hospital resuscitation (so-called shock-resistant VF patients) 
we found significantly more ACOs during post-arrest coronary angiography (CAG) than in 
patients with 3 or less defibrillation attempts.44 Appreciating that prolonged resuscitation 
and multiple shocks are negatively correlated with survival, it has been hypothesized whether 
early hospital transportation for percutaneous intervention may be beneficial for this specific 
patient subset with an ACO.16, 24, 43 However, ACO-diagnosis is currently restricted to patients 
who regain organized rhythm, making etiology-driven strategies impossible in very early 
phases of resuscitation.45 Hence, there is need for new methods to diagnose ACO during VF, 
prior to restoration of organized rhythm.
FIGURE 3. DISCRIMINATION BETWEEN ICD PATIENTS WITH ANTERIOR AND INFERIOR PREVIOUS MI.
Figure presenting receiver operating characteristic (ROC) curves. The blue ROC-curve represents a model using VF-
characteristics of a single lead model (II) only, C-statistic = 0.77. The red ROC-curve is based on a machine learning 
model with VF-waveform characteristic input of 12 ECG leads, C-statistic = 0.89. ECG = electrocardiogram; ICD = 
implantable cardioverter defibrillator; MI = myocardial infarction; VF = ventricular fibrillation. Figure adapted from 
Thannhauser et al, JAHA 2020.41
General discussion and future perspectives
225
12
FROM PREVIOUS MI TO ACUTE MI
To translate our findings of MI-detection with VF-waveform analysis to the clinical setting, 
there are some issues to discuss. First, in our proof-of-concept study we investigated induced 
VF in the electrophysiology lab. Such rhythm recordings reflect very early VF, in an earlier 
stage than observed during OHCA, and has previously been reported to be more organized 
than spontaneous, in-field VF.46 This may limit generalizability to VF in the OHCA setting. 
Moreover, the method with multiple leads is not possible during OHCA, as in real-world VF-
patients the defibrillator ECG only measures one single lead.
On the other hand, animal data have demonstrated that, when compared to a previous MI, 
acute MI seems to have an even larger effect on VF-characteristics.32, 34 This led to a first 
experimental swine study on MI-identification, which showed a discriminative ability of AMSA 
for acute MI of 0.85.34 Evidence in humans is contradictory, as some studies have observed 
differences between OHCA patients with and without acute MI, while others did not.47-49 
Results of a recent study indicated that a STEMI results into more apparent VF-waveform 
differences than a previous MI.48 Interestingly, in that study Hulleman et al demonstrated 
that OHCA-patients with a previous MI, who presented with a STEMI, had the lowest AMSA 
values (Figure 4).
To provide first insights into the diagnostic ability of VF-analysis to detect acute MI in real-
world cardiac arrest patients, we performed a pilot study on patients of our prospective 
OHCA-cohort with available VF-waveform and CAG data. In this study we demonstrated that 
the AMSA – derived from a 3-second VF segment prior to the first shock delivery – had a 
moderate discriminative ability for identification of an ACO during post-arrest CAG (C-statistic 
0.66).50 This is in line with our proof-of-concept study, in which we found a C-statistic of 0.61 
for the AMSA-only approach.41 Interestingly, information on the course of the VF-waveform 
(ΔAMSA) seemed to improve the diagnostic yield to 0.80. From a mechanistic perspective, it 
has been hypothesized that such an increase, which can occur following chest compressions, 
indicates an improvement in myocardial metabolic state.25, 51, 52
It seems plausible that patients with an ACO do not experience AMSA-increases, as coronary 
perfusion may not improve due to CPR in these patients. Although of a limited sample 
size (n=111), our observations on ACO-detection are very promising and suggest that VF-
waveform information from the paddle-ECG can contribute to early identification of an acute 
MI during out-of-hospital cardiac arrest.
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FIGURE 4. TUKEY BOX PLOT OF AMSA VALUES IN VF CARDIAC ARREST PATIENTS.
Patients are divided based on the presence of a ST-elevation myocardial infarction (STEMI) and a medical history of 
a previous MI. AMSA = amplitude spectrum are; VF = ventricular fibrillation. Data: Amsterdam Resuscitation Studies 
(ARREST). Figure reprinted from the thesis of M. Hulleman, 2020, with permission.48
Future directions
Over the years, technical-medical innovations have played a key role in improved OHCA-
outcomes, in the whole cascade of prehospital treatment. The first step towards maintaining 
this trend is optimized bystander care in terms of improved cardiac arrest recognition and 
accessible CPR training. Text-message alert systems have proven their benefits and should 
be developed in such a way that all OHCA-victims can be reached within the crucial first 6 
minutes of a cardiac arrest. A major challenge is to improve the network of trained civilians 
and registered AEDs, not only in densely populated regions but also in suburban and rural 
areas. Innovative, incomprehensive training methods such as VR applications, together with 
optimization of our national AED network, seem promising and warrant further study.
After arrival of EMS-personnel, current developments in advanced life support have been 
aiming towards more individualized treatment strategies. As opposed to the conventional 
“stay and play” approach, in which OHCA-patients are treated at-the-scene until return 
of spontaneous circulation is achieved, EMS-personnel now have the opportunity for so-
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called “scoop and run” strategies. With use of mechanical chest compression devices and 
extracorporeal membrane oxygenation (ECMO), OHCA-patients can be transported during 
the resuscitation attempt, to facilitate early, specialized treatment.
A target group for such early invasive strategies seem patients with refractory cardiac arrests. 
This patient subset with prolonged resuscitation attempts and multiple defibrillation attempts, 
are at a high risk of mortality and poor neurologic outcome, and have gained increasing 
interest in recent years. A wide variety of treatment strategies has been studied for refractory 
VF patients, ranging from experimental studies to a pilot trial on dual sequential defibrillation, 
and a large randomized trial on amiodarone.53, 54 Recently, more invasive approaches have 
been studied, and a recently published study indicated that a strategy with early, ECMO-based 
transportation may be beneficial.16, 42 Notably, it was shown that significant coronary artery 
disease (CAD) was present in 82% of all patients with refractory VF, with acute thrombotic 
lesions in 64%, and that a ‘scoop and run’ strategy was associated with better outcomes in 
these patients.42 Results of a recent randomized trial underscored the potential of ECMO-
based resuscitative strategies in refractory VF-patients.55
As we described in this thesis, analysis of the VF-waveform may contribute to more 
individualized treatment approaches during OHCA. Although we touched upon some clinical 
and technical issues that have to be optimized in the process of assessment of VF-waveform 
characteristics, this new technique has the potential to provide patient-specific information in 
very early phases of the resuscitation. In the quest towards more patient-tailored strategies 
based on the underlying arrest cause, we showed that the VF-waveform may facilitate early 
diagnosis of VF patients with an underlying ACO, of whom we know to have a high risk to be 
shock-resistant. Incorporation of computerized VF-waveform analysis in triage algorithms for 
early transportation of VF-patients, may therefore potentially cause a paradigm shift in cardiac 
arrest treatment.
In terms of clinical studies, large prospective OHCA registries with protocolized, systematically 
collected VF-waveform and CAG data are warranted to confirm this potential. Analogous to 
our first proof-of-concept study in the experimental setting, we recommend to study the 
benefits of additional recording directions in such prospective studies as well. If successful, 
randomized trials seem the logical next step to investigate whether OHCA-outcomes can be 
improved by early, ECMO-based transportation strategies based on built-in VF-waveform 
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The main topic of the articles described in this thesis is out-of-hospital cardiac arrest (OHCA). 
We introduced the topic in Chapter 1. OHCA is a unique medical emergency in which the 
probability of survival primarily depends on situational factors and the environmental 
infrastructure, e.g. the presence of a witness, the performance of bystander resuscitation, 
adequate activation of the emergency system, and the availability of a public defibrillator. 
Upon arrival of specialized medical personnel, the second important step towards survival 
is taken, with the aim of restoring the heart rhythm (and thus spontaneous circulation). If 
this succeeds, post-arrest care takes place at respectively the intensive care unit, the nursing 
ward and eventually - in the most favorable case – at home. Although survival from OHCA 
has markedly improved over recent years, the percentage of survivors is still very low. In the 
Netherlands, only 1 out of 4 victims survives until hospital discharge. This number is higher 
than the global survival, which is about 10%.
PART I
In cardiac arrest, the most important predictors of survival are those that occur prior to 
hospital admission. In Chapter 2 we provided an overview of technological innovations that 
have recently improved in this prehospital phase of resuscitation care. The prehospital phase 
can be divided into 1) care by bystanders, and 2) care by emergency medical services (EMS). 
With regard to the first part, the goal of the Dutch Heart Foundation is to provide bystander 
care at-the-scene within 6 minutes, for every OHCA-patient in the Netherlands. This has 
markedly improved over recent years, partly through a network of trained volunteers and the 
national text-message alert system HartslagNu. Important aspects that need to continuously 
be optimized include arrest recognition, high-quality basic life support (chest compressions 
and ventilations) and rapid availability of an AED, to apply a defibrillation if necessary. With 
regard to professional care, ambulance personnel have the availability of a growing arsenal of 
medical devices, e.g. in the field of airway management, mechanical chest compressions and 
mobile heart-lung machines (ECMO). Moreover, studies are being conducted investigating 
the application of so-called “smart” defibrillators, which may have the potential to direct 
resuscitation care on an individual basis, targeting the patient’s specific needs. An example is 
analysis of the ventricular fibrillation (VF) waveform, which is the main topic of the studies in 
Part II and Part III of this thesis.
A substantial portion of cardiac arrest victims do not receive bystander CPR, which could be 
due to a lack of civilian training. In this context, the international CPR guidelines highlight 
the importance of CPR training. However, CPR training is time- and cost intensive. In 
Chapter 3 we conducted a randomized trial of CPR training using a virtual reality (VR) mobile 
application. CPR training with a smartphone app has the advantage that it could be a low-
cost, incomprehensive method to reach a broad target population to learn CPR. However, the 
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quality of the chest compressions that can be achieved with VR training remained unknown. 
In a unique study setting, Lowlands Festival 2019, 381 festival-attendees were randomized 
to either VR training or “standard” training by a certified instructor. In short, we found that 
VR training resulted in comparable chest compression rate but inferior chest compression 
depth, compared to the standard method.
PART II
The studies in this section focus on the VF signal, in particular the amplitude spectrum area 
(AMSA). The AMSA is a VF-waveform characteristic combining amplitude- and frequency 
information of the VF signal, thereby providing a measure of the “coarseness” of VF. We 
know from various human and animal studies that AMSA is associated with the duration of 
cardiac arrest and also with the metabolic state of the heart, i.e. myocardial energy levels. 
High-quality chest compressions can improve absolute values of AMSA. In clinical studies, 
AMSA has been shown to predict the likelihood of successful defibrillation and neurologically 
intact survival after OHCA.
In a current randomized trial, investigating the standard resuscitation protocol versus a VF-
waveform guided approach, the AMSA is used to guide shock delivery. In the intervention 
group, VF-waveform analysis is automatically performed by a “smart” defibrillator. Depending 
on the value of AMSA, the shock strategy is determined: the patient either receives immediate 
defibrillation in case of a high AMSA, or additional chest compressions prior to the shock in 
case the AMSA is considered too low. Over the course of resuscitation, AMSA is real-time 
being determined during ventilation pauses. If a certain threshold value (15.5 mVHz),is 
reached at any point during the resuscitation, it is recommended to immediately administer 
a shock. For such a study, it is very important that AMSA-assessment is reproducible, and 
that threshold values  (such as the 15.5 mVHz for “immediate defibrillation”) apply to all 
defibrillation attempts, in all phases of resuscitation.
The abovementioned threshold values  of AMSA have been determined in the largest cohort 
of patients with VF analysis ever described (n = 1617). In this cohort, the median number 
of defibrillation attempts per patient was equal to 2. However, in practice resuscitation 
often takes much longer; 40-50% of all VF patients are shocked 3 times or more. In Chapter 
4 of this thesis, we studied the value of AMSA over a longer period of resuscitation. In a 
prospective cohort of resuscitation patients (n = 139), we performed a per-shock analysis 
on 448 defibrillation attempts. These were divided into the “early phase (shock 1-3)” and 
the “late phase” (shock 4-8) of the resuscitation. We observed that AMSA was associated 
with defibrillation success in both early and late phase, but that the associations were 
most pronounced in the early stages of resuscitation. In addition to absolute AMSA-values, 
we also studied changes of AMSA over time in terms of Δ-characteristics, representing 




increased, but then deteriorated to  ‘fine’ VF. We showed that these Δ-measures were also 
associated with shock success, but only in the early stages of resuscitation. The findings in 
this chapter have two important implications. The first is that both AMSA and ΔAMSA are 
promising parameters in the prediction of shock success and thus have potential to “guide” 
defibrillation therapy, especially in the early stages of resuscitation. The second implication is 
that given the declining AMSA-values, shock success thresholds may vary over the course of 
the resuscitation; it could, for example, become lower than 15.5 mVHz in later phases.
In Chapter 5 we investigated another clinical aspect of determining the AMSA: the recording 
direction of the electrocardiographic registrations. Since the positions of the defibrillator 
pads can vary in clinical practice, it is important to investigate whether - and how - this may 
affect the value of AMSA. For this study, we used recordings of induced VF while performing 
a defibrillation test after implantation of an implantable cardioverter defibrillator (ICD). In 
this ICD cohort (n = 243), we studied standard 12-lead electrocardiogram (ECG) recordings of 
VF, with specific focus on differences between limb leads I and II. We regarded ECG-lead II as 
a reference, because it approximates the recording direction of the defibrillator electrodes. 
The main finding in this study was that the absolute value of AMSA depends on the recording 
direction. We found significant differences between leads I and II, with 20-30% lower values  in 
lead I than in lead II. These findings imply that if defibrillator electrodes are placed in a more 
horizontal direction during resuscitation, the AMSA may be underestimated. In our study, we 
see that this appears to mainly affect the proportion of “high” AMSAs (≥ 15.5 mVHz) and that 
in studies of AMSA-guided defibrillation this may therefore have an impact on the advice of 
prompt defibrillation. The results of this study underscore the importance of fixed protocols 
and uniform positioning of defibrillator electrodes for assessment of AMSA.
In Chapter 6 we studied technical aspects of the methodological approach to determine 
AMSA. In short, this can be divided into three processes: 1) data acquisition 2) selection 
and processing of VF signals and 3) calculation of AMSA. Key factors in these processes are 
respectively 1) the sampling frequency of the used device, 2) the length of the VF segment 
and 3) the interval over which AMSA is being calculated. By means of a systematic review 
we showed that of the 43 studies describing the AMSA in humans, data on at least one of 
these elements was lacking in 49%. We also observed a broad variety of methodological 
approaches among the analyzed studies. We varied the abovementioned 3 key factors 
during AMSA-assessment in our own VF-cohort, and observed up to 3-fold differences in 
the resulting absolute AMSA-values, when calculated using identical VF-signals. Moreover, 
the used AMSA method, especially the VF-segment length, influenced classification into 
“high”, “intermediate” or “low” AMSAs. For future studies and applications, we therefore 





In the third part of this thesis, we focused on another possible application of VF analysis, 
based on the relationship of VF signal characteristics with underlying heart disease. Although 
it was known from animal studies that both a previous and an acute myocardial infarction 
(MI) affects amplitude and frequency characteristics of VF, data in humans was limited. The 
aim of the studies in Chapter 7 and Chapter 8 was to gain more insight into the relationship 
between the VF signal and underlying heart disease. In these chapters, we used data of 
induced VF obtained during defibrillation tests. In Chapter 7 we investigated the influence of 
a previous myocardial infarction on amplitude and frequency characteristics of the VF signal. 
In a cohort of 190 patients, 3 groups were distinguished: patients with a prior inferior MI 
(n = 55), anterior MI (n = 47) and patients without a prior MI (n = 88). The main finding 
was that amplitude-related characteristics were lower in patients with a prior MI, in the ECG 
leads adjacent to the area of  the old scar. In inferior MIs these were leads II and aVF, while 
in anterior MIs lead V3 was affected. Notably, VF characteristics in lead V1, which mainly 
provides information about the right ventricle, did not differ between the groups. To gain 
more insight into the influence of underlying heart disease on the VF signal,  we performed 
a similar study in 193 ICD patients in Chapter 8, aiming to assess the impact of increased left 
ventricular diameter or mass on VF characteristics. We demonstrated that in the presence of 
a moderately to severely dilated left ventricle (LV), frequency characteristics of VF were lower 
in all ECG leads when compared to the patient subset without LV dilatation. No differences 
were found in amplitude characteristics. As for the LV mass, we observed higher amplitude 
characteristics of VF in several ECG-leads, in patients with increased LV masses, compared to 
patients without increased LV-masses. The results of these studies imply that the appearance 
of the VF-waveform during resuscitation is not only a marker for arrest duration and the 
metabolic state of the heart, but is also influenced by underlying heart diseases such as 
MI, ventricular hypertrophy or dilatation. In fact, we see that the VF signal contains patient-
specific information. This potentially paves the way for new developments, such as detecting 
underlying heart disease during VF, using VF-signal analysis. 
In Chapter 9 we built upon the finding that underlying heart disease affects VF signals. In 
follow up on studies on associations between the VF-waveform and underlying heart disease, 
we now focused on the potential diagnostic value of the VF-waveform. As a first step towards 
identification of acute MI during spontaneous VF, we conducted a proof-of-concept study 
on identification of a prior MI using induced VF in patients in the previously mentioned 
ICD cohort (n = 206). The primary research question of this study was whether we could 
distinguish patients with a previous MI (n = 119) from patients without a previous MI (n = 
87) using VF-waveform based discriminative models. In our initial approach, we firstly used 
only the AMSA of lead II, which resulted in a C- statistic of 0.61 (0.54-0.69), representing 
a moderate discriminative ability. When we added more information to the models, using 




directions increased the discriminative power to a C-statistic of 0.75 (0.68-0.81); a reasonable 
to good discriminative ability. Adding extra VF-characteristics than the AMSA (e.g. other 
amplitude, frequency and organization measures) did not improve this further.
In the last two studies of this thesis, we made the step to acute myocardial infarction. 
Acute MI is an important - and potentially reversible - cause of VF. Results from previous 
observational studies suggested that patients in whom ROSC is not achieved after three 
defibrillation attempts may benefit from quick hospital transportation for an emergency 
coronary angiogram (CAG). The rationale behind this hypothesis is that this subgroup may 
often have an underlying acute MI which causes the shock-resistancy of VF. However, to date, 
evidence for this hypothesis is thin as data on this topic are scarce.
In Chapter 10 we studied a cohort of VF patients who were transported to the hospital in 
Nijmegen (n = 301), who underwent a CAG after resuscitation. We studied differences in 
characteristics between patients with and without shock-resistant VF, defined as more than 
three shocks during the resuscitation. We found significantly more acute coronary occlusions 
(ACOs) in case VF was shock-resistant (n = 105) than in the group without shock-resistant 
VF (n = 196), 41% vs. 26%. These findings are in line with previous studies on this topic and 
suggest that patients who require multiple defibrillation attempts are indeed more likely to 
have underlying coronary substrate. This supports future initiatives for early transportation of 
this patient subset, for emergency CAG. A possible limitation in this process is identification 
of patients with an ACO during resuscitation. Ideally, one would detect this patient subset as 
early as possible. However, at present, diagnosis of ACO is restricted to patients with restored 
organized rhythm. Appreciating that ACO patients do often appear with shock-resistant VF, 
there is need for modalities to detect ACO-patients at-the-scene during VF. 
In Chapter 11 we investigated the diagnostic potential of VF-waveform analysis for 
identification of ACO patients. We studied a cohort of 111 VF patients, for whom both VF-
waveform data of the defibrillator ECG as well a post-arrest CAG was available. The primary 
research question was whether ACO could be detected using the AMSA. Secondly, machine 
learning models were constructed in which - in addition to the AMSA-only - the course of 
AMSA over time (ΔAMSA) was used as input feature. In total, 67 of the 111 patients had an 
ACO as the underlying cause of VF. The main finding of this study was that AMSA only had a 
moderate discriminative performance, with a C-statistic of 0.66. Adding ΔAMSA yielded good 
discrimination (C-statistic 0.80). In exploratory analyses, we showed that offering of additional 
signal characteristics to the models did not improve the discriminative ability. Although we 
studied a group with a limited sample size, this is the first human study to investigate the 
discriminative potential of VF signal characteristics for the detection of acute MI during VF, 
in the earliest phase of resuscitation. These results are promising and provide impetus for 
prospective data collection to investigate whether early diagnosis of an acute MI is possible 






Nederlandse samenvatting (Dutch summary)
Het hoofdonderwerp van de artikelen beschreven in dit proefschrift, is een hartstilstand buiten 
het ziekenhuis. In Hoofdstuk 1 wordt dit onderwerp geïntroduceerd. Een plotse hartstilstand 
is een unieke medische noodsituatie, waarin de kans op overleving in de eerste plaats 
afhangt van situationele factoren: is er een getuige van de hartstilstand, is het slachtoffer 
gereanimeerd door een omstander, is er snel 112 gebeld en is er een AED beschikbaar. Bij 
aankomst van gespecialiseerd medisch personeel wordt de tweede belangrijke stap gezet 
naar overleving, met als doel om het hartritme (en daarmee de spontane circulatie van de 
patiënt) te herstellen. Indien dit lukt, begint de laatste stap: post-arrest zorg op de intensive 
care, de verpleegafdeling en daarna – in het meest gunstige geval – in de thuissituatie. 
Hoewel de overleving van een plotse hartstilstand erg is verbeterd over de laatste jaren, ligt 
het percentage overlevers nog steeds erg laag. In Nederland overleeft gemiddeld 23% van 
de slachtoffers tot ontslag uit het ziekenhuis. Dit gemiddelde ligt hoger dan de wereldwijde 
overleving, welke ongeveer 10% is.
DEEL I
Veel van de belangrijke voorspellers van overleving hebben betrekking op factoren vóór 
aankomst van de patiënt in het ziekenhuis. In Hoofdstuk 2 hebben we een overzicht gegeven 
van technologische innovaties die de afgelopen jaren voor een verbetering hebben gezorgd 
in deze zogeheten prehospitale fase van reanimatiezorg. De prehospitale fase kun je indelen 
in twee aparte delen: 1) zorg door omstanders en 2) zorg door professionele hulpverleners. 
Met betrekking tot het eerste deel, de zorg door omstanders, is het doel van de Hartstichting 
om in Nederland bij elke reanimatiepatiënt binnen 6 minuten hulp ter plaatse te hebben. Dit 
is de laatste jaren erg verbeterd, mede door middel van een netwerk van burgerhulpverleners 
en de mobiele app HartslagNu. Belangrijke aspecten die geoptimaliseerd moeten blijven 
worden, zijn o.a. herkenning van het arrest, het geven van kwalitatief goede basic life support 
(borstcompressies en beademingen) en snelle beschikbaarheid over een AED om – indien nodig 
– een defibrillatie te kunnen geven. Over de laatste jaren heeft ook het ambulancepersoneel 
de beschikking gekregen over een arsenaal aan medische hulpmiddelen, op het gebied van 
o.a. beademingsapparatuur, mechanische borstcompressies en mobiele hartlongmachines 
(ECMO). Ook worden steeds meer studies gedaan naar de potentiële toepassing van een 
“slimme” defibrillator, die reanimatiezorg kan sturen op een individuele basis, gericht op 
de specifieke behoeften van een patiënt. Een voorbeeld hiervan is signaalanalyse van het 
defibrillator ECG, waar de studies in Deel II en Deel III van dit proefschrift voornamelijk over 
gaan.
Een aanzienlijke deel van slachtoffers van een hartstilstand ontvangen geen reanimatie door 
omstanders, wat het gevolg zou kunnen zijn van een gebrek aan training van burgers. In 
deze context wordt in de internationale reanimatierichtlijnen het belang aangestipt van 
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reanimatietraining. Echter, reanimatietrainingen zijn tijds- en kostenintensief. In Hoofdstuk 3 
hebben we een gerandomiseerde studie gedaan naar reanimatietraining middels een virtual 
reality (VR) mobiele applicatie. Reanimatietraining via de smartphone heeft als voordeel 
dat het een goedkope, laagdrempelige manier zou kunnen zijn om een groot publiek te 
leren reanimeren. Echter, de kwaliteit van de borstcompressies die bereikt kan worden met 
VR-training was onbekend. In een unieke studiesetting, namelijk Lowlands Festival 2019, 
werden 381 festivalgangers gerandomiseerd naar óf VR-training, óf “standaard” training 
door een instructeur. Concluderend zagen we dat VR-training resulteerde in vergelijkbare 
borstcompressiesnelheid maar inferieure borstcompressiediepte, vergeleken met de 
standaardmethode. 
DEEL II
Het meest voorkomende schokbare ritme tijdens een reanimatie is ventrikelfibrilleren 
(VF).  De studies in dit deel gaan over het VF-signaal, met name de amplitude spectrum 
area (AMSA), een karakteristiek die amplitude- en frequentie-informatie van het VF-signaal 
combineert en daarmee een maat is voor de “grofmazigheid” van het VF. Uit verschillende 
mens- en dierstudies weten we dat AMSA geassocieerd is met de duur van de hartstilstand 
en ook met de metabole staat van het hart, d.w.z. hoeveel energie het hart nog heeft. Door 
borstcompressies te geven kan de AMSA hoger worden tijdens een reanimatie. In klinische 
studies is gebleken dat AMSA de kans voorspelt op een succesvolle defibrillatie en op 
neurologisch intacte overleving na een hartstilstand.
In een huidige gerandomiseerde studie, waarin het huidige reanimatieprotocol wordt 
onderzocht ten opzichte van een nieuw VF-signaal gestuurd protocol, wordt AMSA gebruikt 
om de timing van defibrillatie te sturen. In de interventiegroep wordt de AMSA berekend 
door een “slimme” defibrillator. Afhankelijk van de waarde van AMSA wordt de schokstrategie 
bepaald: de patiënt krijgt direct een defibrillatie in het geval van een hoge AMSA, of 
additionele borstcompressies voor de schok in geval van een (te) lage AMSA. Gedurende de 
reanimatie wordt steeds real-time de AMSA bepaald tijdens beademingspauzes, en bij een 
bepaalde drempelwaarde (15.5 mVHz) wordt direct geadviseerd om een schok toe te dienen, 
ook als men midden in het reanimatieblok zit.
Voor een dergelijke studie is het van groot belang dat AMSA over de hele reanimatie dezelfde 
eigenschappen vertoont en dat drempelwaardes (zoals de 15.5 mVHz voor “direct schokken”) 
gelden voor alle defibrillatiepogingen. Tevens is de reproduceerbaarheid van AMSA cruciaal.
Bovengenoemde drempelwaardes van AMSA zijn bepaald in het tot dusver grootste cohort 
patiënten met VF-analyse ooit beschreven (n = 1617). In dit cohort was het mediane aantal 
defibrillatiepogingen per patiënt gelijk aan 2. Echter, in de praktijk duren reanimaties vaak 
veel langer; 40-50% van alle VF-patiënten wordt 3 keer of vaker geschokt. In Hoofdstuk 4 van 




periode van reanimaties. In een prospectief cohort reanimatiepatiënten (n= 139) hebben 
we een per-schok analyse uitgevoerd op 448 defibrillatiepogingen. Deze werden verdeeld 
in “vroege fase” (schok 1-3) en “late fase” (schok 4-8) van de reanimatie. We vonden dat 
AMSA geassocieerd was met defibrillatiesucces over de hele reanimatie, maar dat vooral 
in de beginfase van de reanimatie de associaties het sterkst waren. Naast absolute AMSA-
waarden, onderzochten we tevens het beloop van AMSA over de tijd. De AMSA werd over de 
tijd eerst iets groter, maar verslechterde daarna, d.w.z. het VF werd ‘fijnmaziger’. Deze AMSA-
veranderingen over de tijd (ΔAMSA) waren geassocieerd met schoksucces, maar alleen in 
de beginfase van de reanimatie. De bevindingen in dit hoofdstuk hebben twee belangrijke 
implicaties. De eerste is dat zowel AMSA als ΔAMSA veelbelovende parameters zijn in het 
voorspellen van schoksucces en daarmee het “sturen” van defibrillatietherapie, vooral in 
de vroege fase van de reanimatie. De tweede implicatie is dat gezien de kleiner wordende 
AMSA, de drempelwaarde voor schoksucces misschien varieert gedurende het beloop van 
de reanimatie; deze zou bijvoorbeeld kleiner kunnen worden dan 15.5 mVHz in latere fases.
In Hoofdstuk 5 onderzochten we een ander klinisch aspect met betrekking tot het bepalen 
van de AMSA: de opnamerichting van de elektrocardiografische (ECG) registratie. Gezien 
het feit dat de posities van de defibrillatorelektrodes kunnen variëren per reanimatie, is het 
van belang om te onderzoeken of – en hoe – dit de waarde van AMSA kan beïnvloeden. 
Voor deze studie hebben we gebruik gemaakt van opnames van VF dat geïnduceerd werd 
tijdens het uitvoeren van een defibrillatietest na implantatie van een ICD (implanteerbare 
cardioverter defibrillator). In dit ICD-cohort (n = 243) hebben we gekeken naar standaard 
12-kanaals elektrocardiogram (ECG)-registraties van VF, met specifieke focus op verschillen 
tussen extremiteitsafleidingen I en II. Lead II zien we als referentie, omdat deze ongeveer 
dezelfde opnamerichting heeft als de stickers van het defibrillator ECG. De hoofdbevinding 
in deze studie is dat de absolute waarde van AMSA afhankelijk is van de opnamerichting. Wij 
vonden significante verschillen tussen afleidingen I en II, met 20-30% lagere waarden in lead I 
dan in lead II. De implicatie van deze bevinding is dat als tijdens een reanimatie de elektrodes 
in een meer horizontale richting worden geplakt, dat de AMSA onderschat kan worden. In 
onze studie zien we dat dit vooral invloed lijkt te hebben op de proportie “hoge” AMSA’s 
(>15.5 mVHz) en dat dit dus mogelijk in studies naar AMSA-gestuurde defibrillatie impact kan 
hebben op het advies om direct te defibrilleren. De resultaten van deze studie onderstrepen 
het belang van vaste protocollen en uniforme positionering van defibrillator elektrodes bij 
het bepalen van de AMSA.
In Hoofdstuk 6 bestudeerden we technische aspecten van het berekenen van AMSA. In het 
kort kun je dit opdelen in drie processen, te weten 1) data-acquisitie 2) selectie- en bewerking 
van VF-signalen en 3) calculatie van AMSA. Belangrijke elementen in deze processen zijn 
respectievelijk 1) de samplefrequentie van het gebruikte apparaat, 2) de lengte van het VF-
segment en 3) het interval waarover AMSA berekend wordt. Middels een systematische 
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review hebben we laten zien dat van de 43 studies waarin de AMSA beschreven is in mensen, 
49% van de studies minstens één van deze drie elementen niet beschrijft. Tevens zagen we 
dat er veel methodologische verschillen waren tussen de studies. Indien we bovenstaande 
drie elementen op ons eigen VF-cohort variëren, zien we grote verschillen ontstaan in de 
resulterende AMSA-waarden, en dat de gebruikte AMSA-methode – vooral de segment 
lengte – ook invloed kan hebben op het classificeren in een “hoge” of “lage” AMSA. Voor 
toekomstig onderzoek concluderen we dat een uniforme methode gebruikt moet worden als 
men gebruik maakt van absolute drempelwaarden om bijvoorbeeld het geven van een schok 
te sturen.
DEEL III
In het derde deel van dit proefschrift ligt de focus op een andere mogelijke toepassing van VF-
analyse, gebaseerd op de relatie van VF-signaalkarakteristieken met onderliggend hartlijden. 
Hoewel uit dierstudies bekend was dat zowel een acuut als een doorgemaakt hartinfarct 
invloed heeft op amplitude- en frequentiekarakteristieken van VF, was informatie hierover 
in mensen gelimiteerd. Het doel van de studies in Hoofdstuk 7 en Hoofdstuk 8 was om meer 
inzicht te krijgen in de relatie tussen het VF-signaal en onderliggende hartziekten. In deze 
hoofdstukken maken we wederom gebruik van data van geïnduceerd VF, verkregen tijdens 
defibrillatietesten. In Hoofdstuk 7 hebben we de invloed onderzocht van een doorgemaakt 
hartinfarct op amplitude- en frequentiekarakteristieken van het VF-signaal. In een groep van 
190 patiënten werden 3 groepen onderscheiden: patiënten met een oud onderwandinfarct 
(n = 55), een oud voorwandinfarct (n = 47) en patiënten zonder infarctlitteken (n = 88). De 
belangrijkste bevinding was dat amplitude-gerelateerde karakteristieken lager waren bij 
patiënten met een oud infarct in de ECG-afleidingen die grenzen aan het gebied van het oude 
litteken. Bij onderwandinfarcten waren dit afleiding II en aVF, bij voorwandinfarcten afleiding 
V3. Een opvallend resultaat was dat VF-karakteristieken in afleiding V1, die vooral informatie 
over de rechter hartkamer geeft, niet verschilden tussen de groepen.
Om nog meer inzicht te krijgen in de invloed van onderliggend hartlijden op het VF-signaal, 
hebben we in Hoofdstuk 8 een soortgelijke studie verricht in 193 ICD-patiënten, met als 
doel de invloed van een verhoogde linkerkamerdiameter of -massa op VF-karakteristieken 
te onderzoeken. De resultaten lieten zien dat bij de aanwezigheid van een matig tot ernstig 
gedilateerde linkerkamer, frequentiekarakteristieken van VF lager waren in alle geanalyseerde 
ECG-afleidingen, dan bij patiënten zonder linkerkamerdilatatie. Er werden geen verschillen 
gevonden in amplitudekarakteristieken. Bij patiënten met een verhoogde linkerkamermassa 
zagen we juist verschillen in VF amplitudekarakteristieken. Deze waren hoger in verschillende 
afleidingen bij patiënten met verhoogde linkerkamermassa’s. 
De resultaten van deze twee studies impliceren dat uiterlijke kenmerken van VF tijdens 




hart, maar ook worden beïnvloed door onderliggende hartziekten zoals een hartinfarct, 
kamerhypertrofie of -dilatatie. Feitelijk zien we dat het VF-signaal patiëntspecifieke informatie 
bevat. Dit maakt mogelijk de weg vrij naar nieuwe ontwikkelingen, zoals het detecteren van 
de onderliggende hartziekte tijdens VF, met behulp van analyse van het VF-signaal.
In Hoofdstuk 9 bouwden we voort op de bevinding dat onderliggend hartlijden het VF-signaal 
beïnvloedt. In navolging van studies die associaties hebben aangetoond tussen het VF-signaal 
en onderliggend hartlijden, focusten we ons nu op de mogelijke diagnostische waarde van 
VF-analyse. Als eerste stap richting detectie van acute hartinfarcten tijdens spontaan VF, 
hebben we een proof-of-concept studie verricht naar het identificeren van een doorgemaakt 
infarct met behulp van geïnduceerd VF, bij patiënten in het ICD-cohort (n = 206). De primaire 
onderzoeksvraag van deze studie was of we met behulp van discriminatieve modellen 
patiënten met een doorgemaakt infarct (n = 119) konden onderscheiden van patiënten 
zonder doorgemaakt infarct (n = 87). In een eerste poging gebruikten we alleen de AMSA van 
afleiding II, wat resulteerde in een C-statistiek van 0.61 (0.54-0.69), gelijk aan een middelmatig 
onderscheidend vermogen. Indien we additionele informatie aan de modellen toevoegden 
met behulp van machine learning technieken, zagen we dat het toevoegen van VF-informatie 
uit meerdere ECG-richtingen het discriminatieve vermogen verhoogde tot een C-statistiek 
van 0.75 (0.68-0.81); een redelijk tot goed onderscheidend vermogen. Het aanbieden van 
extra karakteristieken dan de AMSA (amplitude, frequentie- en organisatiematen) leidde niet 
tot betere discriminatie tussen de groepen.
In de laatste studies die in dit proefschrift zijn beschreven, maken we de stap naar het acute 
hartinfarct, een belangrijke – en mogelijk omkeerbare – oorzaak van VF. In voorgaande, 
observationele studies is gesuggereerd dat patiënten met zogeheten schokbestendig VF (bij 
wie na 3 defibrillatiepogingen nog geen herstel van spontane circulatie optreedt), mogelijk 
baat hebben bij snel transport naar het ziekenhuis voor een spoed coronairangiogram (CAG). 
De gedachte hierachter is dat deze groep mogelijk vaker een acuut hartinfarct heeft als 
oorzaak van schokbestendig VF. Echter, wetenschappelijk bewijs voor deze hypothese is tot 
op heden dun.
In Hoofdstuk 10 hebben we een cohort VF-patiënten bestudeerd die naar het ziekenhuis in 
Nijmegen zijn getransporteerd (n = 301) en die een CAG hebben ondergaan na afloop van de 
reanimatie. Wij onderzochten verschillen in karakteristieken tussen patiënten met en zonder 
“schokbestendig VF”, gedefinieerd als het hebben gekregen van meer dan 3 defibrillaties 
tijdens de reanimatie. In de groep patiënten met schokbestendig VF (n = 105) zagen we 
significant vaker een acute coronaire occlusie (ACO) dan bij de groep zonder schokbestendig 
VF (n = 196), 41% vs. 26%. Deze uitkomst ondersteunt de resultaten van voorgaande studies 
naar dit onderwerp en suggereert dat patiënten die veel defibrillatiepogingen nodig hebben, 
inderdaad vaker een onderliggend coronair substraat hebben. Dit ondersteunt toekomstige 
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initiatieven om deze patiëntengroep snel te transporteren naar het ziekenhuis voor spoed 
CAG. Een mogelijke limitatie in dit proces is de identificatie van patiënten met een ACO 
tijdens een reanimatie. In de ideale situatie zou je deze patiëntengroep zo snel mogelijk 
willen identificeren, echter in de huidige situatie kan dit alleen bij patiënten met herstel van 
georganiseerd hartritme. Derhalve is er vraag naar methoden om ACO-patiënten al in een 
vroege fase te identificeren.
In Hoofdstuk 11 hebben we de diagnostische waarde van VF-analyse onderzocht voor 
identificatie van ACO-patiënten. Voor deze onderzoeksvraag gebruikten we een cohort van 
111 VF-patiënten, van wie zowel VF signaaldata van het defibrillator ECG als een post-arrest 
CAG beschikbaar was. De primaire onderzoeksvraag was of met behulp van de AMSA een 
ACO kon worden gedetecteerd. Secundair werden machine learning modellen onderzocht 
waarbij – naast AMSA alleen – ook het beloop van AMSA over tijd (ΔAMSA) aan het model 
werd aangeboden. In totaal hadden 67 van de 111 patiënten een ACO als onderliggende 
oorzaak van het VF. De belangrijkste bevinding van deze studie was dat AMSA-alleen een 
matig onderscheidend vermogen had, met een C-statistiek van 0.66. Het toevoegen van 
ΔAMSA leverde een goed onderscheidend vermogen op (C-statistiek 0.80). In exploratieve 
analyses lieten we zien dat het aanbieden van extra signaalkarakteristieken geen verbetering 
van de modellen gaf. Hoewel het een kleine groep betreft, is dit de eerste studie ooit in 
mensen waarin het onderscheidend vermogen van VF-signaalkarakteristieken is onderzocht 
voor detectie van een acuut hartinfarct tijdens VF, in de vroegste fase van een reanimatie. 
Deze resultaten zijn veelbelovend en geven aanleiding tot prospectieve dataverzameling, 
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Dan nu aandacht voor het belangrijkste hoofdstuk van dit proefschrift: het dankwoord. Het 
onderdeel dat het meest gelezen wordt (terecht) en dat mijns inziens pas écht het einde van 
je promotietijd vertegenwoordigt. Bovenal is het een blijk van waardering naar een ieder die 
heeft bijgedragen aan dit werk, want in je eentje is het simpelweg niet mogelijk om onderzoek 
te doen. Derhalve wil ik de volgende personen bedanken voor deze  teamprestatie.
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Enschede naar de “grote stad” Nijmegen kwam voor mijn tweede masterstage. Ik werd 
direct enthousiast van het door jou opgezette VF-project. Zonder jouw hulp was het zeker 
niet gelukt om deze onderzoekslijn samen met Joris voort te zetten. Hopelijk kunnen we ons 
project in de toekomst het vervolg geven dat het verdient, door middel van een succesvolle 
subsidieaanvraag.
Prof. dr. B.R. Bloem, beste Bas, dank voor jouw rol die je als mentor hebt vervuld tijdens mijn 
promotietraject. Jij bent een echte inspiratiebron voor toekomstige wetenschappers.
De manuscriptcommissie, bestaande uit prof. dr. J.G. van der Hoeven, prof. dr. A.P.M. 
Gorgels en dr. M.T. Blom ben ik zeer erkentelijk voor het zitting nemen in de commissie en 
het lezen en beoordelen van mijn manuscript. Tevens wil ik alle andere leden van de corona 




Dit werk had niet tot stand kunnen komen zonder de patiënten over wie de artikelen in dit 
proefschrift geschreven zijn. Het gros ken ik enkel van studienummer, maar zonder u was het 
niet mogelijk geweest om onderzoek te doen naar een plotse hartstilstand. Ik hoop dat het 
werk in dit proefschrift kan bijdragen aan een betere behandeling en overlevingskans voor 
slachtoffers van een hartstilstand in de toekomst.
Alle collega’s van de afdeling cardiologie wil ik bedanken voor de unieke mogelijkheid om 
hier als Technisch Geneeskundige promotieonderzoek te doen. Met name prof. dr. J.L.R.M. 
Smeets voor uw goede begeleiding en het kritisch lezen van onze gezamenlijke artikelen, 
drs. Sjoerd Westra voor jouw expertise op het gebied van elektrofysiologie, maar bovenal 
toch je humor en gezelligheid, en drs. Etienne Cramer voor je eeuwige rust en levenslessen. 
Ik kijk uit naar jouw promotie! Verder prof. dr. Robin Nijveldt voor het managen van de 
onderzoeksafdeling in het tweede deel van mijn promotietijd en Linda van den Brink - Drok 
voor al je inspanningen tijdens de overgang van Diagram naar Radboudumc. Ook wil ik alle 
(research)verpleegkundigen en secretaresses bedanken voor de prettige samenwerking, met 
speciale benoeming van Sandra, Dorothée, Mieke, Lydia en Maaike!
Vanuit de Universiteit Twente wil ik graag prof. dr. H.J. Zwart en dr. G. Meinsma bedanken 
voor het superviseren van de wiskundige kant van ons onderzoek, alsmede de samenwerking 
met betrekking tot het begeleiden van TG-studenten. Verder wil ik alle andere coauteurs 
bedanken voor hun bijdrage aan de stukken!
De afgelopen jaren heb ik samengewerkt met veel generaties collega-onderzoekers. Op 
volgorde van “eendjes”: Jeroen, jij was de eerste die promoveerde toen ik begon op de 
afdeling. Bedankt voor de eerste lessen en je interesse in mijn onderzoek. Frank, ontzag is er 
voor jouw gestructureerde manier van werken; ik heb daar veel van geleerd maar te weinig 
van opgestoken. Hopelijk kunnen we snel weer een pijltje gooien bij Bianca! Sander, jouw 
oneliners en algemene kennis zijn onnavolgbaar. Bedankt voor je kritische blik en ongezouten 
mening. Stijn, als kapitein (Kapistijn) van de kamer wist jij in roerige tijden mijn vaarwater altijd 
rustig te houden. Jouw rust, samen met je inzet voor anderen, maakt jou een uniek mens en 
geweldige collega. Hella, wij kregen door minder leuke omstandigheden een bijzondere band 
gedurende onze promotietijd. Al spreken we elkaar niet iedere week, ik denk regelmatig aan 
jou. Kees, ouwe regenvogel, jij weet altijd precies wat je wil en werkt hier dan ook naartoe. 
In de voorbereiding naar mijn promotie heb ik dankbaar gebruik mogen maken van deze 
eigenschap. Bedankt hiervoor, alsmede voor je enthousiasme, vele inspirerende hobby’s en 
Brabantse humor. Regina, laatste van de “oude garde”, bedankt voor de gezellige tijd. Met 
jouw prachtige artikel in JACC zal jouw promotie ook niet lang op zich laten wachten.
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De nieuwe generatie onderzoekers, die dan (hopelijk) ook weer iets van mij hebben geleerd… 
Allereerst de “Vlotjes” Yvonne, Dominique, Jacqueline, Jan-Quinten en “can’t you see 
he’s the man, let me hear you applaud, he is more than a man, he’s a shiny golden god” 
Goaris. Nadat ik als laatste der Brouwer-Mohikanen overbleef, heb ik echt toptijden met jullie 
beleefd. Bedankt voor de mooie zomerdagen in de zon op de boot, alsmede voor de feestjes 
die altijd net iets later worden dan gepland. 
Kamergenoten Casper - de man die altijd op tafel staat - en Max “mien Brúúr”, dank voor 
de mooie tijd. Lara, Frans en Tijn, met jullie heb ik i.v.m. corona minder tijd fysiek op de 
afdeling doorgebracht; bedankt voor het kritisch lezen van mijn manuscript en succes met 
jullie PhD!
De twee uitvinders in ons midden: Daniel van Dort en Stefan Hummelink. Het Radboud 
heeft met jullie uniek talent in huis. Bedankt voor het  verruimen van mijn blik de afgelopen 
jaren. 
De vele TG studenten, van wie vooral de afstudeerders een belangrijke bijdrage hebben 
geleverd aan het onderzoek in dit proefschrift: Dennis, Eliene, Jeanne, Seraya, Sarah en 
Koen.
Alle vrienden uit Nijmegen, met name Sjoerd, Wouter en Roland. Jullie hebben met mij in 
huis gewoond en kennen mijn leuke, maar zéker ook mijn minder leuke kanten. Dank voor 
jullie steun, lekkere eten en gezellige borrels. Schulti, bedankt voor alle inspanningen die je 
hebt geleverd om dit proefschrift te ontwerpen.
De vriendengroep uit Apeldoorn, bedankt voor de nodige ontspanning als ik in de weekenden 
thuis was. Aaron, “ibzbdimjovbg”, vriend voor het leven, meer woorden zijn hier niet nodig. 
Eervolle vermelding ook voor Pato, Wimpel, Coon, Mattie, Okocha, Hessel, Birze, Nase. 
Dank voor de mooie dagen slenteren door Amsterdam, jullie zijn stuk voor stuk prachtlui. 
Paranimfen, als echte “Brouweriaan” heb ik bewust gekozen voor deze combinatie van 
vrienden uit jeugd en werk. Rutger, wij kennen elkaar al ongeveer ons hele leven. Hoewel jij 
altijd weer op vrij grote afstand weet te gaan wonen, weet ik dat ik jou altijd kan bellen en 
op je kan rekenen. Thanks voor het naast mij staan op deze dag, dat doet me erg goed. Nas, 
ouwe dibbes, eigenlijk had jij de verdediging vóór mij moeten doen, zoals je de afgelopen 
jaren vaak als encyclopedie hebt gefungeerd. Ik word vaak zwetend wakker van de uitspraak 
'ken je stukken'. En hoe toevallig is het dat je directe collega precies dezelfde muziek luistert 




Het “thuisfront”, beginnend bij mijn ooms, tantes, schoonfamilie en andere naasten. Bedankt 
voor jullie interesse in mijn onderzoek en jullie aanwezigheid tijdens mijn promotie!
Lieve Oma Zwolle, wat vind ik het speciaal dat jij mijn promotie meemaakt! Tegelijkertijd 
denk ik ook aan Opa en hoe jammer ik het vind dat hij dit proefschrift niet kan lezen. Ik ben 
er trots op een halve Zwollenaar te zijn en kom gauw weer koffie drinken naast de Peperbus!
Lieve Jorien en Mike, grote zus en broer. Als jongste van drie Thannhausers zijn jullie voor 
mij een voorbeeld. Jorien, ik kijk op naar jouw lieve karakter en nauwkeurigheid. Mike, van 
jouw doortastendheid en attentie (lees: het sturen van kaartjes) kan ik nog veel leren. Ik ben 
enorm trots op jullie en hoop samen met Bart, Jolijn en jullie lieve gezinnen nog vele mooie 
momenten mee te maken!
Lieve mama en papa, het fundament onder dit proefschrift en van mijn leven in het algemeen. 
Altijd hebben jullie mij gesteund, in mooie en in minder mooie tijden. Ik ben jullie voor altijd 
dankbaar voor het fijne kind-zijn en het vormen van de persoon die ik nu ben. Mama, wat ben 
jij een geweldig persoon. Allereerst ontzettend knap, een geweldige stem, onbevooroordeeld 
en met heel veel humor. We weten allemaal dat er binnenkort een tijd komt dat jij onze steun 
nodig hebt in plaats van wij die van jou. We gaan dat met zijn allen doen, want we zijn een 
sterk gezin. Papa, jouw rust, zorgzaamheid en behulpzaamheid zijn prachtig. Wat ik vijf jaar 
geleden in het lied voor jouw 60e verjaardag schreef, geldt nog steeds. Jullie zijn de beste 
ouders die ik me had kunnen wensen; ik hou van jullie!
Lieve Lieke, met jou is het leven leuker. Hoe wij samen in het leven staan vind ik geweldig. We 
laten elkaar vrij in ons doen en laten, maar staan altijd op elkaars eerste plaats als het nodig 







Al vanaf de derde week van de embryonale ontwikkeling worden hart en bloedvaten gevormd. 
Vanaf dat moment zal het hart zich ontwikkelen tot een vitaal orgaan dat zuurstofrijk bloed 
rondpompt en daarmee tot de drijvende kracht van energie in het menselijk lichaam. Voor 
iedereen zal er ook een moment komen dat het daarmee ophoudt; het moment dat het leven 
van dat individu eindigt. In het geval van ouderdom, een ziekbed of een anderszins voltooid 
leven kan men in dit lot berusten en kan de dood worden gezien als een welkome vriend. 
Een plotse hartstilstand daarentegen is een verschijnsel waardoor men verrast wordt en dat 
behandeling behoeft. Met adequaat ingrijpen en een flinke dosis geluk is er kans op overleving.
Een hartstilstand spreekt tot de verbeelding. Vaak gebeurt het ver weg, soms dichtbij. In 
ons collectieve geheugen staat de reanimatie van Abdelhak Nouri tijdens de wedstrijd Ajax- 
Werder Bremen. De meeste mensen hebben er wel eens over nagedacht: “wat als het mij, 
of iemand in mijn omgeving overkomt?”. Het lijkt willekeurig te gebeuren, als een dartpijl 
afgevuurd op een wereldkaart. 
Ook in mijn omgeving zijn de voorbeelden te noemen. Zonder uitzondering kan ik mij de 
plaats en tijd herinneren waar ik was toen het bericht mij ter ore kwam. De eerste keer dat dit 
gebeurde was in januari 2007 toen Hans de Brouwer, de vader van mijn lieve zwager Bart, een 
hartstilstand kreeg na deelname aan de midwintermarathon. Hij was een gezonde, sportieve 
man, pas 48 jaar, maar ze hebben hem niet kunnen redden. Een tweede moment dat in mijn 
geheugen gegrift staat is mei 2017, toen ik door mijn broer gebeld werd dat zijn goede vriend 
Jorret “Avi” Averdijk, plots was overleden na zijn voetbaltraining.
Ik draag dit proefschrift op aan Hans, Jorret, Abdelhak en alle anderen wier toekomst na een 
reanimatie verloren is gegaan. Tevens wil ik met dit proefschrift een lans breken voor meer 
onderzoek naar een hartstilstand en de optimale behandeling ervan. Het is mijns inziens een 
ziektebeeld waar wereldwijd te weinig onderzoek naar wordt gefaciliteerd. Ter illustratie: het 
NIH (het grootste medische financieringsorgaan in de VS), besteedde in 2017 slechts 0,2% 
van het totale budget aan onderzoek naar een hartstilstand. Omgerekend was dit $91 per 
sterfgeval, beduidend minder dan onderzoek naar beroerte ($2200) of kanker ($9000).
Toekomstige PhD-studenten zouden gestimuleerd moeten worden om meer onderzoek te 
doen naar een hartstilstand, want alleen op die manier kunnen we de overlevingskansen 
verbeteren. Mede dankzij dit onderzoek zijn er namelijk ook positieve voorbeelden te 
noemen. Christian Eriksen werd onlangs, tijdens de EK-wedstrijd Denemarken-Finland, 
succesvol gereanimeerd door adequaat herkennen en handelen door omstanders en snel 
gebruik van een AED. Laat dit een voorbode zijn voor de toekomst, want ons hart mag niet 
zomaar stoppen. Niet als het nog een leven voor zich heeft.
Jos Thannhauser, 27 juli 2021
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On the road to a smart defibrillator
Op donderdag 30 september 2021
om 14:30 precies 
in de aula van de Radboud Universiteit, 
Comeniuslaan 2 te Nijmegen
Vanwege restricties met betrekking tot de 
COVID-19 pandemie, kan ik u helaas niet 
fysiek welkom heten. 
Ik nodig u daarom van harte uit om deze 
plechtigheid via de livestream te volgen:
www.ru.nl/aula/livestream
Jos Thannhauser
Thijmstraat 17e
6531 CM Nijmegen
Paranimfen
Joris Nas
Rutger Meijer
Thannhauser.PhD@gmail.com

